Index of Molecular Images

To facilitate comparison of similar structures, the images are listed by clan and family.

Clan	MEROPS ID	Peptidase	Comment	PDB Entry
AA	A01.003	gastricsin	activation intermediate 2	1AVF
AA	A01.003	gastricsin	precursor	1HTR
AA	A01.004	BACE1 g.p. (Homo sapiens)	protease domain; complex with Glu-Val-Asn-leucinol-2-methyl-propionyl-Ala-Glu-Phe inhibitor	1FKN_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with inhibitor OM00-3	1M4H
AA	A01.004	BACE1 g.p. (Homo sapiens)	unbound catalytic domain	1SGZ
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with inhibitor	1TQF_A
AA	A01.004	BACE1 g.p. (Homo sapiens)		1W50
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with 3-[((1S,2R)-1-benzyl-2-hydroxy-3-[(3-methoxybenzyl)amino]propylamino)(hydroxy)methyl]-N,N-dipropylbenzamide	1W51
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with nvp-aur200	1YM2_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with nvp-amk640	1YM4_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with inhibitor	2B8L_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with l- l000430,469	2B8V_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with axq093, a macrocyclic inhibitor	2F3E_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with bdf488, a macrocyclic inhibitor	2F3F_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with inhibitor	2HIZ_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with inhibitor	2IRZ_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with inhibitor	2IS0_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with inhibitor	2NTR_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with inhibitor	2OAH_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with isophthalamide s2 hydroxyethylamine inhibitor	2P83_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with inhibitor	2P8H_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with inhibitor	2PH6_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with inhibitor	2PH8_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with compound 1	2Q11_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with compound 3a	2Q15_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with compound 1	2QU2_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with compound 2	2QU3_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with i21	2QZK_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with ixs	2QZL_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	human bace-1 in complex with n-((1s,2r)-1-benzyl-2-hydroxy-3-((1,1,5- trimethylhexyl)amino)propyl)-3-(ethylamino)-5-(2-oxopyrrolidin-1-yl) benzamide	2VIE_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with 3-(1,1-dioxidotetrahydro-2h-1,2-thiazin- 2-yl)-5-(ethylamino)-n-((1s,2r)-2-hydroxy-1-(phenylmethyl)-3-(1,2,3, 4- tetrahydro-1-naphthalenylamino)propyl)benzamide	2VIJ_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with n-((1s,2r)-3-(((1s)-2-(cyclohexylamino)- 1-methyl-2-oxoethyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-3- (pentylsulfonyl)benzamide	2VIY_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with n-((1s,2r)-3-(((1s)-2-(cyclohexylamino)- 1-methyl-2-oxoethyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-3-(2- oxo- 1-pyrrolidinyl)-5-(propyloxy)benzamide	2VIZ_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with n-((1s,2r)-3-(((1s)-2-(cyclohexylamino)- 1-methyl-2-oxoethyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-3- (ethylamino)-5-(2-oxo-1-pyrrolidinyl)benzamide	2VJ6_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	human bace-1 in complex with 3-(ethylamino)-n-((1s,2r)-2-hydroxy-1- (phenylmethyl)-3-(((3-(trifluoromethyl)phenyl)methyl)amino)propyl)-5-(2-oxo-1-pyrrolidinyl)benzamide	2VJ7_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	human bace-1 in complex with n-((1s,2r)-3-(cyclohexylamino)-2-hydroxy-1-(phenylmethyl)propyl)-3-(ethylamino)-5-(2-oxo-1-pyrrolidinyl) benzamide	2VJ9_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	human bace-1 in complex with 3-(1,1-dioxidotetrahydro-2h-1,2-thiazin- 2-yl)-5-(ethylamino)-n-((1s,2r)-2-hydroxy-1-(phenylmethyl)-3-(((3- (trifluoromethyl)phenyl)methyl)amino)propyl)benzamide	2VNM_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	human bace-1 in complex with 7-ethyl-n-((1s,2r)-2-hydroxy-1- (phenylmethyl)-3-(((3-(trifluoromethyl)phenyl)methyl)amino)propyl)-1-methyl-3,4-dihydro-1h-(1,2,5)thiadiazepino(3,4,5-hi)indole-9- carboxamide 2,2-dioxide	2VNN_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	human bace-1 in complex with 1-ethyl-n-((1s,2r)-2-hydroxy-3-(((3- (methyloxy)phenyl)methyl)amino)-1-(phenylmethyl)propyl)-4-(2-oxo-1- pyrrolidinyl)-1h-indole-6-carboxamide	2WEZ_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	human bace-1 in complex with 4-ethyl-n-((1s,2r)-2-hydroxy-1- (phenylmethyl)-3-(((3-(trifluoromethyl)phenyl)methyl)amino)propyl)-8-(2-oxo-1-pyrrolidinyl)-6-quinolinecarboxamide	2WF0_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	human bace-1 in complex with 7-ethyl-n-((1s,2r)-2-hydroxy-3-(((3- (methyloxy)phenyl(methyl)amino)-1-(phenylmethyl)propyl)-1-methyl-3,4-dihydro-1h-(1,2,5)thiadiazepino(3,4,5-hi)indole-9-carboxamide 2,2- dioxide	2WF1_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	human bace-1 in complex with 8-ethyl-n-((1s,2r)-2-hydroxy-3-(((3- (methyloxy)phenyl)methyl)amino)-1-(phenylmethyl)propyl)-1-methyl-3,4,7, 8-tetrahydro-1h,6h-(1,2,5)thiadiazepino(5,4,3-de)quinoxaline-10- carboxamide 2,2-dioxide	2WF2_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	human bace-1 in complex with 6-(ethylamino)-n-((1s,2r)-2-hydroxy-3- (((3-(methyloxy)phenyl)methyl)amino)-1-(phenylmethyl)propyl)-1- methyl-1, 3,4,5-tetrahydro-2,1-benzothiazepine-8-carboxamide 2,2- dioxide	2WF3_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	human bace-1 in complex with 6-ethyl-1-methyl-n-((1s)-2-oxo-1- (phenylmethyl)-3-(tetrahydro-2h-pyran-4-ylamino)propyl)-1,3,4,6- tetrahydro(1,2)thiazepino(5,4,3-cd)indole-8-carboxamide 2,2-dioxide	2WF4_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	human bace-1 in complex with n-((1s,2r)-3-(((1s)-2-(cyclohexylamino)- 1-methyl-2-oxoethyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-3- ((methylsulfonyl)(phenyl)amino)benzamide	2XFI_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	human bace-1 in complex with n-((1s,2r)-3-(((1s)-2-(cyclohexylamino)- 1-methyl-2-oxoethyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-3- (ethylamino)-5-(2-oxo-1-pyrrolidinyl)benzamide	2XFJ_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	human bace-1 in complex with n-((1s,2r)-3-(((1s)-2-(cyclohexylamino)- 1-methyl-2-oxoethyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-3- (ethylamino)-5-((methylsulfonyl)(phenyl)amino)benzamide	2XFK_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with compound 3.b.10	2ZDZ_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with compound 6g	2ZE1_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with inhibitor OM99-2 at pH 5.0	2ZHR
AA	A01.004	BACE1 g.p. (Homo sapiens)	at pH 4.0	2ZHS
AA	A01.004	BACE1 g.p. (Homo sapiens)	at pH 4.5	2ZHT
AA	A01.004	BACE1 g.p. (Homo sapiens)	at pH 5.0	2ZHU
AA	A01.004	BACE1 g.p. (Homo sapiens)	at pH 7.0	2ZHV
AA	A01.004	BACE1 g.p. (Homo sapiens)	catalytic domain; complex with 4-(4-fluoro-benzyl)-piperazine-2-carboxylic acid(3-mercapto-propyl)-amide	2ZJK_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	catalytic domain; complex with n-[1-(5-chloro-2-isopropoxy-3-methoxy-benzyl)- piperidin-4-yl]-2-(4-sulfamoyl-phenoxy)-acetamide	2ZJM_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	catalytic domain; complex with n-[1-(5-chloro-2-isopropoxy-3-methoxy-benzyl)- piperidin-4-yl]-2-(2-methyl-4-sulfamoyl-phenoxy)-acetamide	2ZJN_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with compound 1	3BRA_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with compound 2	3BUF_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with compound 3	3BUG_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with compound 4	3BUH_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with statine-based inhibitor	3DM6_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with nvp-afj144	3DUY_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with nvp-arv999	3DV1_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with nvp-bav544	3DV5_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with inhibitor	3EXO_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with spiropiperdine iminohydantoin inhibitor	3FKT_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	discovery of aminoheterocycles as a novel beta-secretase inhibitor class	3H0B_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with ev0	3HVG_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with ligand ev2	3HW1_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	potent beta-secretase 1 hydroxyethylene inhibitor	3I25_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with compound 3	3IGB_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with compound 30	3IN3_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with compound 38	3IN4_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with the aminohydantoin compound 29	3IND_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with the aminohydantoin compound s-34	3INE_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with the aminohydantoin compound 37	3INF_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with the aminohydantoin compound r-58	3INH_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	potent beta-secretase 1 inhibitor	3IXK_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	human bace-1 complex with nb-216	3K5C_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with ahm178	3K5D_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	human bace-1 complex with ayh011	3K5F_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	human bace-1 complex with bjc060	3K5G_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with a norstatine type inhibitor	3KYR_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with the aminopyridine compound 44	3L38_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with the aminopyridine compound 32	3L3A_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with sch589432	3L58_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with sch710413	3L59_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with sch713601	3L5B_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with sch723871	3L5C_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with sch723873	3L5D_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with sch736062	3L5E_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with sch736201	3L5F_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with the aminohydantoin compound 4g	3LHG_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with sch745132	3LPI_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with sch743641	3LPJ_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with sch747123	3LPK_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with inhibitor	3MSJ_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	fragment based discovery and optimisation of bace-1 inhibitors	3MSK_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	fragment based discovery and optimisation of bace-1 inhibitors	3MSL_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with bms-655295 aka n~3~-((1s,2r)-1- benzyl-2-hydroxy-3-((3- methoxybenzyl)amino)propyl)-n~1~, n~1~-dibutyl-1h-indole-1,3- dicarboxamide	3OHF_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with bms-681889 aka n~1~-butyl-5-cyano- n~3~-((1s,2r)-1-(3,5- difluorobenzyl)-2-hydroxy-3-((3- methoxybenzyl)amino)propyl)-n~1~- methyl-1h-indole-1,3- dicarboxamide	3OHH_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with the aminohydantoin compound 102	3OOZ_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with bfg356	3PI5_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	structure based design, synthesis and sar of cyclic hydroxyethylamine (hea) bace-1 inhibitors	3QBH_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	design and synthesis of hydroxyethylamine (hea) bace-1 inhibitors: prime side chromane-containing inhibitors	3QI1_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with bms-693391 aka (2s)-2-((3r)-3-acetamido-3-isobutyl-2-oxo-1- pyrrolidinyl)-n-((1s,2r)-1-(3,5-difluorobenzyl)-2-hydroxy-2-((2r,4r)-4-propoxy-2-pyrrolidinyl)ethyl)-4-phenylbutanamide	3R2F_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with 3-(2- aminoquinolin-3-yl)-n-(cyclohexylmethyl)propanamide	3RU1_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with 2-((2-amino-6-o- tolylquinolin-3-yl)methyl)-n-(cyclohexylmethyl)pentanamide	3RVI_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	fragment based discovery and optimisation of bace-1 inhibitors	3S2O_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	pyrazolyl and thienyl aminohydantoins as potent bace1 inhibitors	3S7L_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	pyrazolyl and thienyl aminohydantoins as potent bace1 inhibitors	3S7M_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with (2s)-2-((3s)-3-(acetylamino)-3-(butan-2-yl)-2-oxopyrrolidin-1- yl)-n-((2s,3r)-3-hydroxy-4-((3-methoxybenzyl)amino)-1-phenylbutan-2- yl)-4-phenylbutanamide	3SKF_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with (2s)-2-((3r)-3-acetamido-3-isobutyl-2-oxo-1-pyrrolidinyl)-n- ((1s,2r)-1-(3,5-difluorobenzyl)-2-hydroxy-2-(1,2,3,4-tetrahydro-3- isoquinolinyl)ethyl)-4-phenylbutanamide	3SKG_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	apo form	3TPJ_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	apo form	3TPL_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with an inhibitor	3TPP_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with an inhibitor	3TPR_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	rational design and synthesis of aminopiperazinones as beta secretase (bace) inhibitors	3U6A_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with an inhibitor	3UQP_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with an inhibitor	3UQR_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with an inhibitor	3UQU_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with an inhibitor	3UQW_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with an inhibitor	3UQX_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with nvp-avi326	3VEU_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with nvp-bqq711	3VF3_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with nvp-bur436, derived from a soaking experiment	3VG1_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with 2-amino-3-methyl-6-((1s, 2r)-2-phenylcyclopropyl)pyrimidin-4(3h)-one	3VV6_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with 2-amino-3,6- dimethyl-6-(2-phenylethyl)-3,4,5,6-tetrahydropyrimidin-4-one	3WB4_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with (6s)-2-amino-3,6- dimethyl-6-[(1r,2r)-2-phenylcyclopropyl]-3,4,5,6-tetrahydropyrimidin-4-one	3WB5_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with chemical ligand	3ZMG_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with chemical ligand	3ZOV_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with compound 14	4ACU_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with compound 23	4ACX_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	design and synthesis of bace1 inhibitors with in vivo brain reduction of beta-amyloid peptides (compound 10)	4AZY_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	design and synthesis of bace1 inhibitors with in vivo brain reduction of beta-amyloid peptides (compound (r)-41)	4B00_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with azd3839	4B05_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	new aminoimidazoles as bace-1 inhibitors: from rational design to ab- lowering in brain	4B1C_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	aminoimidazoles as bace-1 inhibitors: from de novo design to ab-lowering in brain	4B70_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	aminoimidazoles as bace-1 inhibitors: from de novo design to ab-lowering in brain	4B72_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	aminoimidazoles as bace-1 inhibitors: from de novo design to ab-lowering in brain	4B77_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	aminoimidazoles as bace-1 inhibitors: from de novo design to ab-lowering in brain	4B78_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with chemical ligand	4BEK_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with chemical ligand	4BFD_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with nvp-bur436, derived from a co-crystallization experiment	4D83_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with nvp-bvi151	4D85_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with nvp-bxq490	4D88_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with nvp-bxd552, derived from a soaking experiment	4D89_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with nvp-bxd552, derived from a co-crystallization experiment	4D8C_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with hydroxyethylamine inhibitor37	4DI2_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with 2-imino-3-methyl-5,5-diphenylimidazolidin- 4-one	4DJU_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with 2-imino-3-methyl-5-phenyl-5-(3-(pyridin-3- yl)phenyl)imidazolidin-4-one	4DJW_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with 5-(3-(5-chloropyridin-3-yl)phenyl)-5- cyclopropyl-2-imino-3-methylimidazolidin-4-one	4DJX_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with (r)-5-cyclopropyl-2-imino-3-methyl-5-(3-(5-(prop-1-yn-1-yl)pyridin-3-yl)phenyl)imidazolidin-4-one	4DJY_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with a hea-macrocyclic type inhibitor	4DPF_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with hea-macrocyclic inhibitor, mv078512	4DPI_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with an inhibitor	4DV9_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with an inhibitor	4DVF_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	design and synthesis of potent hydroxyethylamine (hea) bace-1 inhibitors	4EWO_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	design and synthesis of potent hydroxyethylamine (hea) bace-1 inhibitors	4EXG_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with an inhibitor	4FCO_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with an inhibitor	4FGX_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with compound 14g	4FM7_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with compound 12a	4FM8_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with biarylspiro aminooxazoline 6	4FRI_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with aminooxazoline xanthene 9l	4FRJ_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with aminooxazoline xanthene 11a	4FRK_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with (s)-4-(3-chloro-5-(5-(prop-1-yn-1- yl)pyridin-3-yl)thiophen-2-yl)-1,4-dimethyl-6-oxotetrahydropyrimidin-2(1h)-iminium	4FRS_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with n-(n-(4-amino-3,5- dichlorobenzyl)carbamimidoyl)-3-(4- methoxyphenyl)-5- methyl-4-isothiazolecarboxamide	4FSE_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	bace-db-mutant; complex with n-(n-(4- acetamido-3-chloro-5-methylbenzyl) carbamimidoyl)-3-(4- methoxyphenyl)-5-methyl-4-isothiazolecarboxamide	4FSL_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with inhibitor	4GID_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with hea-type macrocyclic inhibitor, mv078571	4GMI_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with (7ar)-6-benzoyl-7a-(4-(3-cyanophenyl) thiophen-2-yl)-3-methyl-4-oxohexahydro-1h-pyrrolo[3,4-d]pyrimidin- 2(3h)-iminium	4H1E_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with 3-(5-((7ar)-2-imino-6-(6-methoxypyridin-2- yl)-3-methyl-4-oxooctahydro-1h-pyrrolo[3,4-d]pyrimidin-7a-yl) thiophen-3-yl)benzonitrile	4H3F_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with 2-((7ar)-7a-(4-(3-cyanophenyl)thiophen-2- yl)-2-imino-3-methyl-4-oxohexahydro-1h-pyrrolo[3,4-d]pyrimidin-6(2h)-yl)nicotinonitrile	4H3G_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with 3-(5-((7ar)-2-imino-6-(3-methoxypyridin-2- yl)-3-methyl-4-oxooctahydro-1h-pyrrolo[3,4-d]pyrimidin-7a-yl) thiophen-3-yl)benzonitrile	4H3I_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with 2-fluoro-5-(5-(2-imino-3-methyl-4-oxo-6- phenyloctahydro-1h-pyrrolo[3,4-d]pyrimidin-7a-yl)thiophen-2-yl) benzonitrile	4H3J_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with (s)-3-(5-(2-imino-1,4-dimethyl-6- oxohexahydropyrimidin-4-yl)thiophen-3-yl)benzonitrile	4HA5_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	structure-based design of novel dihydroisoquinoline bace-1 inhibitors that do not engage the catalytic aspartates	4HZT_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	design and synthesis of thiophene dihydroisoquinolins as novel bace-1 inhibitors *caveat 4i0d a his 423 ca has chirality not corresponding to the amino *caveat 2 4i0d acid definition. some close contacts	4I0D_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	design and synthesis of thiophene dihydroisoquinolins as novel bace-1 inhibitors ***caveat 4i0e several close contacts	4I0E_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	design and synthesis of thiophene dihydroisoquinolins as novel bace-1 inhibitors	4I0F_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	design and synthesis of thiophene dihydroisoquinolins as novel bace-1 inhibitors ***caveat 4i0g few water molecules are involved in close contacts	4I0G_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	spr and structural analysis yield insight towards mechanism of inhibition of bace inhibitors.	4I0H_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	spr and structural analysis yield insight towards mechanism of inhibition of bace inhibitors	4I0I_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	spr and structural analysis yield insight towards mechanism of inhibition of bace inhibitors	4I0J_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	structure-based design of novel dihydroisoquinoline bace-1 inhibitors that do not engage the catalytic aspartates	4I0Z_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	structure-based design of novel dihydroisoquinoline bace-1 inhibitors that do not engage the catalytic aspartates	4I10_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	structure-based design of novel dihydroisoquinoline bace-1 inhibitors that do not engage the catalytic aspartates.	4I11_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	design and synthesis of thiophene dihydroisoquinolins as novel bace-1 inhibitors	4I12_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	design and synthesis of thiophene dihydroisoquinolins as novel bace-1 inhibitors	4I1C_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with an inhibitor	4IVS_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with an inhibitor	4IVT_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with 5-cyano-pyridine-2- carboxylic acid [3-((s)-2-amino-4-methyl-5,6-dihydro-4h-[1,3]oxazin- 4-yl)-4-fluoro-phenyl]-amide	4J0P_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with 5-ethoxy-pyridine-2- carboxylic acid [3-((r)-2-amino-5,5-difluoro-4-methyl-5,6-dihydro-4h-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide	4J0T_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with 5-cyano-pyridine-2- carboxylic acid [3-((4r,5r)-2-amino-5-fluoro-4-methyl-5,6-dihydro-4h-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide	4J0V_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with 5-cyano-pyridine-2- carboxylic acid [3-((4r,5s)-2-amino-5-fluoro-4-methyl-5,6-dihydro-4h-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide	4J0Y_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with 5-cyano-pyridine-2- carboxylic acid [3-((4s,5r)-2-amino-5-fluoro-4-fluoromethyl-5,6- dihydro-4h-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide	4J0Z_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with 5-cyano-pyridine-2- carboxylic acid [3-((s)-2-amino-4-difluoromethyl-5,6-dihydro-4h-[1, 3]oxazin-4-yl)-4-fluoro-phenyl]-amide	4J17_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with 5-cyano-pyridine-2- carboxylic acid [3-((s)-2-amino-5,5-difluoro-4-fluoromethyl-5,6- dihydro-4h-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide	4J1C_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with 5-cyano-pyridine-2- carboxylic acid [3-((4s,6s)-2-amino-4-fluoromethyl-6-trifluoromethyl-5,6-dihydro-4h-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide	4J1E_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with 5-cyano-pyridine-2- carboxylic acid [3-((4s,6s)-2-amino-4-methyl-6-trifluoromethyl-5,6- dihydro-4h-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide	4J1F_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with 5-cyano-pyridine-2- carboxylic acid [3-((4s,6r)-2-amino-4-methyl-6-trifluoromethyl-5,6- dihydro-4h-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide	4J1H_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with 5-cyano-pyridine-2- carboxylic acid [3-((4r,5r,6r)-2-amino-5-fluoro-4-methyl-6- trifluoromethyl-5,6-dihydro-4h-[1,3]oxazin-4-yl)-4-fluoro-phenyl]- amide	4J1I_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with 5-cyano-pyridine-2- carboxylic acid [3-((4r,5r,6s)-2-amino-5-fluoro-4-methyl-6- trifluoromethyl-5,6-dihydro-4h-[1,3]oxazin-4-yl)-4-fluoro-phenyl]- amide	4J1K_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	spirocyclic beta-site amyloid precursor protein cleaving enzyme 1 (bace1) inhibitors	4JOO_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	spirocyclic beta-site amyloid precursor protein cleaving enzyme 1 (bace1) inhibitors	4JP9_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	spirocyclic beta-site amyloid precursor protein cleaving enzyme 1 (bace1) inhibitors	4JPC_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	spirocyclic beta-site amyloid precursor protein cleaving enzyme 1 (bace1) inhibitors	4JPE_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	hydroxyethylamine-based inhibitors of bace1: p1-p3 macrocyclization can improve potency, selectivity, and cell activity	4K8S_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with inhibitor	4K9H_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with hydroxyethylamine- macrocyclic inhibitor 13	4KE0_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with hydroxyethylamine- macrocyclic inhibitor 19	4KE1_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	diethylaminosulfur trifluoride-mediated intramolecular cyclization of 2-hydroxy-benzylureas to fused bicyclic aminooxazoline compounds and evaluation of their biochemical activity against beta-secretase-1 (bace1)	4L7G_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	diethylaminosulfur trifluoride-mediated intramolecular cyclization of 2-hydroxy-benzylureas to fused bicyclic aminooxazoline compounds and evaluation of their biochemical activity against beta-secretase-1 (bace-1)	4L7H_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	diethylaminosulfur trifluoride-mediated intramolecular cyclization of 2-hydroxy-benzylureas to fused bicyclic aminooxazoline compounds and evaluation of their biochemical activity against beta-secretase-1 (bace-1)	4L7J_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	aminooxazoline inhibitor of bace-1	4LC7_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with compound 11a	4LXA_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with compound 11d	4LXK_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with compound 12a	4LXM_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	discovery of 7-thp chromans: bace1 inhibitors that reduce a-beta in the cns	4N00_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	synthesis, characterization and pk/pd studies of a series of spirocyclic pyranochromene bace1 inhibitors	4PZW_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	synthesis, characterization and pk/pd studies of a series of spirocyclic pyranochromene bace1 inhibitors	4PZX_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	8-tetrahydropyran-2-yl chromans: highly selective beta-site amyloid precursor protein cleaving enzyme 1 (bace1) inhibitors	4R5N_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with (r)-4-(2-cyclohexylethyl)-4-(((r)-1-(2- cyclopentylacetyl)pyrrolidin-3-yl)methyl)-1-methyl-5-oxoimidazolidin-2-iminium	4R8Y_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with (r)-4-(2-cyclohexylethyl)-4-(((1s,3r)-3- (cyclopentylamino)cyclohexyl)methyl)-1-methyl-5-oxoimidazolidin-2- iminium	4R91_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with (r)-4-(2-cyclohexylethyl)-4-(((1s,3r)-3- (isonicotinamido)cyclohexyl)methyl)-1-methyl-5-oxoimidazolidin-2- iminium	4R92_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with (r)-4-(2-cyclohexylethyl)-1-methyl-5-oxo-4- (((1s,3r)-3-(3-phenylureido)cyclohexyl)methyl)imidazolidin-2-iminium	4R93_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with 2-(((1r,3s)-3-(((r)-4-(2-cyclohexylethyl)-2- iminio-1-methyl-5-oxoimidazolidin-4-yl)methyl)cyclohexyl)amino) quinolin-1-ium	4R95_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with a 2-aminooxazoline 4- azaxanthene inhibitor	4RCD_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with aminooxazoline xanthene inhibitor 2	4RCE_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with 2-aminooxazoline 4- fluoroxanthene inhibitor 49	4RCF_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	8-tetrahydropyran-2-yl chromans: highly selective beta-site amyloid precursor protein cleaving enzyme 1 (bace1) inhibitors	4RRN_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	8-tetrahydropyran-2-yl chromans: highly selective beta-site amyloid precursor protein cleaving enzyme 1 (bace1) inhibitors	4RRO_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	8-tetrahydropyran-2-yl chromans: highly selective beta-site amyloid precursor protein cleaving enzyme 1 (bace1) inhibitors	4RRS_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with a syn-hea-type inhibitor	4TRW_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with a hea-type inhibitor	4TRY_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with 2-thiophenyl hea-type inhibitor	4TRZ_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with 2-aminooxazoline 3-aza-4- fluoro-xanthene inhibitor 22	4WTU_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with compound 24b	4WY1_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with compound 36	4WY6_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with compound 6	4X2L_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with amino thiazine inhibitor ly2886721	4X7I_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with 2-aminooxazoline 3- azaxanthene inhibitor 28	4XKX_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with a pyrazole-substituted tetrahydropyranthioamidine	4XXS_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with amino thiazine inhibitor ly2811376	4YBI_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with 4-(cyclohexylamino)-1-(3-fluorophenyl)-8-(3- isopropoxybenzyl)-1,3,8-triazaspiro[4.5]dec-3-en-2-one	4ZPE_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with 8-(3-((1-aminopropan-2-yl)oxy)benzyl)-4- (cyclohexylamino)-1-(3-fluorophenyl)-1,3,8-triazaspiro[4.5]dec-3-en- 2-one	4ZPF_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with 8-benzyl-4-(cyclohexylamino)-1-(3-fluorophenyl)-7-methyl-1,3,8-triazaspiro[4.5]dec-3-en-2-one	4ZPG_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with bicyclic aminothiazine fragment	4ZSM_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with bicyclic aminothiazine inhibitor	4ZSP_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with tricyclic aminothiazine inhibitor	4ZSQ_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with tricyclic aminothiazine inhibitor	4ZSR_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	1,4-oxazine bace1 inhibitors	5CLM_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with compound 0211	5DQC_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with compound 18	5ENK_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with compound 10	5ENM_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with (1r,2r)-2-[(r)-2-amino-4-(4-difluoromethoxy-phenyl)-4,5-dihydro-oxazol-4-yl]-cyclopropyl-(5- chloro-pyridin-3-yl)-methanone	5EZX_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with (4s)-4-[3-(5-chloro-3- pyridyl)phenyl]-4-[4-(difluoromethoxy)-3-methyl-phenyl]-5h-oxazol-2- amine	5EZZ_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with 5-[3-[(3-chloro-8- quinolyl)amino]phenyl]-5-methyl-2,6-dihydro-1,4-oxazin-3-amine	5F00_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with (1sr,2sr)-2-((r)-2-amino- 5,5-difluoro-4-methyl-5,6-dihydro-4h-1,3-oxazin-4-yl)-n-(3- chloroquinolin-8-yl)cyclopropanecarboxamide	5F01_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with (7ar)-7a-(4-(3-cyanophenyl)thiophen-2-yl)-6-(5-fluoropyrimidin-2-yl)-3-methyl-4-oxooctahydro-2h-pyrrolo[3,4- d]pyrimidin-2-iminium	5HD0_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with (7ar)-7a-(4-(3-cyanophenyl)thiophen-2-yl)-6-(5- fluoro-4-methoxypyrimidin-2-yl)-3-methyl-4-oxooctahydro-2h-pyrrolo[3,4-d]pyrimidin-2-iminium	5HDU_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with (7ar)-7a-(5-cyanothiophen-2-yl)-6-(5-fluoro-4- methoxy-6-methylpyrimidin-2-yl)-3-methyl-4-oxooctahydro-2h-pyrrolo[3,4-d]pyrimidin-2-iminium	5HDV_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with (7ar)-7a-(5-cyanothiophen-2-yl)-6-(4-ethoxy-5- fluoro-6-methylpyrimidin-2-yl)-3-methyl-4-oxooctahydro-2h-pyrrolo[3, 4-d]pyrimidin-2-iminium	5HDX_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with (7ar)-7a-(5-cyanothiophen-2-yl)-6-(5-fluoro-4- methyl-6-(methylthio)pyrimidin-2-yl)-3-methyl-4-oxooctahydro-2h- pyrrolo[3,4-d]pyrimidin-2-iminium	5HDZ_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with (4ar,7as)-7a-(2,6-difluorophenyl)-6-(5-fluoro- 4-methoxy-6-methylpyrimidin-2-yl)-3-methyl-4-oxooctahydro-2h- pyrrolo[3,4-d]pyrimidin-2-iminium	5HE4_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with (7ar)-7a-(5-cyanothiophen-2-yl)-6-(5-fluoro-4- methyl-6-(methylamino)pyrimidin-2-yl)-3-methyl-4-oxooctahydro-2h- pyrrolo[3,4-d]pyrimidin-2-iminium	5HE5_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with (4ar,7as)-7a-(2,4-difluorophenyl)-6-(5-fluoro- 4-methoxy-6-methylpyrimidin-2-yl)-2-imino-3-methyloctahydro-4h- pyrrolo[3,4-d]pyrimidin-4-one	5HE7_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with (s)-5-(3-chloro-5-(5-(prop-1-yn-1-yl)pyridin-3- yl)thiophen-2-yl)-2,5-dimethyl-1,2,4-thiadiazinan-3-iminium 1,1- dioxide	5HTZ_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with 4-(3-(furan-2-carboxamido)phenyl)-1-methyl-5- oxo-4-phenylimidazolidin-2-iminium	5HU0_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with (r)-n-(3-(3-amino-2,5-dimethyl-1,1-dioxido-5,6- dihydro-2h-1,2,4-thiadiazin-5-yl)-4-fluorophenyl)-5- fluoropicolinamide	5HU1_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with aminoquinoline compound 1	5I3V_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with 2-aminooxazoline-3- azaxanthene inhibitor 2	5I3W_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with aminoquinoline inhibitor 6	5I3X_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with aminoquinoline inhibitor 9	5I3Y_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with 3-(2-amino-6-(o-tolyl) quinolin-3-yl)-n-(3,3-dimethylbutyl)propanamide	5IE1_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	(4~s,6~s)-4-[2,4-bis(fluoranyl)phenyl]-4-methyl-6-pyrimidin-5-yl- 5,6-dihydro-1,3-thiazin-2-amine (compound 12) bound to bace1	5KQF_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	(4~s,6~s)-4-[2,4-bis(fluoranyl)phenyl]-6-(3,5-dimethyl-1,2-oxazol-4-yl)-4-methyl-5,6-dihydro-1,3-thiazin-2-amine (compound 5) bound to bace1	5KR8_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with active site inhibitor GRL-8234 and exosite peptide	5MCO_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with active site and exosite binding peptide inhibitor	5MCQ_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with ligand 32397778	5MXD_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	aminomethyl-derived beta secretase (bace1) inhibitors: engaging gly230without an anilide functionality	5T1U_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	aminomethyl-derived beta secretase (bace1) inhibitors: engaging gly230without an anilide functionality	5T1W_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with n-(3-((4as,7as)-2-amino-4,4a,5,6-tetrahydro-7ah-furo[2,3-d][1, 3]thiazin-7a-yl)-4-fluorophenyl)-5-bromo-2-pyridinecarboxamide	5TOL_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with 2-aminooxazoline-3- azaxanthene compound 12	5UYU_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with inhibitor 5g	5V0N_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with n-(3-((4r,5r,6s)-2-amino-6-(1,1- difluoroethyl)-5-fluoro-4-methyl-5,6-dihydro-4h-1,3-oxazin-4-yl)-4- fluorophenyl)-5-(fluoromethoxy)pyrazine-2-carboxamide	5YGX_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with (s)-n-(3-(2-amino-6- (fluoromethyl)-4 -methyl-4h-1,3-oxazin-4-yl)-4-fluorophenyl)-5- cyanopicolinamide	5YGY_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with hydroxy pyrrolidine inhibitor	6BFD_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with hydroxy pyrrolidine inhibitor	6BFE_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with hydroxy morpholine inhibitor	6BFW_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with hydroxy pyrrolidine inhibitor	6BFX_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with : n-(3-((1r,5s, 6r)-3-amino-5-methyl-2-oxa-4-azabicyclo[4.1.0]hept-3-en-5-yl)-4- fluorophenyl)-5-methoxypyrazine-2-carboxamide	6C2I_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with a bicyclic isoxazoline carboxamide as the p3 ligand	6DHC_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with a multiconformer ligand 5t5	6DMI_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with compound 28	6EJ2_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with B7T ((1r,4r)-4-methoxy-6'-(5-methyl-3-pyridinyl)-3'H-dispiro[cyclohexane-1,2'-indene-1',4''-[1,3]oxazol]-2''-amine)	6EJ3_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with cnp520	6EQM_A
AA	A01.004	BACE1 g.p. (Homo sapiens)	complex with amino-1,4-oxazine compound 4	6FGY_A
AA	A01.006	chymosin	recombinant	1CMS
AA	A01.006	chymosin	complex with inhibitor CP-113972	1CZI
AA	A01.006	chymosin	Val111Phe mutant	3CMS
AA	A01.006	chymosin		4AA8
AA	A01.006	chymosin	complex with pepstatin	4AUC
AA	A01.006	chymosin		4CMS
AA	A01.006	chymosin	camel chymosin at 1.6a resolution	4AA9_A
AA	A01.007	renin	recombinant glycosylated form	1BBS
AA	A01.007	renin	complex with butanediamide inhibitor BILA 1908	1BIL
AA	A01.007	renin	complex with butanediamide inhibitor BILA 2151	1BIM
AA	A01.007	renin	complex with polyhydroxymonoamide inhibitor BILA 980	1HRN
AA	A01.007	renin	complex with CGP 38,560	1RNE
AA	A01.007	renin	complex with PF00074777	2BKS_A
AA	A01.007	renin	complex with PF00257567	2BKT_A
AA	A01.007	renin	ketopiperazine-based renin inhibitors: optimization of the c ring	2FS4_A
AA	A01.007	renin	ketopiperazine-based renin inhibitors: optimization of the "c" ring	2G1N_A
AA	A01.007	renin	ketopiperazine-based renin inhibitors: optimization of the "c" ring	2G1O_A
AA	A01.007	renin	ketopiperazine-based renin inhibitors: optimization of the c ring	2G1R_A
AA	A01.007	renin	ketopiperazine-based renin inhibitors: optimization of the c ring	2G1S_A
AA	A01.007	renin	ketopiperazine-based renin inhibitors: optimization of the "c" ring	2G1Y_A
AA	A01.007	renin	ketopiperazine-based renin inhibitors: optimization of the c ring	2G20_A
AA	A01.007	renin	ketopiperazine-based renin inhibitors: optimization of the "c" ring	2G21_A
AA	A01.007	renin	ketopiperazine-based renin inhibitors: optimization of the "c" ring	2G22_A
AA	A01.007	renin	ketopiperazine-based renin inhibitors: optimization of the "c" ring	2G24_A
AA	A01.007	renin	ketopiperazine-based renin inhibitors: optimization of the "c" ring	2G26_A
AA	A01.007	renin	ketopiperazine-based renin inhibitors: optimization of the "c" ring	2G27_A
AA	A01.007	renin	complex with PF02342674	2I4Q_A
AA	A01.007	renin	complex with 5-4-[(3,5-difluorobenzyl)amino]phenyl-6-ethylpyrimidine-2,4-diamine	2IKO_A
AA	A01.007	renin	complex with 6-ethyl-5-[(2S)-1-(3-methoxypropyl)-2-phenyl-1,2,3,4-tetrahydroquinolin-7-yl]pyrimidine-2,4-diamine	2IKU_A
AA	A01.007	renin	complex with N-[2-(2-amino-6-ethyl-5-[4-(3-methoxypropyl)-2,2-dimethyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl]pyrimidin-4-ylamino)ethyl]naphthalene-2-sulfonamide	2IL2_A
AA	A01.007	renin	recombinant	2REN
AA	A01.007	renin	complex with inhibitor 10 (aliskiren)	2V0Z_C
AA	A01.007	renin	complex with inhibitor 9 ((2R,4S,5S,7S)-5-amino-N-butyl-4-hydroxy-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-2,8-dimethylnonanamide)	2V10_C
AA	A01.007	renin	complex with inhibitor 6 ((2S,4S,5R,7R)-4-amino-8-(butylamino)-5-hydroxy-2,7-dimethyl-8-oxooctyl 1-benzyl-1H-indole-3-carboxylate)	2V11_C
AA	A01.007	renin	complex with inhibitor 8 (N-[(2S,4S,5S,7R)-4-amino-8-(butylamino)-5-hydroxy-7-methyl-2-(1-methylethyl)-8-oxooctyl]-2-(3-methoxypropoxy)benzamide)	2V12_C
AA	A01.007	renin	complex with inhibitor 7 (N-[(2R,4S,5S,7R)-4-amino-8-(butylamino)-5-hydroxy-2,7-dimethyl-8-oxooctyl]-2-(3-methoxypropoxy)benzamide)	2V13_A
AA	A01.007	renin	complex with inhibitor 3	2V16_A
AA	A01.007	renin	complex with inhibitor 3	2V16_C
AA	A01.007	renin	complex with human angiotensinogen	2X0B_A
AA	A01.007	renin	complex with remikiren	3D91
AA	A01.007	renin		3G6Z
AA	A01.007	renin		3G70
AA	A01.007	renin		3G72
AA	A01.007	renin		3GW5
AA	A01.007	renin		3K1W
AA	A01.007	renin		3KM4
AA	A01.007	renin		3O9L
AA	A01.007	renin		3OAD
AA	A01.007	renin	complex with piperidine inhibitor	3OAG
AA	A01.007	renin		3OOT
AA	A01.007	renin		3OQF
AA	A01.007	renin		3OQK
AA	A01.007	renin		3OWN
AA	A01.007	renin		3Q3T
AA	A01.007	renin		3Q4B
AA	A01.007	renin		3Q5H
AA	A01.007	renin		3SFC
AA	A01.007	renin		3VCM
AA	A01.007	renin		3VSW
AA	A01.007	renin		3VSX
AA	A01.007	renin		3VUC
AA	A01.007	renin		3VYD
AA	A01.007	renin		3VYE
AA	A01.007	renin		3VYF
AA	A01.007	renin		4AMT
AA	A01.007	renin		4GJ5
AA	A01.007	renin		4GJ6
AA	A01.007	renin		4GJ7
AA	A01.007	renin		4GJ8
AA	A01.007	renin		4GJ9
AA	A01.007	renin		4GJA
AA	A01.007	renin		4GJB
AA	A01.007	renin		4GJC
AA	A01.007	renin		4GJD
AA	A01.007	renin		4PYV
AA	A01.007	renin		4Q1N
AA	A01.007	renin		4RYC
AA	A01.007	renin		4RYG
AA	A01.007	renin		4RZ1
AA	A01.007	renin		4S1G
AA	A01.007	renin		4XX3
AA	A01.007	renin		4XX4
AA	A01.007	renin	discovery of tak-272: a novel, potent and orally active renin in- hibitor ***caveat 5koq nag b 401 has wrong chirality at atom c1	5KOQ_A
AA	A01.007	renin	discovery of tak-272: a novel, potent and orally active renin in- hibitor	5KOS_A
AA	A01.007	renin	discovery of tak-272: a novel, potent and orally active renin in- hibitor	5KOT_A
AA	A01.007	renin	structure-based design of a new series of n-piperidin-3-ylpyrimidine- 5-carboxamides as renin inhibitors	5SXN_A
AA	A01.007	renin	structure-based design of a new series of n-piperidin-3-ylpyrimidine- 5-carboxamides as renin inhibitors	5SY2_A
AA	A01.007	renin	structure-based design of a new series of n-piperidin-3-ylpyrimidine- 5-carboxamides as renin inhibitors	5SY3_A
AA	A01.007	renin	structure-based design of a new series of n-piperidin-3-ylpyrimidine- 5-carboxamides as renin inhibitors	5SZ9_A
AA	A01.007	renin	novel approach of fragment-based lead discovery applied to renin inhibitors	5T4S_A
AA	A01.007	renin	optimization of 3,5-disubstitued piperidine: discovery of non-peptide mimetics as an orally active renin inhibitor	5TMG_A
AA	A01.007	renin	optimization of 3,5-disubstitued piperidine: discovery of non-peptide mimetics as an orally active renin inhibitor	5TMK_A
AA	A01.007	renin	complex with a biphenylpipderidinylcarbinol	5V8V_A
AA	A01.007	renin	complex with a biphenylpipderidinylcarbinol	5VPM_A
AA	A01.007	renin	complex with a biphenylpipderidinylcarbinol	5VRP_A
AA	A01.007	renin	complex with human angiotensinogen	6I3F_B
AA	A01.008	renin-2	complex with inhibitor CH-66	1SMR_A
AA	A01.008	renin-2	precursor	5MLG_A
AA	A01.009	cathepsin D		1LYA
AA	A01.009	cathepsin D	complex with pepstatin	1LYB
AA	A01.009	cathepsin D	pH 7.5	1LYW_A
AA	A01.009	cathepsin D		4OBZ
AA	A01.009	cathepsin D		4OC6
AA	A01.009	cathepsin D		4OD9
AA	A01.010	cathepsin E	theoretical model	1LCG
AA	A01.010	cathepsin E	activation intermediate	1TZS
AA	A01.011	penicillopepsin	complex with isoval-Val-Val-Lysta-O-Et	1APT
AA	A01.011	penicillopepsin	complex with isoval-Val-Val-Sta-O-Et	1APU
AA	A01.011	penicillopepsin	complex with isoval-Val-Val-hydrated difluorostatone-N-methylamide	1APV
AA	A01.011	penicillopepsin	complex with isoval-Val-Val-difluorostatone-N-methylamide	1APW
AA	A01.011	penicillopepsin	complex with ethyl cyclo[(2S)-2-[[(1R)-1-(N-(l-N-(3-methylbutanoyl)valyl-L-aspartyl)amino)-3-methylbutyl]hydroxyphosphinyloxy]-3-(3-aminomethyl)phenylpropanoate	1BXO
AA	A01.011	penicillopepsin	complex with phosphonate inhibitor	1BXQ
AA	A01.011	penicillopepsin	complex with isoval-Val-Val-Sta(P)-O-Et	1PPK
AA	A01.011	penicillopepsin	complex with isoval-Val-Val-Leu(P)-O(Phe)-OME	1PPL
AA	A01.011	penicillopepsin	complex with CBZ-Ala-Ala-Leu(P)-(O)Phe-OME	1PPM
AA	A01.011	penicillopepsin	complex with phosphonate inhibitor methyl[cyclo-7[(2R)-((N-valyl)amino)-2-(hydroxyl-(1S)-1-methyloxycarbonyl-2-phenylethoxy)phosphinyloxy-ethyl]-1-naphthaleneacetamide]	2WEA
AA	A01.011	penicillopepsin	complex with phosphonate inhibitor methyl (2S)-[1-((N-formyl)-l-valyl)amino-2-(2-naphthyl)ethyl)hydroxyphosphinyloxy]-3-phenyl propanoate	2WEB
AA	A01.011	penicillopepsin	complex with phosphonate inhibitor methyl (2S)-[1-((N-(naphthaleneacetyl))-L-valyl)aminomethyl)hydroxyphosphinyloxy]-3-phenyl propanoate	2WEC
AA	A01.011	penicillopepsin	complex with phosphonate macrocyclic inhibitor	2WED
AA	A01.011	penicillopepsin		3APP
AA	A01.012	rhizopuspepsin	pH 4.6	1UH7
AA	A01.012	rhizopuspepsin	pH 8.0	1UH8
AA	A01.012	rhizopuspepsin	pH 7.0	1UH9
AA	A01.012	rhizopuspepsin		2APR
AA	A01.012	rhizopuspepsin	complex with psi-(CH2-NH)-D-His-Pro-Phe-His-Phe-Phe-Val-Tyr	3APR
AA	A01.012	rhizopuspepsin	complex with a pepstatin-like renin inhibitor	4APR
AA	A01.012	rhizopuspepsin	complex with a pepstatin-like renin inhibitor	5APR
AA	A01.012	rhizopuspepsin	complex with pepstatin	6APR
AA	A01.013	mucorpepsin		2ASI
AA	A01.013	mucorpepsin	complex with pepstatin A	2RMP_A
AA	A01.013	mucorpepsin		1MPP
AA	A01.014	candidapepsin SAP1		2QZW
AA	A01.016	aspergillopepsin I		1IZD
AA	A01.016	aspergillopepsin I		1IZE
AA	A01.016	aspergillopepsin I		1IBQ_A
AA	A01.017	endothiapepsin	complex with inhibitor DB2	1E5O
AA	A01.017	endothiapepsin	complex with renin inhibitor Merck-KGAA-EMD56133	1E80
AA	A01.017	endothiapepsin	complex with renin inhibitor Merck-KGAA-EMD61395	1E81
AA	A01.017	endothiapepsin	complex with renin inhibitor Merck-KGAA-EMD59601	1E82
AA	A01.017	endothiapepsin	complex with cyclohexyl renin inhibitor PD125754	1EED
AA	A01.017	endothiapepsin	complex with inhibitor PD130328	1ENT
AA	A01.017	endothiapepsin	complex with PS1 (Pro-Leu-Glu-PSA-Arg-Leu)	1EPL
AA	A01.017	endothiapepsin	complex with PS2 (Thr-Phe-Gln-Ala-PSA-Leu-Arg-Glu)	1EPM
AA	A01.017	endothiapepsin	complex with CP-80,794 (MOR-Phe-Cys-CH3-NOR)	1EPN
AA	A01.017	endothiapepsin	complex with CP-81,282 (MOR-Phe-Nle-CHF-NME)	1EPO
AA	A01.017	endothiapepsin	complex with PD-130,693 (MAS-Phe-Lys-MTF-Sta-MBA)	1EPP
AA	A01.017	endothiapepsin	complex with PD-133,450 (SOT-Phe-Gly-SCC-GCL)	1EPQ
AA	A01.017	endothiapepsin	complex with PD-135,040 (TSM-DPH-His-CHF-EMR)	1EPR
AA	A01.017	endothiapepsin	complex with H-77 (D-His-Pro-Phe-His-Leu-Leu-Val-Tyr)	1ER8_E
AA	A01.017	endothiapepsin	complex with transition state analogue inhibitor H261	1GKT
AA	A01.017	endothiapepsin	complex with CP-80,794 (N-carbonylmorphine-Phe-S-methyl-Cys-cyclohexyl-norstatine) inhibitor	1GVT
AA	A01.017	endothiapepsin	complex with inhibitor H189	1GVU
AA	A01.017	endothiapepsin	complex with Glu-statine-Leu-meta-di(aminomethyl)benzene inhibitor	1GVV
AA	A01.017	endothiapepsin	complex with PD-130,328 inhibitor	1GVW
AA	A01.017	endothiapepsin	complex with inhibitor H256	1GVX
AA	A01.017	endothiapepsin	complex with PD135,040	1OD1
AA	A01.017	endothiapepsin		1OEW
AA	A01.017	endothiapepsin	complex with transition state analogue inhibitor H261	1OEX
AA	A01.017	endothiapepsin	complex with L364,099 (IVA-His-Pro-Phe-His-CHS-Leu-Phe-NH2)	2ER0
AA	A01.017	endothiapepsin	complex with H-256 (Pro-Thr-Glu-Phe-Phe-Arg-Glu)	2ER6
AA	A01.017	endothiapepsin	complex with H-261	2ER7_E
AA	A01.017	endothiapepsin	complex with L636,564	2ER9
AA	A01.017	endothiapepsin	complex with gem-diol inhibitor PD-135.040	2JJI_A
AA	A01.017	endothiapepsin		2JJJ
AA	A01.017	endothiapepsin	complex with compound 1	2V00
AA	A01.017	endothiapepsin	neutron diffraction structure; complex with gem-diol inhibitor PD-135.040 .	2VS2_A
AA	A01.017	endothiapepsin	complex with CP-71,362	3ER3
AA	A01.017	endothiapepsin	complex with H-189	3ER5_E
AA	A01.017	endothiapepsin		3LZY
AA	A01.017	endothiapepsin		3PB5
AA	A01.017	endothiapepsin		3PBD
AA	A01.017	endothiapepsin		3PBZ
AA	A01.017	endothiapepsin		3PCW
AA	A01.017	endothiapepsin		3PCZ
AA	A01.017	endothiapepsin		3PGI
AA	A01.017	endothiapepsin		3PI0
AA	A01.017	endothiapepsin		3PLD
AA	A01.017	endothiapepsin		3PLL
AA	A01.017	endothiapepsin		3PM4
AA	A01.017	endothiapepsin		3PMU
AA	A01.017	endothiapepsin		3PMY
AA	A01.017	endothiapepsin		3PRS
AA	A01.017	endothiapepsin		3PSY
AA	A01.017	endothiapepsin		3PWW
AA	A01.017	endothiapepsin		3Q6Y
AA	A01.017	endothiapepsin		3T6I
AA	A01.017	endothiapepsin		3T7P
AA	A01.017	endothiapepsin		3T7Q
AA	A01.017	endothiapepsin		3T7X
AA	A01.017	endothiapepsin		3URI
AA	A01.017	endothiapepsin		3URJ
AA	A01.017	endothiapepsin		3URL
AA	A01.017	endothiapepsin		3WZ6
AA	A01.017	endothiapepsin		3WZ7
AA	A01.017	endothiapepsin		3WZ8
AA	A01.017	endothiapepsin		4APE
AA	A01.017	endothiapepsin	complex with PD125967 (BNA-His-CAL-DCI)	4ER1
AA	A01.017	endothiapepsin	complex with pepstatin	4ER2
AA	A01.017	endothiapepsin	complex with Pro-His-Pro-Phe-His-Leu-Val-Ile-His-Lys	4ER4
AA	A01.017	endothiapepsin		4KUP
AA	A01.017	endothiapepsin		4L6B
AA	A01.017	endothiapepsin		4LAP
AA	A01.017	endothiapepsin		4LBT
AA	A01.017	endothiapepsin		4LHH
AA	A01.017	endothiapepsin		4LP9
AA	A01.017	endothiapepsin	complex with BW624 (LOL-CH2-Val-Ile-Phe-OMe)	5ER1
AA	A01.017	endothiapepsin	complex with CP-69,799 (BOC-Phe-His-AHS-Lys-Phe)	5ER2
AA	A01.017	endothiapepsin	endothiapepsin in complex with biacylhydrazone	5HCT_A
AA	A01.017	endothiapepsin	treated with fragment 115	5P1W_A
AA	A01.017	endothiapepsin	treated with fragment 116	5P1X_A
AA	A01.017	endothiapepsin	treated with fragment 117	5P1Y_A
AA	A01.017	endothiapepsin	treated with fragment 118	5P1Z_A
AA	A01.017	endothiapepsin	treated with fragment 119	5P20_A
AA	A01.017	endothiapepsin	treated with fragment 120	5P22_A
AA	A01.017	endothiapepsin	treated with fragment 121	5P23_A
AA	A01.017	endothiapepsin	treated with fragment 122	5P24_A
AA	A01.017	endothiapepsin	treated with fragment 123	5P25_A
AA	A01.017	endothiapepsin	treated with fragment 124	5P26_A
AA	A01.017	endothiapepsin	treated with fragment 125	5P27_A
AA	A01.017	endothiapepsin	treated with fragment 126	5P28_A
AA	A01.017	endothiapepsin	treated with fragment 127	5P29_A
AA	A01.017	endothiapepsin	treated with fragment 128	5P2A_A
AA	A01.017	endothiapepsin	treated with fragment 129	5P2B_A
AA	A01.017	endothiapepsin	treated with fragment 130	5P2C_A
AA	A01.017	endothiapepsin	treated with fragment 131	5P2D_A
AA	A01.017	endothiapepsin	treated with fragment 132	5P2E_A
AA	A01.017	endothiapepsin	treated with fragment 133	5P2F_A
AA	A01.017	endothiapepsin	treated with fragment 134	5P2G_A
AA	A01.017	endothiapepsin	treated with fragment 135	5P2H_A
AA	A01.017	endothiapepsin	treated with fragment 136	5P2I_A
AA	A01.017	endothiapepsin	treated with fragment 137	5P2J_A
AA	A01.017	endothiapepsin	treated with fragment 138	5P2K_A
AA	A01.017	endothiapepsin	treated with fragment 139	5P2L_A
AA	A01.017	endothiapepsin	treated with fragment 140	5P2M_A
AA	A01.017	endothiapepsin	treated with fragment 141	5P2N_A
AA	A01.017	endothiapepsin	treated with fragment 142	5P2O_A
AA	A01.017	endothiapepsin	treated with fragment 143	5P2Q_A
AA	A01.017	endothiapepsin	treated with fragment 144	5P2R_A
AA	A01.017	endothiapepsin	treated with fragment 145	5P2S_A
AA	A01.017	endothiapepsin	treated with fragment 146	5P2T_A
AA	A01.017	endothiapepsin	treated with fragment 147	5P2U_A
AA	A01.017	endothiapepsin	treated with fragment 148	5P2V_A
AA	A01.017	endothiapepsin	treated with fragment 149	5P2W_A
AA	A01.017	endothiapepsin	treated with fragment 150	5P2X_A
AA	A01.017	endothiapepsin	treated with fragment 151	5P2Y_A
AA	A01.017	endothiapepsin	treated with fragment 152	5P2Z_A
AA	A01.017	endothiapepsin	treated with fragment 153	5P30_A
AA	A01.017	endothiapepsin	treated with fragment 154	5P31_A
AA	A01.017	endothiapepsin	treated with fragment 155	5P32_A
AA	A01.017	endothiapepsin	treated with fragment 156	5P33_A
AA	A01.017	endothiapepsin	treated with fragment 157	5P34_A
AA	A01.017	endothiapepsin	treated with fragment 158	5P35_A
AA	A01.017	endothiapepsin	treated with fragment 159	5P36_A
AA	A01.017	endothiapepsin	treated with fragment 160	5P37_A
AA	A01.017	endothiapepsin	treated with fragment 161	5P38_A
AA	A01.017	endothiapepsin	treated with fragment 162	5P39_A
AA	A01.017	endothiapepsin	treated with fragment 163	5P3A_A
AA	A01.017	endothiapepsin	treated with fragment 164	5P3B_A
AA	A01.017	endothiapepsin	treated with fragment 165	5P3C_A
AA	A01.017	endothiapepsin	treated with fragment 166	5P3D_A
AA	A01.017	endothiapepsin	treated with fragment 167	5P3E_A
AA	A01.017	endothiapepsin	treated with fragment 168	5P3F_A
AA	A01.017	endothiapepsin	treated with fragment 169	5P3G_A
AA	A01.017	endothiapepsin	treated with fragment 170	5P3H_A
AA	A01.017	endothiapepsin	treated with fragment 171	5P3I_A
AA	A01.017	endothiapepsin	treated with fragment 172	5P3J_A
AA	A01.017	endothiapepsin	treated with fragment 173	5P3K_A
AA	A01.017	endothiapepsin	treated with fragment 174	5P3L_A
AA	A01.017	endothiapepsin	treated with fragment 175	5P3M_A
AA	A01.017	endothiapepsin	treated with fragment 176	5P3N_A
AA	A01.017	endothiapepsin	treated with fragment 177	5P3O_A
AA	A01.017	endothiapepsin	treated with fragment 178	5P3P_A
AA	A01.017	endothiapepsin	treated with fragment 179	5P3Q_A
AA	A01.017	endothiapepsin	treated with fragment 180	5P3R_A
AA	A01.017	endothiapepsin	treated with fragment 181	5P3S_A
AA	A01.017	endothiapepsin	treated with fragment 182	5P3T_A
AA	A01.017	endothiapepsin	treated with fragment 183	5P3U_A
AA	A01.017	endothiapepsin	treated with fragment 184	5P3V_A
AA	A01.017	endothiapepsin	treated with fragment 185	5P3W_A
AA	A01.017	endothiapepsin	treated with fragment 186	5P3X_A
AA	A01.017	endothiapepsin	treated with fragment 187	5P3Y_A
AA	A01.017	endothiapepsin	treated with fragment 188	5P3Z_A
AA	A01.017	endothiapepsin	treated with fragment 189	5P40_A
AA	A01.017	endothiapepsin	treated with fragment 190	5P41_A
AA	A01.017	endothiapepsin	treated with fragment 191	5P42_A
AA	A01.017	endothiapepsin	treated with fragment 192	5P43_A
AA	A01.017	endothiapepsin	treated with fragment 193	5P44_A
AA	A01.017	endothiapepsin	treated with fragment 194	5P45_A
AA	A01.017	endothiapepsin	treated with fragment 195	5P46_A
AA	A01.017	endothiapepsin	treated with fragment 196	5P47_A
AA	A01.017	endothiapepsin	treated with fragment 197	5P48_A
AA	A01.017	endothiapepsin	treated with fragment 198	5P49_A
AA	A01.017	endothiapepsin	treated with fragment 199	5P4A_A
AA	A01.017	endothiapepsin	treated with fragment 200	5P4B_A
AA	A01.017	endothiapepsin	treated with fragment 201	5P4C_A
AA	A01.017	endothiapepsin	treated with fragment 202	5P4D_A
AA	A01.017	endothiapepsin	treated with fragment 203	5P4E_A
AA	A01.017	endothiapepsin	treated with fragment 204	5P4F_A
AA	A01.017	endothiapepsin	treated with fragment 205	5P4G_A
AA	A01.017	endothiapepsin	treated with fragment 206	5P4H_A
AA	A01.017	endothiapepsin	treated with fragment 207	5P4I_A
AA	A01.017	endothiapepsin	treated with fragment 208	5P4J_A
AA	A01.017	endothiapepsin	treated with fragment 209	5P4K_A
AA	A01.017	endothiapepsin	treated with fragment 210	5P4L_A
AA	A01.017	endothiapepsin	treated with fragment 211	5P4M_A
AA	A01.017	endothiapepsin	treated with fragment 212	5P4N_A
AA	A01.017	endothiapepsin	treated with fragment 213	5P4O_A
AA	A01.017	endothiapepsin	treated with fragment 214	5P4P_A
AA	A01.017	endothiapepsin	treated with fragment 215	5P4Q_A
AA	A01.017	endothiapepsin	treated with fragment 216	5P4R_A
AA	A01.017	endothiapepsin	treated with fragment 217	5P4S_A
AA	A01.017	endothiapepsin	treated with fragment 218	5P4T_A
AA	A01.017	endothiapepsin	treated with fragment 219	5P4U_A
AA	A01.017	endothiapepsin	treated with fragment 220	5P4V_A
AA	A01.017	endothiapepsin	treated with fragment 221	5P4W_A
AA	A01.017	endothiapepsin	treated with fragment 222	5P4X_A
AA	A01.017	endothiapepsin	treated with fragment 223	5P4Y_A
AA	A01.017	endothiapepsin	treated with fragment 224	5P4Z_A
AA	A01.017	endothiapepsin	treated with fragment 225	5P50_A
AA	A01.017	endothiapepsin	treated with fragment 226	5P51_A
AA	A01.017	endothiapepsin	treated with fragment 227	5P52_A
AA	A01.017	endothiapepsin	treated with fragment 228	5P53_A
AA	A01.017	endothiapepsin	treated with fragment 229	5P54_A
AA	A01.017	endothiapepsin	treated with fragment 230	5P55_A
AA	A01.017	endothiapepsin	treated with fragment 231	5P56_A
AA	A01.017	endothiapepsin	treated with fragment 232	5P57_A
AA	A01.017	endothiapepsin	treated with fragment 233	5P58_A
AA	A01.017	endothiapepsin	treated with fragment 234	5P59_A
AA	A01.017	endothiapepsin	treated with fragment 235	5P5A_A
AA	A01.017	endothiapepsin	treated with fragment 236	5P5B_A
AA	A01.017	endothiapepsin	treated with fragment 237	5P5C_A
AA	A01.017	endothiapepsin	treated with fragment 238	5P5D_A
AA	A01.017	endothiapepsin	treated with fragment 239	5P5E_A
AA	A01.017	endothiapepsin	treated with fragment 240	5P5F_A
AA	A01.017	endothiapepsin	treated with fragment 241	5P5G_A
AA	A01.017	endothiapepsin	treated with fragment 242	5P5H_A
AA	A01.017	endothiapepsin	treated with fragment 243	5P5I_A
AA	A01.017	endothiapepsin	treated with fragment 244	5P5J_A
AA	A01.017	endothiapepsin	treated with fragment 245	5P5K_A
AA	A01.017	endothiapepsin	treated with fragment 246	5P5L_A
AA	A01.017	endothiapepsin	treated with fragment 247	5P5M_A
AA	A01.017	endothiapepsin	treated with fragment 248	5P5N_A
AA	A01.017	endothiapepsin	treated with fragment 249	5P5O_A
AA	A01.017	endothiapepsin	treated with fragment 250	5P5P_A
AA	A01.017	endothiapepsin	treated with fragment 251	5P5Q_A
AA	A01.017	endothiapepsin	treated with fragment 252	5P5R_A
AA	A01.017	endothiapepsin	treated with fragment 253	5P5S_A
AA	A01.017	endothiapepsin	treated with fragment 254	5P5T_A
AA	A01.017	endothiapepsin	treated with fragment 255	5P5U_A
AA	A01.017	endothiapepsin	treated with fragment 256	5P5V_A
AA	A01.017	endothiapepsin	treated with fragment 257	5P5W_A
AA	A01.017	endothiapepsin	treated with fragment 258	5P5X_A
AA	A01.017	endothiapepsin	treated with fragment 259	5P5Y_A
AA	A01.017	endothiapepsin	treated with fragment 260	5P5Z_A
AA	A01.017	endothiapepsin	treated with fragment 261	5P60_A
AA	A01.017	endothiapepsin	treated with fragment 262	5P61_A
AA	A01.017	endothiapepsin	treated with fragment 263	5P62_A
AA	A01.017	endothiapepsin	treated with fragment 264	5P63_A
AA	A01.017	endothiapepsin	treated with fragment 265	5P64_A
AA	A01.017	endothiapepsin	treated with fragment 266	5P65_A
AA	A01.017	endothiapepsin	treated with fragment 267	5P66_A
AA	A01.017	endothiapepsin	treated with fragment 268	5P67_A
AA	A01.017	endothiapepsin	treated with fragment 269	5P68_A
AA	A01.017	endothiapepsin	treated with fragment 270	5P69_A
AA	A01.017	endothiapepsin	treated with fragment 271	5P6A_A
AA	A01.017	endothiapepsin	treated with fragment 272	5P6B_A
AA	A01.017	endothiapepsin	treated with fragment 273	5P6C_A
AA	A01.017	endothiapepsin	treated with fragment 274	5P6D_A
AA	A01.017	endothiapepsin	treated with fragment 275	5P6E_A
AA	A01.017	endothiapepsin	treated with fragment 276	5P6F_A
AA	A01.017	endothiapepsin	treated with fragment 277	5P6G_A
AA	A01.017	endothiapepsin	treated with fragment 278	5P6H_A
AA	A01.017	endothiapepsin	treated with fragment 279	5P6I_A
AA	A01.017	endothiapepsin	treated with fragment 280	5P6J_A
AA	A01.017	endothiapepsin	treated with fragment 281	5P6K_A
AA	A01.017	endothiapepsin	treated with fragment 282	5P6L_A
AA	A01.017	endothiapepsin	treated with fragment 283	5P6M_A
AA	A01.017	endothiapepsin	treated with fragment 284	5P6N_A
AA	A01.017	endothiapepsin	treated with fragment 285	5P6O_A
AA	A01.017	endothiapepsin	treated with fragment 286	5P6P_A
AA	A01.017	endothiapepsin	treated with fragment 287	5P6Q_A
AA	A01.017	endothiapepsin	treated with fragment 288	5P6R_A
AA	A01.017	endothiapepsin	treated with fragment 289	5P6S_A
AA	A01.017	endothiapepsin	treated with fragment 290	5P6T_A
AA	A01.017	endothiapepsin	treated with fragment 291	5P6U_A
AA	A01.017	endothiapepsin	treated with fragment 292	5P6V_A
AA	A01.017	endothiapepsin	treated with fragment 293	5P6W_A
AA	A01.017	endothiapepsin	treated with fragment 294	5P6X_A
AA	A01.017	endothiapepsin	treated with fragment 295	5P6Y_A
AA	A01.017	endothiapepsin	treated with fragment 296	5P6Z_A
AA	A01.017	endothiapepsin	treated with fragment 297	5P70_A
AA	A01.017	endothiapepsin	treated with fragment 298	5P71_A
AA	A01.017	endothiapepsin	treated with fragment 299	5P72_A
AA	A01.017	endothiapepsin	treated with fragment 300	5P73_A
AA	A01.017	endothiapepsin	treated with fragment 301	5P74_A
AA	A01.017	endothiapepsin	treated with fragment 302	5P75_A
AA	A01.017	endothiapepsin	treated with fragment 303	5P76_A
AA	A01.017	endothiapepsin	treated with fragment 304	5P77_A
AA	A01.017	endothiapepsin	treated with fragment 305	5P78_A
AA	A01.017	endothiapepsin	treated with fragment 306	5P79_A
AA	A01.017	endothiapepsin	treated with fragment 307	5P7A_A
AA	A01.017	endothiapepsin	treated with fragment 308	5P7B_A
AA	A01.017	endothiapepsin	treated with fragment 309	5P7C_A
AA	A01.017	endothiapepsin	treated with fragment 310	5P7D_A
AA	A01.017	endothiapepsin	treated with fragment 311	5P7E_A
AA	A01.017	endothiapepsin	treated with fragment 312	5P7F_A
AA	A01.017	endothiapepsin	treated with fragment 313	5P7G_A
AA	A01.017	endothiapepsin	treated with fragment 314	5P7H_A
AA	A01.017	endothiapepsin	treated with fragment 315	5P7I_A
AA	A01.017	endothiapepsin	treated with fragment 316	5P7J_A
AA	A01.017	endothiapepsin	treated with fragment 317	5P7K_A
AA	A01.017	endothiapepsin	treated with fragment 318	5P7L_A
AA	A01.017	endothiapepsin	treated with fragment 319	5P7M_A
AA	A01.017	endothiapepsin	treated with fragment 320	5P7N_A
AA	A01.017	endothiapepsin	treated with fragment 321	5P7O_A
AA	A01.017	endothiapepsin	treated with fragment 322	5P7P_A
AA	A01.017	endothiapepsin	treated with fragment 323	5P7Q_A
AA	A01.017	endothiapepsin	treated with fragment 324	5P7R_A
AA	A01.017	endothiapepsin	treated with fragment 325	5P7S_A
AA	A01.017	endothiapepsin	treated with fragment 326	5P7T_A
AA	A01.017	endothiapepsin	treated with fragment 327	5P7U_A
AA	A01.017	endothiapepsin	treated with fragment 328	5P7V_A
AA	A01.017	endothiapepsin	treated with fragment 329	5P7W_A
AA	A01.017	endothiapepsin	treated with fragment 330	5P7X_A
AA	A01.017	endothiapepsin	treated with fragment 331	5P7Y_A
AA	A01.017	endothiapepsin	treated with fragment 332	5P7Z_A
AA	A01.017	endothiapepsin	treated with fragment 333	5P80_A
AA	A01.017	endothiapepsin	treated with fragment 334	5P81_A
AA	A01.017	endothiapepsin	treated with fragment 335	5P82_A
AA	A01.017	endothiapepsin	treated with fragment 336	5P83_A
AA	A01.017	endothiapepsin	treated with fragment 337	5P84_A
AA	A01.017	endothiapepsin	treated with fragment 338	5P85_A
AA	A01.017	endothiapepsin	treated with fragment 339	5P86_A
AA	A01.017	endothiapepsin	treated with fragment 340	5P87_A
AA	A01.017	endothiapepsin	treated with fragment 341	5P88_A
AA	A01.017	endothiapepsin	treated with fragment 342	5P89_A
AA	A01.017	endothiapepsin	treated with fragment 343	5P8A_A
AA	A01.017	endothiapepsin	treated with fragment 344	5P8B_A
AA	A01.017	endothiapepsin	treated with fragment 345	5P8C_A
AA	A01.017	endothiapepsin	treated with fragment 346	5P8D_A
AA	A01.017	endothiapepsin	treated with fragment 347	5P8E_A
AA	A01.017	endothiapepsin	treated with fragment 348	5P8F_A
AA	A01.017	endothiapepsin	treated with fragment 349	5P8G_A
AA	A01.017	endothiapepsin	treated with fragment 350	5P8H_A
AA	A01.017	endothiapepsin	treated with fragment 351	5P8I_A
AA	A01.017	endothiapepsin	treated with fragment 352	5P8J_A
AA	A01.017	endothiapepsin	treated with fragment 353	5P8K_A
AA	A01.017	endothiapepsin	treated with fragment 354	5P8L_A
AA	A01.017	endothiapepsin	treated with fragment 355	5P8M_A
AA	A01.017	endothiapepsin	treated with fragment 356	5P8N_A
AA	A01.017	endothiapepsin	treated with fragment 357	5P8O_A
AA	A01.017	endothiapepsin	treated with fragment 358	5P8P_A
AA	A01.017	endothiapepsin	treated with fragment 359	5P8Q_A
AA	A01.017	endothiapepsin	treated with fragment 360	5P8R_A
AA	A01.017	endothiapepsin	treated with fragment 361	5P8S_A
AA	A01.017	endothiapepsin	treated with fragment 362	5P8T_A
AA	A01.017	endothiapepsin	treated with fragment 363	5P8U_A
AA	A01.017	endothiapepsin	treated with fragment 364	5P8V_A
AA	A01.018	saccharopepsin	complex with IA3 mutant inhibitor	1DP5_A
AA	A01.018	saccharopepsin	complex with IA3 inhibitor	1DPJ_A
AA	A01.018	saccharopepsin		1FMU
AA	A01.018	saccharopepsin		1FMX
AA	A01.018	saccharopepsin	complex with hydroxythylene inhibitor CP-108,420	1FQ4
AA	A01.018	saccharopepsin	complex with cyclic statine inhibitor PD-129,541	1FQ5
AA	A01.018	saccharopepsin	complex with glycol inhibitor PD-133,450	1FQ6
AA	A01.018	saccharopepsin	complex with inhibitor CP-72,647	1FQ7
AA	A01.018	saccharopepsin	complex with difluorostatine inhibitor CP81,198	1FQ8
AA	A01.018	saccharopepsin	complex with proteinase A inhibitor 3 mutant	1G0V_A
AA	A01.018	saccharopepsin	complex with N-carbonylmorpholine-Phe-norLeu-cyclohexylfluorostatone-methylamine	2JXR
AA	A01.019	polyporopepsin		1WKR
AA	A01.020	phytepsin	zymogen	1QDM
AA	A01.020	phytepsin		1B5F_A
AA	A01.020	phytepsin		5NFG_A
AA	A01.021	plasmepsin (Plasmodium sp.)		1MIQ
AA	A01.021	plasmepsin (Plasmodium sp.)	complex with pepstatin A inhibitor	1QS8
AA	A01.021	plasmepsin (Plasmodium sp.)	complex with allophenylnorstatine inhibitor KNI-764	2ANL
AA	A01.021	plasmepsin (Plasmodium sp.)	theoretical model	1KBX
AA	A01.022	plasmepsin-1	theoretical model	1LCR
AA	A01.022	plasmepsin-1		1LDU
AA	A01.022	plasmepsin-1		3QRV
AA	A01.022	plasmepsin-1	complex with KNI-10006 inhibitor	3QS1
AA	A01.023	plasmepsin-2	theoretical model	1J8J
AA	A01.023	plasmepsin-2	complex with inhibitor RS367	1LEE
AA	A01.023	plasmepsin-2	complex with inhibitor RS370	1LF2
AA	A01.023	plasmepsin-2	complex with EH58 inhibitor	1LF3
AA	A01.023	plasmepsin-2		1LF4
AA	A01.023	plasmepsin-2	complex with pepstatin A	1M43
AA	A01.023	plasmepsin-2	complex with a statine based inhibitor	1ME6
AA	A01.023	plasmepsin-2	precursor	1PFZ
AA	A01.023	plasmepsin-2	complex with pepstatin A	1SME
AA	A01.023	plasmepsin-2	complex with TIT inhibitor	1W6H
AA	A01.023	plasmepsin-2	complex with pepstatin A	1W6I
AA	A01.023	plasmepsin-2	complex with pepstatin A	1XDH
AA	A01.023	plasmepsin-2	complex with a pepstatin analogue	1XE5
AA	A01.023	plasmepsin-2	complex with a pepstatin analogue	1XE6
AA	A01.023	plasmepsin-2	complex with N-(R-carboxy-ethyl)-alpha-(S)-(2-phenylethyl)	2BJU
AA	A01.023	plasmepsin-2		2BL3
AA	A01.023	plasmepsin-2	achiral, cheap and potent inhibitors of plasmepsins ii	2IGX_A
AA	A01.023	plasmepsin-2	achiral, cheap and potent inhibitors of plasmepsins ii	2IGY_A
AA	A01.023	plasmepsin-2	complex with KPFS-(CH2-NH)-LQF	2R9B_A
AA	A01.023	plasmepsin-2	re-refinement of uncomplexed plasmepsin ii from plasmodium falciparum.	3F9Q_A
AA	A01.023	plasmepsin-2		4CKU
AA	A01.023	plasmepsin-2		4Y6M
AA	A01.023	plasmepsin-2		4YA8
AA	A01.027	trichodermapepsin		3C9X
AA	A01.027	trichodermapepsin	complex with pepstatin A	3C9Y
AA	A01.027	trichodermapepsin	complex with pepstatin A	3EMY
AA	A01.030	yapsin-1	theoretical model	1YPS
AA	A01.037	canditropsin	Complex with Thr-Ile-Thr-Ser	1J71
AA	A01.038	candiparapsin	complex with pepstatin	3FV3
AA	A01.038	candiparapsin		3TNE
AA	A01.041	BACE2 g.p. (Homo sapiens)	complex with hydroxyethylenamine transition-state inhibitor N-(1S,2R)-1-benzyl-2-hydroxy-3-[(3-methylbenzyl)amino]propyldibenzo[B,F]oxepine-10-carboxamide	2EWY_A
AA	A01.041	BACE2 g.p. (Homo sapiens)		3ZKG
AA	A01.041	BACE2 g.p. (Homo sapiens)		3ZKI
AA	A01.041	BACE2 g.p. (Homo sapiens)		3ZKM
AA	A01.041	BACE2 g.p. (Homo sapiens)		3ZKN
AA	A01.041	BACE2 g.p. (Homo sapiens)		3ZKQ
AA	A01.041	BACE2 g.p. (Homo sapiens)		3ZKS
AA	A01.041	BACE2 g.p. (Homo sapiens)		3ZKX
AA	A01.041	BACE2 g.p. (Homo sapiens)		3ZL7
AA	A01.041	BACE2 g.p. (Homo sapiens)		3ZLQ
AA	A01.041	BACE2 g.p. (Homo sapiens)		4BEL
AA	A01.041	BACE2 g.p. (Homo sapiens)		4BFB
AA	A01.043	histoaspartic peptidase (Plasmodium falciparum)	ON HOLD; apoenzyme	3FNS
AA	A01.043	histoaspartic peptidase (Plasmodium falciparum)	complex with pepstatin A	3FNT
AA	A01.043	histoaspartic peptidase (Plasmodium falciparum)	complex with inhibitor KNI-10006	3FNU
AA	A01.043	histoaspartic peptidase (Plasmodium falciparum)		3QVC_A
AA	A01.043	histoaspartic peptidase (Plasmodium falciparum)	complex with kni-10395	3QVI_A
AA	A01.055	Mername-AA047 peptidase		1AM5
AA	A01.059	plasmepsin-4	complex with pepstatin A	1LS5_A
AA	A01.060	candidapepsin SAP2	complex with A70450	1EAG_A
AA	A01.060	candidapepsin SAP2	complex with N-ethyl-N-[(4-methylpiperazin-1-yl)carbonyl]- D-phenylalanyl-N-[(1S,2S,4R)-4-(butylcarbamoyl)- 1-(cyclohexylmethyl)-2-hydroxy-5-methylhexyl]- L-norleucinamide	1ZAP
AA	A01.061	candidapepsin SAP3	secreted aspartic proteinase (sap) 3 from candida albicans	2H6S_A
AA	A01.061	candidapepsin SAP3	complex with pepstatin A	2H6T_A
AA	A01.063	candidapepsin SAP5	complex with pepstatin A	2QZX
AA	A01.070	pepsin A4	Uropepsin	1FLH
AA	A01.070	pepsin A4	pepsin 3A	1PSN
AA	A01.070	pepsin A4	pepsin 3A; complex with pepstatin	1PSO
AA	A01.070	pepsin A4	complex with phosphonate inhibitor Iva-Val-Val-Leu(P)-(O)Phe-Ala-Ala-Ome	1QRP
AA	A01.070	pepsin A4		3UTL
AA	A01.075	plasmepsin-5 (Plasmodium sp.)	plasmepsin v from plasmodium vivax bound to a transition state mimetic(wehi-842)	4ZL4_A
AA	A01.075	plasmepsin-5 (Plasmodium sp.)	plasmepsin v from plasmodium vivax bound to a transition state mimetic(wehi-601)	6C4G_A
AA	A01.076	Sapp2p peptidase (Candida parapsilosis)	aspartic proteinase sapp2 secreted from candida parapsilosis at 0.82 aresolution.	4Y9W_A
AA	A01.076	Sapp2p peptidase (Candida parapsilosis)	aspartic proteinase sapp2 secreted from candida parapsilosis at 1.25 aresolution	4YBF_A
AA	A01.950	cockroach allergen	Asn93Gln mutant	1YG9
AA	A01.950	cockroach allergen	Asn93Gln mutant; complex with monoclonal antibody	2NR6_A
AA	A01.950	cockroach allergen		3LIZ
AA	A01.950	cockroach allergen		4RLD
AA	A01.974	xylanase inhibitor precursor		1T6E_X
AA	A01.974	xylanase inhibitor precursor	complex with Aspergillus niger xylanase-I	1T6G_A
AA	A01.974	xylanase inhibitor precursor	complex with Bacillus subtilis xylanase	2B42_A
AA	A01.974	xylanase inhibitor precursor	complex with bacillus subtilis xylanase	3HD8_A
AA	A01.UNB	subfamily A1B non-peptidase homologues		3VLA_A
AA	A01.UNB	subfamily A1B non-peptidase homologues		3VLB_A
AA	A01.UNB	subfamily A1B non-peptidase homologues		4PPH_A
AA	A01.UNB	subfamily A1B non-peptidase homologues		3AUP
AA	A01.UPA	subfamily A1A unassigned peptidases		1IZD
AA	A01.UPA	subfamily A1A unassigned peptidases		1IZE
AA	A01.UPA	subfamily A1A unassigned peptidases	complex with the n-terminal octapeptide of the propeptid	5N70_A
AA	A01.UPA	subfamily A1A unassigned peptidases		5N71_A
AA	A01.UPA	subfamily A1A unassigned peptidases	zymogen	5N7N_A
AA	A01.UPA	subfamily A1A unassigned peptidases	complex with the inhibitor pepstatin a	5N7Q_A
AA	A01.UPA	subfamily A1A unassigned peptidases	complex with kni-10343	5YIA_A
AA	A01.UPA	subfamily A1A unassigned peptidases	complex with kni-10743	5YIB_A
AA	A01.UPA	subfamily A1A unassigned peptidases	complex with kni-10333	5YIC_A
AA	A01.UPA	subfamily A1A unassigned peptidases	complex with kni-10395	5YID_A
AA	A01.UPA	subfamily A1A unassigned peptidases	complex with kni-10742	5YIE_A
AA	A01.UPA	subfamily A1A unassigned peptidases	precursor	5MKT_A
AA	A02.001	HIV-1 retropepsin	complex with Glu-Asp-Leu inhibitor	1A30
AA	A02.001	HIV-1 retropepsin	complex with SDZ283-910 inhibitor	1A8G
AA	A02.001	HIV-1 retropepsin	complex with CA-P2 peptide substrate analogue	1A8K
AA	A02.001	HIV-1 retropepsin	complex with Arg-Val-Leu-Phe-Glu-Ala-norLeu-NH2	1A94
AA	A02.001	HIV-1 retropepsin	complex with U-89360E inhibitor	1A9M
AA	A02.001	HIV-1 retropepsin	complex with methyl N-(4S,5S)-5-[(L-alanyl-L-alanyl)amino]- 4-hydroxy-6-phenylhexanoyl-L-valyl-L-valinate	1AAQ
AA	A02.001	HIV-1 retropepsin	complex with UCSF8 inhibitor	1AID
AA	A02.001	HIV-1 retropepsin	complex with AHA006 inhibitor	1AJV
AA	A02.001	HIV-1 retropepsin	complex with AHA001 inhibitor	1AJX
AA	A02.001	HIV-1 retropepsin	Ala28Ser mutant	1AXA
AA	A02.001	HIV-1 retropepsin	complex with macrocyclic peptidomimetic inhibitor 1	1B6J
AA	A02.001	HIV-1 retropepsin	complex with macrocyclic peptidomimetic inhibitor 5	1B6K
AA	A02.001	HIV-1 retropepsin	complex with macrocyclic peptidomimetic inhibitor 4	1B6L
AA	A02.001	HIV-1 retropepsin	complex with macrocyclic peptidomimetic inhibitor 6	1B6M
AA	A02.001	HIV-1 retropepsin	complex with macrocyclic peptidomimetic inhibitor 3	1B6N
AA	A02.001	HIV-1 retropepsin	complex with macrocyclic peptidomimetic inhibitor 2	1B6O
AA	A02.001	HIV-1 retropepsin	complex with macrocyclic peptidomimetic inhibitor 7	1B6P
AA	A02.001	HIV-1 retropepsin	mutant; complex with SB203386 inhibitor	1BDL
AA	A02.001	HIV-1 retropepsin	complex with SB203386 inhibitor	1BDQ
AA	A02.001	HIV-1 retropepsin	mutant; complex with SB203386 inhibitor	1BDR
AA	A02.001	HIV-1 retropepsin	Val3Ile, Ile64Val, Val77Ile mutant; complex with cyclic urea amide XV638	1BV7
AA	A02.001	HIV-1 retropepsin	mutant; complex with XV638 (Dupont Pharmaceuticals)	1BV9
AA	A02.001	HIV-1 retropepsin	NMR structure; complex with DMP323	1BVE
AA	A02.001	HIV-1 retropepsin	NMR structure; complex with DMP323	1BVG
AA	A02.001	HIV-1 retropepsin	Val82Phe and Ile84Val double mutant; complex with XV638 (Dupont Pharmaceuticals)	1BWA
AA	A02.001	HIV-1 retropepsin	Val82Phe and Ile84Val double mutant; complex with SD146 (Dupont Pharmaceuticals)	1BWB
AA	A02.001	HIV-1 retropepsin	complex with L-739,622 inhibitor	1C6X
AA	A02.001	HIV-1 retropepsin	complex with L-735,524 inhibitor	1C6Y
AA	A02.001	HIV-1 retropepsin	complex with ROC 505 inhibitor	1C6Z
AA	A02.001	HIV-1 retropepsin	complex with L-756,423 inhibitor	1C70
AA	A02.001	HIV-1 retropepsin	complex with a cyclic peptide inhibitor	1CPI
AA	A02.001	HIV-1 retropepsin	complex with inhibitor BEA435	1D4H
AA	A02.001	HIV-1 retropepsin	complex with inhibitor BEA425	1D4I
AA	A02.001	HIV-1 retropepsin	complex with inhibitor MSL370	1D4J
AA	A02.001	HIV-1 retropepsin	complex with N-13-[(10S,13S)-9,12-dioxo-10-(2-butyl)-2-oxa-8,11-diazabicyclo [13.2.2] nonadeca-15,17,18-triene] (2R)-benzyl-(4S)-hydroxy-5-aminopentanoic (1R)- hydroxy-(2S)-indaneamide	1D4K
AA	A02.001	HIV-1 retropepsin	complex with (10S,13S,1'R)-13-[1'-hydroxy-2'-(N-P-aminobenzenesulfonyl-1''-amino-3''-methylbutyl)ethyl]-8,11-dioxo-10-isopropyl-2-oxa-9,12-diazabicyclo [13.2.2]nonadeca-15,17,18-triene	1D4L
AA	A02.001	HIV-1 retropepsin	Val82Phe, Ile84Val double mutant; complex with tipranavir inhibitor	1D4S
AA	A02.001	HIV-1 retropepsin	Gln7Lys, Leu33Ile, Leu63Ile mutant: complex with tipranavir	1D4Y
AA	A02.001	HIV-1 retropepsin	drug resistant mutant; complex with peptide inhibitor	1DAZ
AA	A02.001	HIV-1 retropepsin	complex with a difluoroketone containing inhibitor A79285	1DIF
AA	A02.001	HIV-1 retropepsin	complex with DMP450 (Dupont-Merck)	1DMP
AA	A02.001	HIV-1 retropepsin	complex with inhibitor analogue of CA-P2 processing site	1DW6
AA	A02.001	HIV-1 retropepsin	drug-resistant mutant	1EBK
AA	A02.001	HIV-1 retropepsin	complex with inhibitor BEA322	1EBW
AA	A02.001	HIV-1 retropepsin	complex with inhibitor BEA369	1EBY
AA	A02.001	HIV-1 retropepsin	complex with inhibitor BEA388	1EBZ
AA	A02.001	HIV-1 retropepsin	complex with inhibitor BEA403	1EC0
AA	A02.001	HIV-1 retropepsin	complex with inhibitor BEA409	1EC1
AA	A02.001	HIV-1 retropepsin	complex with inhibitor BEA428	1EC2
AA	A02.001	HIV-1 retropepsin	complex with inhibitor MSA367	1EC3
AA	A02.001	HIV-1 retropepsin	complex with Lys-Ala-Arg-Val-Leu-Ala-Glu-Ala-Met-Ser substrate	1F7A
AA	A02.001	HIV-1 retropepsin	Val48Gly, Met90Leu mutant; complex with saquinavir	1FB7
AA	A02.001	HIV-1 retropepsin	complex with substrate acetyl-Thr-Ile-norLeu-norLeu-Gln-Arg	1FEJ
AA	A02.001	HIV-1 retropepsin	engineered; complex with acetyl-Thr-Ile-norLeu-norLeu-Gln-Arg inhibitor	1FF0
AA	A02.001	HIV-1 retropepsin	engineered; complex with Arg-Val-2-amino-4-methyl-pentan-1-ol-Phe-Glu-Ala-norLeu-NH2 inhibitor	1FFF
AA	A02.001	HIV-1 retropepsin	engineered; complex with acetyl-Thr-Ile-norLeu-norLeu-Gln-Arg inhibitor	1FFI
AA	A02.001	HIV-1 retropepsin	engineered; complex with acetyl-Thr-Ile-norLeu-norLeu-Gln-Arg inhibitor	1FG6
AA	A02.001	HIV-1 retropepsin	engineered; complex with Arg-Val-2-amino-4-methyl-pentan-1-ol-Phe-Glu-Ala-norLeu-NH2 inhibitor	1FG8
AA	A02.001	HIV-1 retropepsin	engineered; complex with acetyl-Thr-Ile-norLeu-norLeu-Gln-Arg inhibitor	1FGC
AA	A02.001	HIV-1 retropepsin	complex with Boc-3(S)-amino-4-phenyl-butan-2(S)-yl-Phe-Glu-Phe-NH2 inhibitor	1FQX
AA	A02.001	HIV-1 retropepsin	complex with cyclic sulfamide inhibitor AHA047	1G2K
AA	A02.001	HIV-1 retropepsin	complex with AHA024 inhibitor	1G35
AA	A02.001	HIV-1 retropepsin	homodimer covalently linked through engineered pentapeptide linker	1G6L
AA	A02.001	HIV-1 retropepsin	Val82Asp mutant; complex with U89360E inhibitor	1GNM
AA	A02.001	HIV-1 retropepsin	Val82Asn mutant; complex with U89360E inhibitor	1GNN
AA	A02.001	HIV-1 retropepsin	complex with U89360E inhibitor	1GNO
AA	A02.001	HIV-1 retropepsin	complex with SB203238	1HBV
AA	A02.001	HIV-1 retropepsin	recombinant	1HEF
AA	A02.001	HIV-1 retropepsin	recombinant	1HEG
AA	A02.001	HIV-1 retropepsin	recombinant	1HHP
AA	A02.001	HIV-1 retropepsin	complex with CGP 53820	1HIH
AA	A02.001	HIV-1 retropepsin		1HIV
AA	A02.001	HIV-1 retropepsin	complex with SB204144	1HOS
AA	A02.001	HIV-1 retropepsin	mutant form; complex with benzenesulfonamide inhibitor U103265	1HPO
AA	A02.001	HIV-1 retropepsin		1HPS
AA	A02.001	HIV-1 retropepsin	complex with VX-478	1HPV
AA	A02.001	HIV-1 retropepsin	complex with inhibitor KNI-272	1HPX
AA	A02.001	HIV-1 retropepsin	complex with L-735,524	1HSG
AA	A02.001	HIV-1 retropepsin	complex with GR123976	1HTE
AA	A02.001	HIV-1 retropepsin	complex with GR126045	1HTF
AA	A02.001	HIV-1 retropepsin	complex with GR137615	1HTG
AA	A02.001	HIV-1 retropepsin	complex with A-76928	1HVC
AA	A02.001	HIV-1 retropepsin	complex with Q8261 inhibitor	1HVH
AA	A02.001	HIV-1 retropepsin	complex with A77003	1HVI
AA	A02.001	HIV-1 retropepsin	complex with A78791	1HVJ
AA	A02.001	HIV-1 retropepsin	complex with A-76928	1HVK
AA	A02.001	HIV-1 retropepsin	complex with A76889	1HVL
AA	A02.001	HIV-1 retropepsin	theoretical model	1HVP
AA	A02.001	HIV-1 retropepsin	complex with XK263	1HVR
AA	A02.001	HIV-1 retropepsin	Val82Ala mutant; complex with A77003	1HVS
AA	A02.001	HIV-1 retropepsin	complex with synthetic cyclic urea inhibitor XK216	1HWR
AA	A02.001	HIV-1 retropepsin	complex with RO 31-8959	1HXB
AA	A02.001	HIV-1 retropepsin	complex with A-84538	1HXW
AA	A02.001	HIV-1 retropepsin		1IHV
AA	A02.001	HIV-1 retropepsin		1IHW
AA	A02.001	HIV-1 retropepsin	complex with hydroxyethylamine peptidomimetic inhibitor Boc-Pso-Phe-Gln-Phe-NH2	1IIQ
AA	A02.001	HIV-1 retropepsin	complex with inhibitor Q50	1IZH
AA	A02.001	HIV-1 retropepsin	complex with inhibitor Q50	1IZI
AA	A02.001	HIV-1 retropepsin	engineered multiple mutant form	1K1T
AA	A02.001	HIV-1 retropepsin	engineered multiple mutant form	1K1U
AA	A02.001	HIV-1 retropepsin	engineered multiple mutant form	1K2B
AA	A02.001	HIV-1 retropepsin	engineered multiple mutant form	1K2C
AA	A02.001	HIV-1 retropepsin	complex with inhibitor MK1	1K6C
AA	A02.001	HIV-1 retropepsin	complex with inhibitor XN3	1K6P
AA	A02.001	HIV-1 retropepsin	complex with inhibitor XN1	1K6T
AA	A02.001	HIV-1 retropepsin	complex with inhibitor XN2	1K6V
AA	A02.001	HIV-1 retropepsin	complex with GAG protein fragment	1KJ4
AA	A02.001	HIV-1 retropepsin	complex with GAG protein fragment	1KJ7
AA	A02.001	HIV-1 retropepsin	complex with GAG protein fragment	1KJF
AA	A02.001	HIV-1 retropepsin	complex with decapeptide substrate	1KJG
AA	A02.001	HIV-1 retropepsin	complex with POL protein fragment	1KJH
AA	A02.001	HIV-1 retropepsin	complex with inhibitor JE-2147	1KZK
AA	A02.001	HIV-1 retropepsin	engineered tethered dimer	1LV1
AA	A02.001	HIV-1 retropepsin	Ala71Val, Val82Thr, Ile84Val mutant; complex with Boc-Phe-Psi[CH2CH2NH]-Phe-Glu-Phe-NH2	1LZQ
AA	A02.001	HIV-1 retropepsin	complex with Boc-Phe-Psi[CH2CH2NH]-Phe-Glu-Phe-NH2	1M0B_A
AA	A02.001	HIV-1 retropepsin	complex with DMP450	1MER
AA	A02.001	HIV-1 retropepsin	Ile84Val mutant; complex with DMP323	1MES
AA	A02.001	HIV-1 retropepsin	Val82Phe mutant; complex with DMP323	1MET
AA	A02.001	HIV-1 retropepsin	Val82Phe, Ile84Val mutant; complex with DMP323	1MEU
AA	A02.001	HIV-1 retropepsin	Gln7lys/Leu33Ile/Leu63Ile mutant; complex with kni-577	1MRW_A
AA	A02.001	HIV-1 retropepsin	mutant q7k l33i l63i v82f i84v; complex with kni-577	1MRX_A
AA	A02.001	HIV-1 retropepsin	Gln7Lys, Leu33Ile, Leu63Ile mutant; complex with KNI-764 inhibitor	1MSM_A
AA	A02.001	HIV-1 retropepsin	Gln7Lys, Leu33Ile, Leu63Ile, Val82Phe, Ile84Valmutant; complex with KNI-764 inhibitor	1MSN_A
AA	A02.001	HIV-1 retropepsin	complex with GAG protein fragment	1MT7
AA	A02.001	HIV-1 retropepsin	complex with GAG protein fragment	1MT8
AA	A02.001	HIV-1 retropepsin	complex with GAG protein fragment	1MT9
AA	A02.001	HIV-1 retropepsin	complex with Saquinavir	1MTB
AA	A02.001	HIV-1 retropepsin	complex with a cyclic Phe-Ile-Val peptidomimetic inhibitor	1MTR
AA	A02.001	HIV-1 retropepsin	complex with lopinavir	1MUI
AA	A02.001	HIV-1 retropepsin	complex with Ritonavir	1N49
AA	A02.001	HIV-1 retropepsin	1.03 a structure of hiv-1 protease: inhibitor binding inside and outside the active site	1NH0_A
AA	A02.001	HIV-1 retropepsin	complex with LDC271	1NPV
AA	A02.001	HIV-1 retropepsin	complex with inhibitor LGZ479	1NPW
AA	A02.001	HIV-1 retropepsin		1ODW
AA	A02.001	HIV-1 retropepsin	Ala71Thr, Val82Ala mutant	1ODX
AA	A02.001	HIV-1 retropepsin	complex with inhibitor LP-130	1ODY
AA	A02.001	HIV-1 retropepsin	complex with nelfinavir mesylate AG1343 inhibitor	1OHR
AA	A02.001	HIV-1 retropepsin	dimer; complex with A-98881	1PRO
AA	A02.001	HIV-1 retropepsin	complex with inhibitor XV638	1QBR
AA	A02.001	HIV-1 retropepsin	complex with inhibitor DMP323	1QBS
AA	A02.001	HIV-1 retropepsin	complex with inhibitor SD146	1QBT
AA	A02.001	HIV-1 retropepsin	complex with inhibitor Q8467 (Dupont-Merck)	1QBU
AA	A02.001	HIV-1 retropepsin	resistant strain (Val82Ala mutant); complex with ritonavir	1RL8_A
AA	A02.001	HIV-1 retropepsin	multidrug-resistant hiv-1 protease	1RV7_A
AA	A02.001	HIV-1 retropepsin	complex with SB203386	1SBG
AA	A02.001	HIV-1 retropepsin	Val82Ala and Ile90Met mutant; complex with indinavir	1SDT_A
AA	A02.001	HIV-1 retropepsin	Val82Ala and Ile90Met mutant	1SDU_A
AA	A02.001	HIV-1 retropepsin	Val82Ala and Ile90Met mutant	1SDV_A
AA	A02.001	HIV-1 retropepsin	comparing the accumulation of active site and non-active site mutations in the hiv-1 protease	1SGU_A
AA	A02.001	HIV-1 retropepsin	comparing the accumulation of active site and non-active site mutations in the hiv-1 protease	1SH9_A
AA	A02.001	HIV-1 retropepsin	complex with a product of autoproteolysis	1SP5_A
AA	A02.001	HIV-1 retropepsin	complex with TMC114 inhibitor	1T3R_A
AA	A02.001	HIV-1 retropepsin	triple mutant; complex with SB203386	1TCX
AA	A02.001	HIV-1 retropepsin	Val82Ala/Asp25Asn mutant; complex with AP2V substrate variant of NC-P1 decamer peptide	1TSQ_A
AA	A02.001	HIV-1 retropepsin	Val82Ala/Asp25Asn mutant; complex with AP2V substrate variant of NC-P1 decamer peptide	1TSQ_P
AA	A02.001	HIV-1 retropepsin	wild-type Asp25Asn variant; complex with decamer NCP1 substrate peptide	1TSU_A
AA	A02.001	HIV-1 retropepsin	wild-type Asp25Asn variant; complex with decamer NCP1 substrate peptide	1TSU_P
AA	A02.001	HIV-1 retropepsin	peptidase domain only; multi-drug resistant isolate	1TW7
AA	A02.001	HIV-1 retropepsin	complex with peptidomimetic inhibitor KI2-Phe-Glu-Glu-NH2	1U8G_A
AA	A02.001	HIV-1 retropepsin	complex with [3-[1-(4-bromophenyl)isobutyl]-4-hydroxycoumarin (U095438)	1UPJ
AA	A02.001	HIV-1 retropepsin	complex with HOE/BAY 793 inhibitor	1VIJ
AA	A02.001	HIV-1 retropepsin	compex with HOE/BAY 793 inhibitor, orthorhombic form	1VIK
AA	A02.001	HIV-1 retropepsin	complex with fluoro substituted diol- based c2-symmetric inhibitor N,N-[2,5-O-di-3-fluoro-benzyl-glucaryl]-di-[1-amino-indan-2-ol]	1W5V_A
AA	A02.001	HIV-1 retropepsin	complex with fluoro substituted diol- based c2-symmetric inhibitor (2R,3R,4R,5R)-2,5-bis[(2,4-difluorobenzyl)oxy]-3,4-dihydroxy-N,N'-bis[(1R,2S)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]hexanediamide	1W5W_A
AA	A02.001	HIV-1 retropepsin	complex with fluoro substituted diol- based c2-symmetric inhibitor (2R,3R,4R,5R)-2,5-bis[(2,3-difluorobenzyl)oxy]-3,4-dihydroxy-N,N'-bis[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]hexanediamide	1W5X_A
AA	A02.001	HIV-1 retropepsin	complex with fluoro substituted diol- based c2-symmetric inhibitor (2R,3R,4R,5R)-2,5-bis[(2,5-difluorobenzyl)oxy]-3,4-dihydroxy-N,N'-bis[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]hexanediamide	1W5Y_A
AA	A02.001	HIV-1 retropepsin	complex with asymmetric inhibitor BEA568	1WBK_A
AA	A02.001	HIV-1 retropepsin	complex with symmetric inhibitor BEA450	1WBM_A
AA	A02.001	HIV-1 retropepsin	complex with pyrrolidinmethanamine	1XL2_A
AA	A02.001	HIV-1 retropepsin	complex with amidhyroxysulfone	1XL5_A
AA	A02.001	HIV-1 retropepsin	complex with Pro-Ile-Val-NH2 peptide product	1YTG
AA	A02.001	HIV-1 retropepsin	complex with ac-Ser-Leu-Asn-Phe peptide product	1YTH
AA	A02.001	HIV-1 retropepsin	complex with macrocyclic peptidomimetic inhibitor 3	1Z1H_A
AA	A02.001	HIV-1 retropepsin	complex with macrocyclic peptidomimetic inhibitor 2	1Z1R_A
AA	A02.001	HIV-1 retropepsin	lle63Pro, Ala71Val, Val82Thr, Ile84Val mutant; complex with a hydroxyethylamine peptidomimetic inhibitor Boc-Phe-psi[r-CH(OH)CH2NH]-Phe-Glu-Phe-NH2	1Z8C_A
AA	A02.001	HIV-1 retropepsin	Ala71Val, Val82Thr, Ile84Val mutant; complex with a hydroxyethylamine peptidomimetic inhibitor Boc-Phe-psi[r-CH(OH)CH2NH]-Phe-Glu-Phe-NH2	1ZBG_A
AA	A02.001	HIV-1 retropepsin	Ala71Val, Val82Thr, Ile84Val mutant; complex with a hydroxyethylamine peptidomimetic inhibitor Boc-Phe-psi[r-CH(OH)CH2NH]-Phe-Glu-Phe-NH2	1ZJ7_A
AA	A02.001	HIV-1 retropepsin	Ala71Val, Val82Thr, Ile84Val mutant; complex with a hydroxyethylamine peptidomimetic inhibitor	1ZLF_A
AA	A02.001	HIV-1 retropepsin	Ala71Val, Val82Thr, Ile84Val mutant; complex with a hydroxyethylamine peptidomimetic inhibitor Boc-Phe-psi[r-CH(OH)CH2NH]-Phe-Glu-Phe-NH2	1ZPK_A
AA	A02.001	HIV-1 retropepsin	complex with a hydroxyethylamine inhibitor N-(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-4-phenylbutyl-L-phenylalanyl-L-alpha-glutamyl-L-phenylalaninamide	1ZSF_A
AA	A02.001	HIV-1 retropepsin	complex with a hydroxyethylamine peptidomimetic inhibitor Boc-Phe-psi[r-CH(OH)CH2NH]-Phe-Glu-Phe-NH2	1ZSR_A
AA	A02.001	HIV-1 retropepsin	complex with cobalt bis(1,2-dicarbollide)	1ZTZ_A
AA	A02.001	HIV-1 retropepsin	complex with ts-126	2A1E_A
AA	A02.001	HIV-1 retropepsin	synthesis and activity of n-axyl azacyclic urea hiv-1 protease inhibitors with high potency against multiple drug resistant viral strains.	2A4F_A
AA	A02.001	HIV-1 retropepsin	complex with UCSF8 inhibitor	2AID
AA	A02.001	HIV-1 retropepsin	Ile84Val mutant; complex with a substrate analog p2-nc	2AOC_A
AA	A02.001	HIV-1 retropepsin	complex with a substrate analog p2-nc	2AOD_A
AA	A02.001	HIV-1 retropepsin	Val82Ala mutant; complex with a substrate analog ca-p2	2AOE_A
AA	A02.001	HIV-1 retropepsin	Val82Ala mutant; complex with a substrate analog p1-p6	2AOF_A
AA	A02.001	HIV-1 retropepsin	Val82Ala mutant; complex with a substrate analog p2-nc	2AOG_A
AA	A02.001	HIV-1 retropepsin	Val82Ala mutant; complex with a substrate analog p6-pr	2AOH_A
AA	A02.001	HIV-1 retropepsin	complex with a substrate analog p1-p6	2AOI_A
AA	A02.001	HIV-1 retropepsin	complex with a substrate analog p6-pr	2AOJ_A
AA	A02.001	HIV-1 retropepsin	complex with atazanavir	2AQU_A
AA	A02.001	HIV-1 retropepsin	kinetics, stability, and structural changes in high resolution crystalstructures of hiv-1 protease with drug resistant mutations l24i, i50v, and g73s	2AVM_A
AA	A02.001	HIV-1 retropepsin	kinetics, stability, and structural changes in high resolution crystalstructures of hiv-1 protease with drug resistant mutations l24i, i50v, and g73s	2AVO_A
AA	A02.001	HIV-1 retropepsin	kinetics, stability, and structural changes in high resolution crystalstructures of hiv-1 protease with drug resistant mutations l24i, i50v, and g73s	2AVQ_A
AA	A02.001	HIV-1 retropepsin	kinetics, stability, and structural changes in high resolution crystal structures of hiv-1 protease with drug resistant mutations l24i, i50v, and g73s	2AVS_A
AA	A02.001	HIV-1 retropepsin	kinetics, stability, and structural changes in high resolution crystal structures of hiv-1 protease with drug resistant mutations l24i, i50v, and g73s	2AVV_A
AA	A02.001	HIV-1 retropepsin	ML4-3 mutant; complex with inhibitorTL3	2AZ8_A
AA	A02.001	HIV-1 retropepsin	hiv-1 protease nl4-3 1x mutant	2AZ9_A
AA	A02.001	HIV-1 retropepsin	NL4-3 3X mutant; complex with inhibitorTL-3	2AZB_A
AA	A02.001	HIV-1 retropepsin	hiv-1 protease nl4-3 6x mutant ***caveat 2azc incorrect chirality at ca of ala j 201	2AZC_A
AA	A02.001	HIV-1 retropepsin	complex with ritonavir	2B60_A
AA	A02.001	HIV-1 retropepsin	mutant; complex with indinavir	2B7Z_B
AA	A02.001	HIV-1 retropepsin	complex with akc4p_133a	2BB9_A
AA	A02.001	HIV-1 retropepsin	complex with hh1_173_3a	2BBB_A
AA	A02.001	HIV-1 retropepsin	complex with L-738,317 inhibitor	2BPV
AA	A02.001	HIV-1 retropepsin	complex with L-738,317 inhibitor	2BPW
AA	A02.001	HIV-1 retropepsin	complex with L-735,524 inhibitor	2BPX
AA	A02.001	HIV-1 retropepsin	complex with L-739,622 inhibitor	2BPY
AA	A02.001	HIV-1 retropepsin	complex with L-739,622 inhibitor	2BPZ
AA	A02.001	HIV-1 retropepsin	complex with inhibitor AHA455	2BQV_A
AA	A02.001	HIV-1 retropepsin	wild-type; complex with r01	2F3K_A
AA	A02.001	HIV-1 retropepsin	Asp30Asn mutant; complex with inhibitor TMC114	2F80_A
AA	A02.001	HIV-1 retropepsin	Leu90Met mutant; complex with inhibitor TMC114	2F81_A
AA	A02.001	HIV-1 retropepsin	Ile50Val mutant; complex with inhibitor TMC114	2F8G_A
AA	A02.001	HIV-1 retropepsin	Thr80Ser variant; complex with the inhibitor saquinavir	2FGU_A
AA	A02.001	HIV-1 retropepsin	Thrt80Asn variant; complex with the inhibitor saquinavir	2FGV_A
AA	A02.001	HIV-1 retropepsin	Asp25Asn mutant; complex with wild-type HIV-1 NC-P1 substrate.	2FNS_A
AA	A02.001	HIV-1 retropepsin	drug-resistant (Val82Ala) inactive (Asp25Asn) mutant; complex with AP2V variant of hiv-1 NC-P1 substrate.	2FNT_A
AA	A02.001	HIV-1 retropepsin	structure of hiv protease 6x mutant in apo form	2HB2_A
AA	A02.001	HIV-1 retropepsin	complex with potent inhibitor GRL06579	2HB3_A
AA	A02.001	HIV-1 retropepsin	structure of hiv protease nl4-3 in an unliganded state	2HB4_A
AA	A02.001	HIV-1 retropepsin	6x mutant; complex with AB-2.	2HC0_A
AA	A02.001	HIV-1 retropepsin	recombinant	2HVP
AA	A02.001	HIV-1 retropepsin	complex with KB-19	2I0A_A
AA	A02.001	HIV-1 retropepsin	complex with AD-81	2I0D_A
AA	A02.001	HIV-1 retropepsin	complex with inhibitor jg-365	2J9J_A
AA	A02.001	HIV-1 retropepsin	complex with inhibitor MVT-101	2J9K_A
AA	A02.001	HIV-1 retropepsin	complex with jg-365	2JE4_A
AA	A02.001	HIV-1 retropepsin	Val82Ala mutant; complex with a inhibitor saquinavir	2NMY_A
AA	A02.001	HIV-1 retropepsin	Val82Ala mutant; complex with a inhibitor saquinavir	2NMZ_A
AA	A02.001	HIV-1 retropepsin	Ile84Val mutant; complex with a inhibitor saquinavir	2NNK_A
AA	A02.001	HIV-1 retropepsin	Ile84Val mutant; complex with a inhibitor saquinavir	2NNP_A
AA	A02.001	HIV-1 retropepsin	complex with product in situ	2NPH_A
AA	A02.001	HIV-1 retropepsin	Asp25Asn mutant; complex with rt-rh analogue peptide gly-ala-asp-ile-phe*tyr-leu-asp-gly-ala	2NXD_A
AA	A02.001	HIV-1 retropepsin	Asp25Asn mutant; complex with peptide Gly-Ala-Glu-Val-Phe*Tyr-Val-Asp-Gly-Ala	2NXL_A
AA	A02.001	HIV-1 retropepsin	Asp25Asn mutant; complex with the rt-rh analogue peptide gly-ala-gln-thr-phe*tyr-val-asp-gly-ala	2NXM_A
AA	A02.001	HIV-1 retropepsin	Gln7Lys mutant; complex with Atazanavir	2O4K_A
AA	A02.001	HIV-1 retropepsin	Gln7Lys, Ile50Val mutant; complex with Tipranavir	2O4L_A
AA	A02.001	HIV-1 retropepsin	TRM mutant; complex with Tipranavir	2O4N_A
AA	A02.001	HIV-1 retropepsin	Gln7Lys mutant; complex with Tipranavir	2O4P_A
AA	A02.001	HIV-1 retropepsin	Gln7Lys mutant; complex with Lopinavir	2O4S_A
AA	A02.001	HIV-1 retropepsin	complex with TL-3 inhibitor	2P3B_A
AA	A02.001	HIV-1 retropepsin	subtype F; complex with TL-3 inhibitor	2P3C_A
AA	A02.001	HIV-1 retropepsin	multi-drug resistant mutant subtype F; complex with TL-3 inhibitor	2P3D_A
AA	A02.001	HIV-1 retropepsin	apo wild-type hiv protease in the open conformation	2PC0_A
AA	A02.001	HIV-1 retropepsin	Gln7Lys, Leu33Ile, Leu63Ile mutant; complex with KNI-10075	2PK5_A
AA	A02.001	HIV-1 retropepsin	Gln7Lys, Leu33Ile, Leu63Ile mutant; complex with KNI-10033	2PK6_A
AA	A02.001	HIV-1 retropepsin	complex with N,N'-(3S,4S)-pyrrolidine-3,4-diylbis(N-benzylbenzenesulfonamide)	2PQZ_A
AA	A02.001	HIV-1 retropepsin	complex with CARB-AD37	2PSU_A
AA	A02.001	HIV-1 retropepsin	complex with CARB-KB45	2PSV_A
AA	A02.001	HIV-1 retropepsin	complex with N,N'-(3S,4S)-pyrrolidine-3,4-diylbis(4-amino-N-benzylbenzenesulfonamide)	2PWC_A
AA	A02.001	HIV-1 retropepsin	complex with 4,4'-(3S,4S)-pyrrolidine-3,4-diylbis[(benzylimino)sulfonyl]dibenzamide	2PWR_A
AA	A02.001	HIV-1 retropepsin	mutant; complex with nelfinavir	2PYM_A
AA	A02.001	HIV-1 retropepsin	mutant; complex with Nelfinavir	2PYN_A
AA	A02.001	HIV-1 retropepsin	complex with a lysine sulfonamide inhibitor	2Q3K_A
AA	A02.001	HIV-1 retropepsin	complex with KB73	2Q54_A
AA	A02.001	HIV-1 retropepsin	complex with KK44	2Q55_A
AA	A02.001	HIV-1 retropepsin	complex with lopinavir	2Q5K_A
AA	A02.001	HIV-1 retropepsin	mutant; complex with nelfinavir	2Q63_A
AA	A02.001	HIV-1 retropepsin	mutant; complex with nelfinavir	2Q64_A
AA	A02.001	HIV-1 retropepsin	mutant; complex with nelfinavir	2QAK_A
AA	A02.001	HIV-1 retropepsin	hiv-1 protease mutant d30n with potent antiviral inhibitor grl-98065	2QCI_A
AA	A02.001	HIV-1 retropepsin	hiv-1 protease mutant i50v with potent antiviral inhibitor grl-98065	2QD6_A
AA	A02.001	HIV-1 retropepsin	hiv-1 protease mutant v82a with potent antiviral inhibitor grl-98065	2QD7_A
AA	A02.001	HIV-1 retropepsin	hiv-1 protease mutant i84v with potent antiviral inhibitor grl-98065	2QD8_A
AA	A02.001	HIV-1 retropepsin	the influence of i47a mutation on reduced susceptibility to the protease inhibitor lopinavir	2QHC_A
AA	A02.001	HIV-1 retropepsin	complex with inhibitor MIT-1-AC6	2QHY_A
AA	A02.001	HIV-1 retropepsin	complex with inhibitor MIT-1-AC87	2QHZ_A
AA	A02.001	HIV-1 retropepsin	complex with inhibitor MIT-1-KK80	2QI0_A
AA	A02.001	HIV-1 retropepsin	complex with inhibitor MIT-1-KK81	2QI1_A
AA	A02.001	HIV-1 retropepsin	complex with inhibitor MIT-2-AD94	2QI3_A
AA	A02.001	HIV-1 retropepsin	complex with inhibitor MIT-2-AD93	2QI4_A
AA	A02.001	HIV-1 retropepsin	complex with inhibitor MIT-2-KC08	2QI5_A
AA	A02.001	HIV-1 retropepsin	complex with inhibitor MIT-2-KB98	2QI6_A
AA	A02.001	HIV-1 retropepsin	complex with inhibitor MIT-2-AD86	2QI7_A
AA	A02.001	HIV-1 retropepsin	complex with PL-100	2QMP_A
AA	A02.001	HIV-1 retropepsin	complex with 4,4'-[(3S,4S)-pyrrolidine-3,4-diylbis([4- (trifluoromethyl)benzyl]iminosulfonyl)]dibenzamide	2QNN_A
AA	A02.001	HIV-1 retropepsin	complex with	2QNP_A
AA	A02.001	HIV-1 retropepsin	complex with a chloro decorated pyrrolidine-based inhibitor	2QNQ_A
AA	A02.001	HIV-1 retropepsin	i84v hiv-1 protease mutant in complex with a carbamoyl decorated pyrrolidine-based inhibitor	2R38_A
AA	A02.001	HIV-1 retropepsin	Ile50Val mutant; complex with a carbamoyl decorated pyrrolidine-based inhibitor	2R3T_A
AA	A02.001	HIV-1 retropepsin	Ile84Val mutant; complex with a amino decorated pyrrolidine-based inhibitor	2R3W_A
AA	A02.001	HIV-1 retropepsin	i50v hiv-1 protease in complex with an amino decorated pyrrolidine-based inhibitor	2R43_A
AA	A02.001	HIV-1 retropepsin	subtype c protease; complex with indinavir	2R5P_A
AA	A02.001	HIV-1 retropepsin	subtype c; complex with nelfinavir	2R5Q_A
AA	A02.001	HIV-1 retropepsin	subtype C	2R8N
AA	A02.001	HIV-1 retropepsin	complex with U100313	2UPJ
AA	A02.001	HIV-1 retropepsin	two-carbon-elongated hiv-1 protease inhibitors with a tertiary-alcohol-containing transition-state mimic	2UXZ_A
AA	A02.001	HIV-1 retropepsin	two-carbon-elongated hiv-1 protease inhibitors with a tertiary-alcohol-containing transition-state mimic	2UY0_A
AA	A02.001	HIV-1 retropepsin	hiv-1 protease inhibitors containing a tertiary alcohol in the transition-state mimic with improved cell-based antiviral activity	2WKZ_A
AA	A02.001	HIV-1 retropepsin	wild type hiv-1 protease with potent antiviral inhibitor grl-98065	2Z4O_A
AA	A02.001	HIV-1 retropepsin	Ile47Ala mutant on reduced susceptibility to the protease inhibitor lopinavir	2Z54_A
AA	A02.001	HIV-1 retropepsin	complex with (3S,4S),-3,4-Bis-[(4-carbamoyl-benzensulfonyl)- (3-methyl-but-2-enyl)-amino]-pyrrolidine	2ZGA_A
AA	A02.001	HIV-1 retropepsin	complex with potent inhibitor KNI-272	2ZYE_A
AA	A02.001	HIV-1 retropepsin	complex with kni-1689	3A2O_A
AA	A02.001	HIV-1 retropepsin	complex with benzoylamino-benzyl-methyl-[2-hydroxy-3-[1-methyl-ethyl-oxy-N-formamidyl]-4-phenyl-butyl]-ammonium	3AID
AA	A02.001	HIV-1 retropepsin	complex with gem-diol-amine tetrahedral intermediate nlltqi	3B7V_A
AA	A02.001	HIV-1 retropepsin	Ile54Val mutant; complex with gem-diol-amine intermediate nlltqi	3B80_A
AA	A02.001	HIV-1 retropepsin	Ile84Val mutant; complex with a pyrrolidine diester	3BC4_A
AA	A02.001	HIV-1 retropepsin	complex with N,N'-(iminodiethane-2,1-diyl)bis[4-amino- N-(2-methylpropyl)benzenesulfonamide]	3BGB_A
AA	A02.001	HIV-1 retropepsin	complex with N,N'-(iminodiethane-2,1-diyl)bis(4-amino- N-benzylbenzenesulfonamide)	3BGC_A
AA	A02.001	HIV-1 retropepsin	complex with a three armed pyrrolidine derivative	3BHE_A
AA	A02.001	HIV-1 retropepsin	Asp25Asn mutant; complex with p2-nc analog inhibitor	3BVA_A
AA	A02.001	HIV-1 retropepsin	cystal structure of hiv-1 active site mutant d25n and inhibitor darunavir	3BVB_A
AA	A02.001	HIV-1 retropepsin	crystal structures of highly constrained substrate and hydrolysis products bound to hiv-1 protease. implications for catalytic mechanism	3BXR_A
AA	A02.001	HIV-1 retropepsin	crystal structures of highly constrained substrate and hydrolysis products bound to hiv-1 protease. implications for catalytic mechanism	3BXS_A
AA	A02.001	HIV-1 retropepsin	complex with (3S,4S),-3,4-Bis-[(4-carbamoyl-benzensulfonyl)- (3-methyl-but-2-enyl)-amino]-pyrrolidine (orthorhombic space group)	3CKT_A
AA	A02.001	HIV-1 retropepsin	effect of flap mutations inhibition by saquinavir and darunavir	3CYW_A
AA	A02.001	HIV-1 retropepsin	Ile50Val mutant; complex with inhibitor saquinavir	3CYX_A
AA	A02.001	HIV-1 retropepsin	Ile54Met mutant; complex with inhibitor saquinavir	3D1X_A
AA	A02.001	HIV-1 retropepsin	Ile54Val mutant; complex with inhibitor saquinavir	3D1Y_A
AA	A02.001	HIV-1 retropepsin	Ile54Met mutant; complex with inhibitor darunavir	3D1Z_A
AA	A02.001	HIV-1 retropepsin	Ile54Val mutant; complex with inhibitor darunavia	3D20_A
AA	A02.001	HIV-1 retropepsin	complex with substrate p1-p6	3D3T_A
AA	A02.001	HIV-1 retropepsin	wild type hiv-1 protease with potent antiviral inhibitor grl-0255a	3DJK_A
AA	A02.001	HIV-1 retropepsin	wild type hiv-1 protease with potent antiviral inhibitor grl-0105a	3DK1_A
AA	A02.001	HIV-1 retropepsin	multidrug resistant variant (Leu10Ile/Gly48Val/Ile54Val/Val64Ile/Val82Ala); complex with inhibitor amprenavir (apv)	3EKP_A
AA	A02.001	HIV-1 retropepsin	multi-drug resistant form (Leu63Pro/Val82Thr/Ile84Val); complex with inhibitor saquinavir (sqv)	3EKQ_A
AA	A02.001	HIV-1 retropepsin	multi-drug resistant variant (Leu10Phe/Gly48Val/Ile54Val/Val64Ile/Val82Ala); complex with darunavir (drv)	3EKT_A
AA	A02.001	HIV-1 retropepsin	wild type; complex with the inhibitor, amprenavir	3EKV_A
AA	A02.001	HIV-1 retropepsin	multi-drug resistance variant (Leu10Ile/Gly48Val/Ile54Val/Val64Ile/Val82Ala); complex with the inhibitor atazanavir (atv) in complex with a refer: flap+ in citation.	3EKW_A
AA	A02.001	HIV-1 retropepsin	wild-type; complex with the inhibitor nelfinavir	3EKX_A
AA	A02.001	HIV-1 retropepsin	wild-type; complex with the inhibitor, atazanavir	3EKY_A
AA	A02.001	HIV-1 retropepsin	multi-drug resistant variant (Leu10Ile/Gly48Val/Ile54Val/Val64Ile/Val82Ala); in complex with inhibitor nelfinavir (nfv)	3EL0_A
AA	A02.001	HIV-1 retropepsin	wild-type; complex with the inhibitor, atazanavir	3EL1_A
AA	A02.001	HIV-1 retropepsin	drug resistant Ile50Leu/Ala71Val variant; complex with amprenavir (apv)	3EM3_A
AA	A02.001	HIV-1 retropepsin	drug- resistant Ile50Val/Ala71Val variant; complex with the protease inhibitor atazanavir	3EM4_A
AA	A02.001	HIV-1 retropepsin	Ile50Leu/Ala71val mutant; complex with inhibitor darunavir	3EM6_A
AA	A02.001	HIV-1 retropepsin	complex with potent inhibitor KNI-272	3FX5_A
AA	A02.001	HIV-1 retropepsin	hiv protease inhibitors with pseudo-symmetric cores	3GGA_G
AA	A02.001	HIV-1 retropepsin	hiv protease, pseudo-symmetric inhibitors	3GGV_B
AA	A02.001	HIV-1 retropepsin	hiv protease, pseudo-symmetric inhibitors	3GGX_A
AA	A02.001	HIV-1 retropepsin	wild type; complex with inhibitor kb60	3GI4_A
AA	A02.001	HIV-1 retropepsin	wild type; complex with inhibitor kb62	3GI5_A
AA	A02.001	HIV-1 retropepsin	wild type; complex with inhibitor ad78	3GI6_A
AA	A02.001	HIV-1 retropepsin	Cys replaced with alpha-amino-N-butyric acid	3HVP
AA	A02.001	HIV-1 retropepsin	complex with mutant resistant inhibitor uic-98038	3I7E_A
AA	A02.001	HIV-1 retropepsin	complex with saquinavir	3K4V_A
AA	A02.001	HIV-1 retropepsin	complex with darunavir	3LZS_A
AA	A02.001	HIV-1 retropepsin	nelfinavir resistant variant (Asn88Ser); complex with the protease inhibitor darunavir.	3LZU_B
AA	A02.001	HIV-1 retropepsin	nelfinavir-resistant variant (Asp30Asn/Asn88Asp); complex with darunavir.	3LZV_A
AA	A02.001	HIV-1 retropepsin	wild-type; complex with inhibitor kc53	3MXD_A
AA	A02.001	HIV-1 retropepsin	wild-type; complex with inhibitor kc32	3MXE_A
AA	A02.001	HIV-1 retropepsin	complex with saquinavir:ritonavir 1:1	3NDT_A
AA	A02.001	HIV-1 retropepsin	complex with saquinavir:ritonavir 1:5	3NDU_A
AA	A02.001	HIV-1 retropepsin	complex with saquinavir:ritonavir 1:15	3NDW_A
AA	A02.001	HIV-1 retropepsin	complex with saquinavir:ritonavir 1:50	3NDX_A
AA	A02.001	HIV-1 retropepsin	wild-type; complex with antiviral drug amprenavir	3NU3_A
AA	A02.001	HIV-1 retropepsin	Val32Ile mutant; complex with antiviral drug amprenavir	3NU4_A
AA	A02.001	HIV-1 retropepsin	Ile50Val mutant; complex with antiviral drug amprenavir	3NU5_A
AA	A02.001	HIV-1 retropepsin	Ile54Met mutant; complex with antiviral drug amprenavir	3NU6_A
AA	A02.001	HIV-1 retropepsin	Ile54Val mutant; complex with antiviral drug amprenavir	3NU9_A
AA	A02.001	HIV-1 retropepsin	Ile54Val mutant; complex with antiviral drug amprenavir	3NUJ_A
AA	A02.001	HIV-1 retropepsin	Ile90Met mutant; complex with antiviral drug amprenavir	3NUO_A
AA	A02.001	HIV-1 retropepsin	wild-type; complex with kd13	3O99_A
AA	A02.001	HIV-1 retropepsin	wild-type; complex with kd14	3O9A_A
AA	A02.001	HIV-1 retropepsin	wild-type; complex with kd25	3O9B_A
AA	A02.001	HIV-1 retropepsin	wild-type; complex with kd20	3O9C_A
AA	A02.001	HIV-1 retropepsin	wild-type; complex with kd19	3O9D_A
AA	A02.001	HIV-1 retropepsin	wild-type; complex with af60	3O9E_A
AA	A02.001	HIV-1 retropepsin	wild-type; complex with kd27	3O9F_A
AA	A02.001	HIV-1 retropepsin	wild-type; complex with af53	3O9G_A
AA	A02.001	HIV-1 retropepsin	wild-type; complex with kd26	3O9H_A
AA	A02.001	HIV-1 retropepsin	wild-type; complex with af61	3O9I_A
AA	A02.001	HIV-1 retropepsin	wild-type; complex with oxatricyclic designed inhibitor GRL-0519a	3OK9_A
AA	A02.001	HIV-1 retropepsin	complex with saquinavir	3OXC_A
AA	A02.001	HIV-1 retropepsin	Ile50Val, Ala71 variant; complex with the protease inhibitor amprenavir.	3OXV_B
AA	A02.001	HIV-1 retropepsin	Ile50Val/Ala71Val variant; complex with the protease inhibitor darunavir	3OXW_B
AA	A02.001	HIV-1 retropepsin	drug- resistant Ile50Val/Ala71Val variant; complex with the protease inhibitor atazanavir	3OXX_B
AA	A02.001	HIV-1 retropepsin	Leu76Val variant; complex with the protease inhibitor darunavir.	3OY4_A
AA	A02.001	HIV-1 retropepsin	recombinant	3PHV
AA	A02.001	HIV-1 retropepsin	wild type; complex with a substituted bis-tetrahydrofuran inhibitor, GRL-044-10a	3QAA_A
AA	A02.001	HIV-1 retropepsin	wild-type; complex with tmc310911	3R4B_A
AA	A02.001	HIV-1 retropepsin	Val32Ile/Ile47Val/Val82Ile mutant; complex with antiviral drug amprenavir	3S43_A
AA	A02.001	HIV-1 retropepsin	triple mutant Val32Ile/Ile47Val/Val82Ile; complex with antiviral drug darunavir in space group p212121	3S53_A
AA	A02.001	HIV-1 retropepsin	triple mutant Val32Ile/Ile47Val/Val82Ile; complex with antiviral drug darunavir in space group p21212	3S54_A
AA	A02.001	HIV-1 retropepsin	triple mutants Val32Ile, Ile47Val, Val82Ile with antiviral drug saquinavir	3S56_A
AA	A02.001	HIV-1 retropepsin	discovery of new hiv protease inhibitors with potential for convenientdosing and reduced side effects: a-790742 and a-792611.	3S85_A
AA	A02.001	HIV-1 retropepsin	wild-type; complex with ag23	3SA3_A
AA	A02.001	HIV-1 retropepsin	wild-type; complex with af72	3SA4_A
AA	A02.001	HIV-1 retropepsin	wild-type; complex with af69	3SA5_A
AA	A02.001	HIV-1 retropepsin	wild-type; complex with af71	3SA6_A
AA	A02.001	HIV-1 retropepsin	wild-type; complex with af55	3SA7_A
AA	A02.001	HIV-1 retropepsin	wild-type; complex with kb83	3SA8_A
AA	A02.001	HIV-1 retropepsin	wild-type; complex with af68	3SA9_A
AA	A02.001	HIV-1 retropepsin	wild-type; complex with af77	3SAA_A
AA	A02.001	HIV-1 retropepsin	wild-type; complex with af78	3SAB_A
AA	A02.001	HIV-1 retropepsin	wild-type; complex with af80	3SAC_A
AA	A02.001	HIV-1 retropepsin	complex with TL-3-093 inhibitor	3TLH
AA	A02.001	HIV-1 retropepsin	South African wild type subtype c	3U71_A
AA	A02.001	HIV-1 retropepsin	wild-type; complex with mkp56	4DJO_A
AA	A02.001	HIV-1 retropepsin	wild-type; complex with mkp73	4DJP_A
AA	A02.001	HIV-1 retropepsin	wild-type; complex with mkp86	4DJQ_A
AA	A02.001	HIV-1 retropepsin	wild-type; complex with mkp97	4DJR_A
AA	A02.001	HIV-1 retropepsin	hiv protease (pr) dimer with acetate in exo site and peptide in activesite	4E43_A
AA	A02.001	HIV-1 retropepsin	apo hiv protease (pr) dimer in closed form with fragment 1f1 in the outside/top of flap	4EJ8_A
AA	A02.001	HIV-1 retropepsin	dimer in closed form with pepstatin in active site and fragment 1f1 in the outside/top of flap	4EJD_A
AA	A02.001	HIV-1 retropepsin	dimer in closed form with pepstatin in active site and fragment 1f1-n in the outside/top of flap	4EJK_A
AA	A02.001	HIV-1 retropepsin	apo hiv protease (pr) dimer in closed form with fragment 1f1-n in the outside/top of flap	4EJL_A
AA	A02.001	HIV-1 retropepsin	inactive single chain wild-type; complex with the substrate rt-rh	4EP2_A
AA	A02.001	HIV-1 retropepsin	inactive single chain wild-type; complex with the substrate rt-rh	4EP2_B
AA	A02.001	HIV-1 retropepsin	inactive single chain variant; complex with the substrate ca-p2	4EP3_A
AA	A02.001	HIV-1 retropepsin	inactive single chain variant; complex with the substrate p2-nc	4EPJ_A
AA	A02.001	HIV-1 retropepsin	inactive single chain variant; complex with the substrate p2-nc	4EQ0_A
AA	A02.001	HIV-1 retropepsin	inactive single chain variant; complex with the substrate rt-rh	4EQJ_A
AA	A02.001	HIV-1 retropepsin	inactive single chain variant; complex with the substrate rt-rh	4EQJ_G
AA	A02.001	HIV-1 retropepsin	complex with the n terminal product of ca-p2 cleavage site	4F73_A
AA	A02.001	HIV-1 retropepsin	complex with the n terminal product of the substrate ma-ca.	4F74_A
AA	A02.001	HIV-1 retropepsin	complex with the n terminal product of the substrate rh-in	4F75_A
AA	A02.001	HIV-1 retropepsin	complex with the products of p1-p6 substrate	4F76_A
AA	A02.001	HIV-1 retropepsin	complex with N-Ac-Thr-Ile-Nle-PSI(CH2-NH)-Nle-Gln-Arg amide	4HVP
AA	A02.001	HIV-1 retropepsin	tl-3 inhibited trp6ala hiv protease	4K4P_A
AA	A02.001	HIV-1 retropepsin	tl-3 inhibited trp6ala hiv protease with 3-bromo-2,6-dimethoxybenzoic acid bound in flap site ***caveat 4k4q chirality error on c10 center of 3tl 108 a	4K4Q_A
AA	A02.001	HIV-1 retropepsin	tl-3 inhibited trp6ala hiv protease with 1-bromo-2-napthoic acid boundin exosite	4K4R_A
AA	A02.001	HIV-1 retropepsin	wild-type; complex with novel tricyclic p2-ligands GRL-0739a	4KB9_A
AA	A02.001	HIV-1 retropepsin	wild-type; complex with darunavir	4LL3_A
AA	A02.001	HIV-1 retropepsin	gs-8374, a novel phosphonate-containing inhibitor of hiv-1 protease, effectively inhibits hiv pr mutants with amino acid insertions	4M8X_A
AA	A02.001	HIV-1 retropepsin	multidrug-resistant clinical isolate; complex with non-peptidic inhibitor, GRL008	4NJS_A
AA	A02.001	HIV-1 retropepsin	multidrug-resistant clinical isolate; complex with darunavir	4NJT_A
AA	A02.001	HIV-1 retropepsin	multidrug-resistant clinical isolate; complex with tipranavir	4NJU_A
AA	A02.001	HIV-1 retropepsin	multidrug-resistant clinical isolate; complex with ritonavir	4NJV_A
AA	A02.001	HIV-1 retropepsin	nelfinavir-resistant, inactive Asp30Asn/Asn88Asp; complex with the p1-p6 substrate variant (Leu449Phe/Ser451Asn)	4OBD_A
AA	A02.001	HIV-1 retropepsin	nelfinavir-resistant, inactive Asp30Asn/Asn88Asp; complex with the p1-p6 substrate variant (Ser451Asn)	4OBF_A
AA	A02.001	HIV-1 retropepsin	nelfinavir-resistant, inactive Asp30Asn/Asn88Asp; complex with the p1-p6 substrate.	4OBG_A
AA	A02.001	HIV-1 retropepsin	complex with N,N-bis(2(R)-hydroxy-1(S)-indanyl)-2,6-(R,R)-diphenylmethyl-4-hydroxy-1,7,-heptandiamide	4PHV
AA	A02.001	HIV-1 retropepsin	multidrug-resistant clinical isolate; complex with non-peptidic inhibitor, GRL0519	4RVI_A
AA	A02.001	HIV-1 retropepsin	multidrug-resistant clinical isolate; complex with amprenavir	4RVJ_A
AA	A02.001	HIV-1 retropepsin	multidrug-resistant clinical isolate; complex with non-peptidic inhibitor, GRL079	4RVX_A
AA	A02.001	HIV-1 retropepsin	dimer in closed form with pepstatin in active site and fragment ak-2097 in the outside/top of flap	4TVG_A
AA	A02.001	HIV-1 retropepsin	hiv protease (pr) dimer in closed form with tl-3 in active site and fragment ak-2097 in the outside/top of flap *caveat 4tvh chiral center atom c10 of 3tl a 200 has sp2 hybridization *caveat 2 4tvh instead of sp3	4TVH_A
AA	A02.001	HIV-1 retropepsin	wild type; complex with GRL-050-10a (a gem-difluoro-bis- tetrahydrofuran as p2-ligand)	4U8W_A
AA	A02.001	HIV-1 retropepsin	multidrug resistant clinical isolate pr20; complex with inhibitor GRL-4410a	4YE3_A
AA	A02.001	HIV-1 retropepsin	multidrug resistant clinical isolate pr20; complex with inhibitor GRL-5010a	4YHQ_A
AA	A02.001	HIV-1 retropepsin	multidrug resistant clinical isolate pr20d25n with open flap	4Z4X_A
AA	A02.001	HIV-1 retropepsin	crystal structure of multidrug resistant hiv-1 protease clinical isolate pr20d25n with tucked flap	4Z50_A
AA	A02.001	HIV-1 retropepsin	wild type; complex with GRL-0648a (a isophthalamide-derived p2- ligand)	4ZIP_A
AA	A02.001	HIV-1 retropepsin	wild type; complex with GRL-096-13a (a boc-derivative p2-ligand,3,-5-dimethylbiphenyl p1-ligand)	4ZLS_A
AA	A02.001	HIV-1 retropepsin	wild type; complex with GRL-011-11a (a methylamine bis- tetrahydrofuran p2-ligand, sulfonamide isostere derivate)	5BRY_A
AA	A02.001	HIV-1 retropepsin	wild type; complex with GRL-047-11a (a methylamine bis- tetrahydrofuran p2-ligand, 4-amino sulfonamide derivative)	5BS4_A
AA	A02.001	HIV-1 retropepsin	complex with inhibitor GRL-004-11a containing substituted fused-tetrahydropyranyl tetrahydrofuran as P2-ligand	5DGU_A
AA	A02.001	HIV-1 retropepsin	complex with inhibitor GRL-105-11a containing substituted fused-tetrahydropyranyl tetrahydrofuran as p2-ligand	5DGW_A
AA	A02.001	HIV-1 retropepsin	triple mutant (Val32Ile/Ile47Val/Val82Ile); complex with darunavir at ph 6.0	5E5J_A
AA	A02.001	HIV-1 retropepsin	complex with acetyl-pepstatin	5HVP
AA	A02.001	HIV-1 retropepsin	complex with methyl n-[(1s)-1- benzhydryl-2-(3-morpholin-4-ium-2-ylpropylamino)-2-oxo- ethyl]carbamate	5IVQ_A
AA	A02.001	HIV-1 retropepsin	complex with methyl n-[(1s)-1-[[2-[(3s)-3-[(4-aminophenyl)methylamino]-4-hydroxy- butyl]phenyl]carbamoyl]-2,2-diphenyl-ethyl]carbamate	5IVR_A
AA	A02.001	HIV-1 retropepsin	complex with methyl n-[(1s)-1- benzhydryl-2-[2-[2-[(2r,5s)-5-(benzylcarbamoyloxymethyl)morpholin-2- yl]ethyl]anilino]-2-oxo-ethyl]carbamate	5IVS_A
AA	A02.001	HIV-1 retropepsin	wild type; complex with GRL- 10413	5KAO_A
AA	A02.001	HIV-1 retropepsin	Val32Ile/Ile47Val/Val82Ile mutant; complex with amprenavir at ph 6.0	5T8H_A
AA	A02.001	HIV-1 retropepsin	wild type; complex with GRL-09510	5V4Y_A
AA	A02.001	HIV-1 retropepsin	hiv protease (pr) with tl-3 in active site and 4-methylbenzene-1,2- diamine in exosite	5VEA_A
AA	A02.001	HIV-1 retropepsin	hiv protease (pr) in open form with mg2+ in active site and hive-9 in eye site	5VJ3_A
AA	A02.001	HIV-1 retropepsin	hiv protease (pr) in open form with mg2+ in active site and hive-9 in eye site	5W5W_A
AA	A02.001	HIV-1 retropepsin	complex with (s)-n-(3-fluoro-2-(2-(1-(phenylsulfonyl)piperazin-2-yl)ethyl)phenyl)-3,3-bis(4- fluorophenyl)propanamide	6B36_A
AA	A02.001	HIV-1 retropepsin	complex with n-(3-fluoro-2-(2- ((2s,6r)-6-methyl-1-(phenylsulfonyl)piperazin-2-yl)ethyl)phenyl)-3,3-bis(4-fluorophenyl)propanamide	6B38_A
AA	A02.001	HIV-1 retropepsin	complex with n-(3-fluoro-2-(2- ((2s,6r)-6-methyl-1-(phenylsulfonyl)piperazin-2-yl)ethyl)phenyl)-3,3-bis(4-fluorophenyl)propanamide	6B3C_A
AA	A02.001	HIV-1 retropepsin	complex with n-(3-fluoro-2-(2- ((2s,5s)-5-methyl-1-(phenylsulfonyl)piperazin-2-yl)ethyl)phenyl)-3,3-bis(4-fluorophenyl)propanamide	6B3F_A
AA	A02.001	HIV-1 retropepsin	complex with n-(3-fluoro-2-(2- ((2s,6s)-6-methyl-1-(phenylsulfonyl)piperazin-2-yl)ethyl)phenyl)-3,3-bis(4-fluorophenyl)propanamide	6B3G_A
AA	A02.001	HIV-1 retropepsin	complex with n-(2-(2-((6r,9s)-2,2-dioxido-2-thia-1,7-diazabicyclo[4.3.1]decan-9-yl)ethyl)-3- fluorophenyl)-3,3-bis(4-fluorophenyl)propanamide	6B3H_A
AA	A02.001	HIV-1 retropepsin	nl4-3 wt; complex with darunavir	6DGX_B
AA	A02.001	HIV-1 retropepsin	nl4-3 wt; complex with umass1	6DGY_B
AA	A02.001	HIV-1 retropepsin	nl4-3 wt; complex with umass6	6DGZ_B
AA	A02.001	HIV-1 retropepsin	nl4-3 v82i mutant; complex with darunavir	6DH3_B
AA	A02.001	HIV-1 retropepsin	nl4-3 Val82Ile mutant; complex with umass1	6DH4_B
AA	A02.001	HIV-1 retropepsin	nl4-3 Val82Ile mutant; complex with umass6	6DH5_B
AA	A02.001	HIV-1 retropepsin	nl4-3 i50v mutant; complex with darunavir	6DH6_B
AA	A02.001	HIV-1 retropepsin	nl4-3 Ile50Val mutant; complex with umass1	6DH7_B
AA	A02.001	HIV-1 retropepsin	nl4-3 Ile50Val mutant; complex with umass6	6DH8_B
AA	A02.001	HIV-1 retropepsin	wild-type hiv-1 protease in complex with tipranavir	6DIF_A
AA	A02.001	HIV-1 retropepsin	Leu76Val mutant; complex with tipranavir	6DIL_A
AA	A02.001	HIV-1 retropepsin	wild-type; complex with lopinavir	6DJ1_A
AA	A02.001	HIV-1 retropepsin	Leu76Val mutant; complex with lopinavir	6DJ2_A
AA	A02.001	HIV-1 retropepsin	Leu76Val mutant; complex with GRL-0519 (tris- tetrahydrofuran as p2 ligand)	6DJ5_A
AA	A02.001	HIV-1 retropepsin	Leu76Val mutant; complex with GRL-5010 (gem- difluoro-bis-tetrahydrofuran as p2 ligand)	6DJ7_A
AA	A02.001	HIV-1 retropepsin	wild type; complex with GRL-02815a, a thiochroman heterocycle with (s)-boc-amine functionality as the p2 ligand	6DV0_A
AA	A02.001	HIV-1 retropepsin	wild type; complex with GRL-04315a, a tetrahydronaphthalene carboxamide with (r)-boc-amine and (s)-hydroxyl functionalities as the p2 ligand	6DV4_A
AA	A02.001	HIV-1 retropepsin	wild type; complex with GRL-042-17a, 3-phenylhexahydro-2h- cyclopenta[d]oxazol-2-one with a bicyclic oxazolidinone scaffold as the p2 ligand	6E7J_A
AA	A02.001	HIV-1 retropepsin	wild type; complex with GRL-034-17a, (3as, 5r, 6ar)-2-oxohexahydcyclopenta[d]-5-oxazolyl urethane with a bicyclic oxazolidinone scaffas the p2 ligand	6E9A_A
AA	A02.001	HIV-1 retropepsin	complex with bpi-11	6IXD_A
AA	A02.001	HIV-1 retropepsin	wild type; complex with GRL-001	6MCR_A
AA	A02.001	HIV-1 retropepsin	wild type; complex with GRL-003	6MCS_A
AA	A02.001	HIV-1 retropepsin	wild-type hiv-1 protease in complex with a substrate analog ca-p2	6O48_A
AA	A02.001	HIV-1 retropepsin	Val32Ile/Ile47Val/Val82Ile mutant; complex with GRL-011-11a (a methylamine bis-tetrahydrofuran p2-ligand, sulfonamide isostere derivate)	6OTG_A
AA	A02.001	HIV-1 retropepsin	complex with ACE-Ser-Leu-Asn-Phe-PSI(CH(OH)-CH2)-Pro-Ile-Val-OME	7HVP
AA	A02.001	HIV-1 retropepsin	complex with U101935	7UPJ
AA	A02.001	HIV-1 retropepsin	complex with Val-Ser-Gln-Asn-Leu-PSI(CH(OH)-CH2)-Val-Ile-Val	8HVP
AA	A02.001	HIV-1 retropepsin	complex with A-74704l	9HVP
AA	A02.002	HIV-2 retropepsin	complex with inhibitor CGP 53820	1HII
AA	A02.002	HIV-2 retropepsin		1HSH
AA	A02.002	HIV-2 retropepsin		1HSI
AA	A02.002	HIV-2 retropepsin	complex with BILA 1906	1IDA
AA	A02.002	HIV-2 retropepsin	complex with BILA 2450	1IDB
AA	A02.002	HIV-2 retropepsin	Lys57Leu mutant; complex with NOA-His-CHA-PSI[CH(OH)CH(OH)]Val-Ile-APY	1IVP
AA	A02.002	HIV-2 retropepsin	Lys57Leu mutant; complex with QNC-Asn-CHA-PSI[CH(OH)CH(OH)]Val-NPT	1IVQ
AA	A02.002	HIV-2 retropepsin	complex with inhibitor containing an (hydroxyethyl) amide isostere	1JLD
AA	A02.002	HIV-2 retropepsin	theoretical model; complex with N-ac-Val-Val-Sta-Ala-Sta	1PHV
AA	A02.002	HIV-2 retropepsin	Lys57Leu mutant	2HPE
AA	A02.002	HIV-2 retropepsin	Lys57Leu mutant	2HPF
AA	A02.002	HIV-2 retropepsin	complex with Phe-Val-Phe-PSI(CH2NH)-Leu-Glu-Ile amide inhibitor	2MIP
AA	A02.002	HIV-2 retropepsin	theoretical model; complex with renin inhibitor H261	2PHV
AA	A02.002	HIV-2 retropepsin	complex with clinical drug darunavir	3EBZ_A
AA	A02.002	HIV-2 retropepsin	complex with antiviral inhibitor GRL-06579a	3EC0_A
AA	A02.002	HIV-2 retropepsin	complex with antiviral inhibitor GRL-98065	3ECG_A
AA	A02.002	HIV-2 retropepsin	wild-type; complex with antiviral drug amprenavir	3S45_A
AA	A02.002	HIV-2 retropepsin	complex with U096333	3UPJ
AA	A02.002	HIV-2 retropepsin	complex with U097410	4UPJ
AA	A02.002	HIV-2 retropepsin	complex with U99283	5UPJ
AA	A02.002	HIV-2 retropepsin	complex with U99294	6UPJ
AA	A02.004	equine infectious anaemia virus retropepsin	theoretical model	1EQI
AA	A02.004	equine infectious anaemia virus retropepsin	complex with inhibitor HBY-793	1FMB
AA	A02.004	equine infectious anaemia virus retropepsin	complex with inhibitor LP-130	2FMB
AA	A02.005	bovine immunodeficiency virus retropepsin		3KKR
AA	A02.005	bovine immunodeficiency virus retropepsin		3KKS
AA	A02.006	Visna lentivirus-type retropepsin		3HPG
AA	A02.006	Visna lentivirus-type retropepsin		3HPH
AA	A02.007	feline immunodeficiency virus retropepsin	complex with TL-3-093 inhibitor	1B11
AA	A02.007	feline immunodeficiency virus retropepsin	complex with acAla-Val-Sta-Glu-Ala-NH2	1FIV
AA	A02.007	feline immunodeficiency virus retropepsin	complex with Ac-naphylAla-Val-Sta-Glu-naphthylaminoAla substrate	2FIV
AA	A02.007	feline immunodeficiency virus retropepsin	complex with tl-3	2HAH_A
AA	A02.007	feline immunodeficiency virus retropepsin	complex with Ac-naphthylAla-Val-Leu-Ala-Glu-naphthylaminoAla substrate	3FIV
AA	A02.007	feline immunodeficiency virus retropepsin	complex with darunavir	3OGP_A
AA	A02.007	feline immunodeficiency virus retropepsin	complex with lopinavir	3OGQ_A
AA	A02.007	feline immunodeficiency virus retropepsin	complex with LP-130 inhibitor	4FIV
AA	A02.007	feline immunodeficiency virus retropepsin	complex with TL-3-093 inhibitor	5FIV
AA	A02.007	feline immunodeficiency virus retropepsin	complex with TL-3-093 inhibitor	6FIV
AA	A02.008	murine leukemia virus-type retropepsin		1D0E
AA	A02.008	murine leukemia virus-type retropepsin		1D1U
AA	A02.008	murine leukemia virus-type retropepsin		1I6J
AA	A02.008	murine leukemia virus-type retropepsin		1MML
AA	A02.008	murine leukemia virus-type retropepsin		1N4L
AA	A02.008	murine leukemia virus-type retropepsin		1NND
AA	A02.008	murine leukemia virus-type retropepsin		1QAI
AA	A02.008	murine leukemia virus-type retropepsin		1QAJ
AA	A02.008	murine leukemia virus-type retropepsin		1ZTT
AA	A02.008	murine leukemia virus-type retropepsin		1ZTW
AA	A02.008	murine leukemia virus-type retropepsin		2FJV
AA	A02.008	murine leukemia virus-type retropepsin		2FJW
AA	A02.008	murine leukemia virus-type retropepsin		2FJX
AA	A02.008	murine leukemia virus-type retropepsin		2FVP
AA	A02.008	murine leukemia virus-type retropepsin		2FVQ
AA	A02.008	murine leukemia virus-type retropepsin		2FVR
AA	A02.008	murine leukemia virus-type retropepsin		2FVS
AA	A02.008	murine leukemia virus-type retropepsin		2HB5
AA	A02.008	murine leukemia virus-type retropepsin		2M9U
AA	A02.008	murine leukemia virus-type retropepsin		2MQV
AA	A02.008	murine leukemia virus-type retropepsin		2MS0
AA	A02.008	murine leukemia virus-type retropepsin		2MS1
AA	A02.008	murine leukemia virus-type retropepsin		2R2R
AA	A02.008	murine leukemia virus-type retropepsin		2R2S
AA	A02.008	murine leukemia virus-type retropepsin		2R2T
AA	A02.008	murine leukemia virus-type retropepsin		2R2U
AA	A02.008	murine leukemia virus-type retropepsin		3FSI
AA	A02.008	murine leukemia virus-type retropepsin		3NNQ
AA	A02.008	murine leukemia virus-type retropepsin	peptidase domain only; complex with TL-3	3SLZ
AA	A02.008	murine leukemia virus-type retropepsin	peptidase domain only; complex with pepstatin	3SM1
AA	A02.008	murine leukemia virus-type retropepsin	peptidase domain only; complex with amprenavir	3SM2
AA	A02.008	murine leukemia virus-type retropepsin	complex with acetyl-pepstatin	4EXH_A
AA	A02.008	murine leukemia virus-type retropepsin		4M94
AA	A02.008	murine leukemia virus-type retropepsin		4M95
AA	A02.008	murine leukemia virus-type retropepsin		4MH8
AA	A02.008	murine leukemia virus-type retropepsin		4NZG
AA	A02.008	murine leukemia virus-type retropepsin		4XO0
AA	A02.008	murine leukemia virus-type retropepsin		4XPC
AA	A02.008	murine leukemia virus-type retropepsin		4XPE
AA	A02.008	murine leukemia virus-type retropepsin		3NR6_A
AA	A02.008	murine leukemia virus-type retropepsin		3P1G
AA	A02.008	murine leukemia virus-type retropepsin		4E89
AA	A02.008	murine leukemia virus-type retropepsin		4HKQ
AA	A02.009	Mason-Pfizer leukemia virus retropepsin		1NSO
AA	A02.009	Mason-Pfizer leukemia virus retropepsin		2D4L
AA	A02.009	Mason-Pfizer leukemia virus retropepsin		2D4M
AA	A02.009	Mason-Pfizer leukemia virus retropepsin		2D4N
AA	A02.009	Mason-Pfizer leukemia virus retropepsin		3SQF
AA	A02.009	Mason-Pfizer leukemia virus retropepsin		3TP1
AA	A02.009	Mason-Pfizer leukemia virus retropepsin		3TPW
AA	A02.012	retropepsin (human T-cell leukemia virus)		2B7F
AA	A02.012	retropepsin (human T-cell leukemia virus)	complex with the inhibitor, kni- 10562	3LIN_A
AA	A02.012	retropepsin (human T-cell leukemia virus)	complex with the inhibitor, kni- 10673	3LIQ_A
AA	A02.012	retropepsin (human T-cell leukemia virus)	complex with the inhibitor kni-10681	3LIT_A
AA	A02.012	retropepsin (human T-cell leukemia virus)	complex with the inhibitor kni- 10683	3LIV_A
AA	A02.012	retropepsin (human T-cell leukemia virus)	complex with the inhibitor kni- 10729	3LIX_A
AA	A02.012	retropepsin (human T-cell leukemia virus)	complex with statine-containing peptide inhibitor	3LIY_A
AA	A02.012	retropepsin (human T-cell leukemia virus)	complex with the hiv-1 protease inhibitor indinavir	3WSJ_A
AA	A02.012	retropepsin (human T-cell leukemia virus)	complex with compound 9	4YDF_A
AA	A02.013	bovine leukemia virus retropepsin		2IM6
AA	A02.013	bovine leukemia virus retropepsin		2IM7
AA	A02.015	Rous sarcoma virus retropepsin	NMR structure	1A6S
AA	A02.015	Rous sarcoma virus retropepsin	complex with Arg-Val-Leu-Phe-Glu-Ala-norLeu-NH2 inhibitor	1BAI
AA	A02.015	Rous sarcoma virus retropepsin		1EM9
AA	A02.015	Rous sarcoma virus retropepsin		1EOQ
AA	A02.015	Rous sarcoma virus retropepsin		1P7N
AA	A02.015	Rous sarcoma virus retropepsin		2IHX
AA	A02.015	Rous sarcoma virus retropepsin		2RSP_B
AA	A02.015	Rous sarcoma virus retropepsin		2X8Q
AA	A02.015	Rous sarcoma virus retropepsin		3G0V
AA	A02.015	Rous sarcoma virus retropepsin		3G1G
AA	A02.015	Rous sarcoma virus retropepsin		3G1I
AA	A02.015	Rous sarcoma virus retropepsin		3G21
AA	A02.015	Rous sarcoma virus retropepsin		3G26
AA	A02.015	Rous sarcoma virus retropepsin		3G28
AA	A02.015	Rous sarcoma virus retropepsin		3G29
AA	A02.015	Rous sarcoma virus retropepsin		5A9E
AA	A02.018	simian T-cell lymphotropic virus retropepsin		1JVR
AA	A02.022	Ty3 transposon peptidase		4OL8
AA	A02.UPA	subfamily A2A unassigned peptidases	open conformation	1AZ5
AA	A02.UPA	subfamily A2A unassigned peptidases		1C6V
AA	A02.UPA	subfamily A2A unassigned peptidases		1ECW
AA	A02.UPA	subfamily A2A unassigned peptidases		1ED1
AA	A02.UPA	subfamily A2A unassigned peptidases		1SIP
AA	A02.UPA	subfamily A2A unassigned peptidases	complex with SKF107457	1SIV
AA	A02.UPA	subfamily A2A unassigned peptidases	complex with SB203386	1TCW
AA	A02.UPA	subfamily A2A unassigned peptidases	complex with Phe-Leu-Glu-Lys peptide product	1YTI
AA	A02.UPA	subfamily A2A unassigned peptidases	complex with p-nitroPhe-Glu-Ala-norLeu-Ser peptide product	1YTJ
AA	A02.UPA	subfamily A2A unassigned peptidases	mutant Ser4His	2SAM
AA	A02.UPA	subfamily A2A unassigned peptidases		3JTS
AA	A02.UPW	family A2 unassigned peptidases		1MVP
AA	A02.UPW	family A2 unassigned peptidases	theoretical model	2MVP
AA	A02.UPW	family A2 unassigned peptidases		1BV7_A
AA	A02.UPW	family A2 unassigned peptidases		1BV9_A
AA	A02.UPW	family A2 unassigned peptidases		1BVE_A
AA	A02.UPW	family A2 unassigned peptidases		1BVG_A
AA	A02.UPW	family A2 unassigned peptidases		1BWA_A
AA	A02.UPW	family A2 unassigned peptidases		1BWB_A
AA	A02.UPW	family A2 unassigned peptidases		1C0T
AA	A02.UPW	family A2 unassigned peptidases		1C0U
AA	A02.UPW	family A2 unassigned peptidases		1C1B
AA	A02.UPW	family A2 unassigned peptidases		1C1C
AA	A02.UPW	family A2 unassigned peptidases		1DMP_A
AA	A02.UPW	family A2 unassigned peptidases		1DTQ
AA	A02.UPW	family A2 unassigned peptidases		1DTT
AA	A02.UPW	family A2 unassigned peptidases		1E6J
AA	A02.UPW	family A2 unassigned peptidases		1EP4
AA	A02.UPW	family A2 unassigned peptidases		1ESK
AA	A02.UPW	family A2 unassigned peptidases		1EX4
AA	A02.UPW	family A2 unassigned peptidases		1EXQ
AA	A02.UPW	family A2 unassigned peptidases	Val48Gly, Met90Leu mutant; complex with saquinavir	1FB7
AA	A02.UPW	family A2 unassigned peptidases		1FK9
AA	A02.UPW	family A2 unassigned peptidases		1FKO
AA	A02.UPW	family A2 unassigned peptidases		1FKP
AA	A02.UPW	family A2 unassigned peptidases		1G6L_A
AA	A02.UPW	family A2 unassigned peptidases		1HIV_A
AA	A02.UPW	family A2 unassigned peptidases		1HVH_A
AA	A02.UPW	family A2 unassigned peptidases		1HVR_A
AA	A02.UPW	family A2 unassigned peptidases		1HWR_A
AA	A02.UPW	family A2 unassigned peptidases		1HXB_A
AA	A02.UPW	family A2 unassigned peptidases		1JKH
AA	A02.UPW	family A2 unassigned peptidases		1JLA
AA	A02.UPW	family A2 unassigned peptidases		1JLB
AA	A02.UPW	family A2 unassigned peptidases		1JLC
AA	A02.UPW	family A2 unassigned peptidases		1JLE
AA	A02.UPW	family A2 unassigned peptidases		1JLF
AA	A02.UPW	family A2 unassigned peptidases		1JLG
AA	A02.UPW	family A2 unassigned peptidases		1JLQ
AA	A02.UPW	family A2 unassigned peptidases		1KLM
AA	A02.UPW	family A2 unassigned peptidases		1LV1_A
AA	A02.UPW	family A2 unassigned peptidases		1LW0
AA	A02.UPW	family A2 unassigned peptidases		1LW2
AA	A02.UPW	family A2 unassigned peptidases		1LWC
AA	A02.UPW	family A2 unassigned peptidases		1LWE
AA	A02.UPW	family A2 unassigned peptidases		1LWF
AA	A02.UPW	family A2 unassigned peptidases		1NCP_N
AA	A02.UPW	family A2 unassigned peptidases		1O1W
AA	A02.UPW	family A2 unassigned peptidases		1ODW_A
AA	A02.UPW	family A2 unassigned peptidases	complex with inhibitor LP-130	1ODY
AA	A02.UPW	family A2 unassigned peptidases		1QBR_A
AA	A02.UPW	family A2 unassigned peptidases		1QBS_A
AA	A02.UPW	family A2 unassigned peptidases		1QBT_A
AA	A02.UPW	family A2 unassigned peptidases		1QBU_A
AA	A02.UPW	family A2 unassigned peptidases		1REV
AA	A02.UPW	family A2 unassigned peptidases		1RT1
AA	A02.UPW	family A2 unassigned peptidases		1RT2
AA	A02.UPW	family A2 unassigned peptidases		1RT3
AA	A02.UPW	family A2 unassigned peptidases		1RT4
AA	A02.UPW	family A2 unassigned peptidases		1RT5
AA	A02.UPW	family A2 unassigned peptidases		1RT6
AA	A02.UPW	family A2 unassigned peptidases		1RT7
AA	A02.UPW	family A2 unassigned peptidases		1RTD
AA	A02.UPW	family A2 unassigned peptidases		1RTH
AA	A02.UPW	family A2 unassigned peptidases		1RTI
AA	A02.UPW	family A2 unassigned peptidases		1RTJ
AA	A02.UPW	family A2 unassigned peptidases		1S1T
AA	A02.UPW	family A2 unassigned peptidases		1S1U
AA	A02.UPW	family A2 unassigned peptidases		1S1V
AA	A02.UPW	family A2 unassigned peptidases		1S1W
AA	A02.UPW	family A2 unassigned peptidases		1S1X
AA	A02.UPW	family A2 unassigned peptidases		1T05
AA	A02.UPW	family A2 unassigned peptidases		1TAM
AA	A02.UPW	family A2 unassigned peptidases		1TKT
AA	A02.UPW	family A2 unassigned peptidases		1TKX
AA	A02.UPW	family A2 unassigned peptidases		1TKZ
AA	A02.UPW	family A2 unassigned peptidases		1TL1
AA	A02.UPW	family A2 unassigned peptidases		1TL3
AA	A02.UPW	family A2 unassigned peptidases		1VRT
AA	A02.UPW	family A2 unassigned peptidases		1VRU
AA	A02.UPW	family A2 unassigned peptidases		2HND
AA	A02.UPW	family A2 unassigned peptidases		2HNY
AA	A02.UPW	family A2 unassigned peptidases		2HNZ
AA	A02.UPW	family A2 unassigned peptidases		2KOD
AA	A02.UPW	family A2 unassigned peptidases		2NPH
AA	A02.UPW	family A2 unassigned peptidases		2OPP
AA	A02.UPW	family A2 unassigned peptidases		2OPQ
AA	A02.UPW	family A2 unassigned peptidases		2OPR
AA	A02.UPW	family A2 unassigned peptidases		2OPS
AA	A02.UPW	family A2 unassigned peptidases		2RF2
AA	A02.UPW	family A2 unassigned peptidases		2RKI
AA	A02.UPW	family A2 unassigned peptidases		2WHH
AA	A02.UPW	family A2 unassigned peptidases		2WOM
AA	A02.UPW	family A2 unassigned peptidases		2WON
AA	A02.UPW	family A2 unassigned peptidases		2YNF
AA	A02.UPW	family A2 unassigned peptidases		2YNG
AA	A02.UPW	family A2 unassigned peptidases		2YNH
AA	A02.UPW	family A2 unassigned peptidases		2YNI
AA	A02.UPW	family A2 unassigned peptidases		3AO2
AA	A02.UPW	family A2 unassigned peptidases		3C6T
AA	A02.UPW	family A2 unassigned peptidases		3C6U
AA	A02.UPW	family A2 unassigned peptidases		3DI6
AA	A02.UPW	family A2 unassigned peptidases		3DLE
AA	A02.UPW	family A2 unassigned peptidases		3DLG
AA	A02.UPW	family A2 unassigned peptidases		3DM2
AA	A02.UPW	family A2 unassigned peptidases		3DMJ
AA	A02.UPW	family A2 unassigned peptidases		3DOK
AA	A02.UPW	family A2 unassigned peptidases		3DOL
AA	A02.UPW	family A2 unassigned peptidases		3DOX
AA	A02.UPW	family A2 unassigned peptidases		3DRP
AA	A02.UPW	family A2 unassigned peptidases		3DRR
AA	A02.UPW	family A2 unassigned peptidases		3DRS
AA	A02.UPW	family A2 unassigned peptidases		3DYA
AA	A02.UPW	family A2 unassigned peptidases		3E01
AA	A02.UPW	family A2 unassigned peptidases		3FFI
AA	A02.UPW	family A2 unassigned peptidases		3I0R
AA	A02.UPW	family A2 unassigned peptidases		3I0S
AA	A02.UPW	family A2 unassigned peptidases		3KJV
AA	A02.UPW	family A2 unassigned peptidases		3KK1
AA	A02.UPW	family A2 unassigned peptidases		3KK2
AA	A02.UPW	family A2 unassigned peptidases		3KK3
AA	A02.UPW	family A2 unassigned peptidases		3KT2
AA	A02.UPW	family A2 unassigned peptidases		3KT5
AA	A02.UPW	family A2 unassigned peptidases		3LAK
AA	A02.UPW	family A2 unassigned peptidases		3LAL
AA	A02.UPW	family A2 unassigned peptidases		3LAM
AA	A02.UPW	family A2 unassigned peptidases		3LAN
AA	A02.UPW	family A2 unassigned peptidases		3LP0
AA	A02.UPW	family A2 unassigned peptidases		3LP1
AA	A02.UPW	family A2 unassigned peptidases		3LP2
AA	A02.UPW	family A2 unassigned peptidases		3M8P
AA	A02.UPW	family A2 unassigned peptidases		3M8Q
AA	A02.UPW	family A2 unassigned peptidases		3MEC
AA	A02.UPW	family A2 unassigned peptidases		3MED
AA	A02.UPW	family A2 unassigned peptidases		3MEE
AA	A02.UPW	family A2 unassigned peptidases		3MEG
AA	A02.UPW	family A2 unassigned peptidases		3MIM
AA	A02.UPW	family A2 unassigned peptidases		3N3I
AA	A02.UPW	family A2 unassigned peptidases		3NBP
AA	A02.UPW	family A2 unassigned peptidases		3PHV_A
AA	A02.UPW	family A2 unassigned peptidases		3QIN
AA	A02.UPW	family A2 unassigned peptidases		3QIO
AA	A02.UPW	family A2 unassigned peptidases		3QIP
AA	A02.UPW	family A2 unassigned peptidases		3T19
AA	A02.UPW	family A2 unassigned peptidases		3T1A
AA	A02.UPW	family A2 unassigned peptidases		3TAM
AA	A02.UPW	family A2 unassigned peptidases		4B3O
AA	A02.UPW	family A2 unassigned peptidases		4B3P
AA	A02.UPW	family A2 unassigned peptidases		4B3Q
AA	A02.UPW	family A2 unassigned peptidases		4I7F
AA	A02.UPW	family A2 unassigned peptidases		4KSE
AA	A02.UPW	family A2 unassigned peptidases		4KV8
AA	A02.UPW	family A2 unassigned peptidases		4NCG
AA	A02.UPW	family A2 unassigned peptidases		4Q1W
AA	A02.UPW	family A2 unassigned peptidases		4Q1X
AA	A02.UPW	family A2 unassigned peptidases		4Q1Y
AA	A02.UPW	family A2 unassigned peptidases		4Q5M
AA	A02.UPW	family A2 unassigned peptidases		4QLH
AA	A02.UPW	family A2 unassigned peptidases		4U1H
AA	A02.UPW	family A2 unassigned peptidases		4U1I
AA	A02.UPW	family A2 unassigned peptidases		4U1J
AA	A02.UPW	family A2 unassigned peptidases		4U7Q
AA	A02.UPW	family A2 unassigned peptidases		4U7V
AA	A02.UPW	family A2 unassigned peptidases	x-ray snapshot of hiv-1 protease in action: observation of tetrahedralintermediate and its sihb with catalytic aspartate	5YRS_A
AC	A08.UPW	family A8 unassigned peptidases		5DIR
AC	A08.UPW	family A8 unassigned peptidases	imisx-ep of se-lspa	6FMS_A
AA	A09.001	spumapepsin		2LSN
AA	A09.001	spumapepsin		2X6N
AA	A09.001	spumapepsin		2X6S
AA	A09.001	spumapepsin		2X74
AA	A09.001	spumapepsin		2X78
AA	A09.001	spumapepsin		3DLR
AA	A09.001	spumapepsin		3L2Q
AA	A09.001	spumapepsin		3L2R
AA	A09.001	spumapepsin		3L2U
AA	A09.001	spumapepsin		3L2V
AA	A09.001	spumapepsin		3L2W
AA	A09.001	spumapepsin		3OS0
AA	A09.001	spumapepsin		3OS1
AA	A09.001	spumapepsin		3OS2
AA	A09.001	spumapepsin		3OY9
AA	A09.001	spumapepsin		3OYA
AA	A09.001	spumapepsin		3OYB
AA	A09.001	spumapepsin		3OYC
AA	A09.001	spumapepsin		3OYD
AA	A09.001	spumapepsin		3OYE
AA	A09.001	spumapepsin		3OYF
AA	A09.001	spumapepsin		3OYG
AA	A09.001	spumapepsin		3OYH
AA	A09.001	spumapepsin		3OYI
AA	A09.001	spumapepsin		3OYJ
AA	A09.001	spumapepsin		3OYK
AA	A09.001	spumapepsin		3OYL
AA	A09.001	spumapepsin		3OYM
AA	A09.001	spumapepsin		3OYN
AA	A09.001	spumapepsin		3S3M
AA	A09.001	spumapepsin		3S3N
AA	A09.001	spumapepsin		3S3O
AA	A09.001	spumapepsin		4BAC
AA	A09.001	spumapepsin		4BDY
AA	A09.001	spumapepsin		4BDZ
AA	A09.001	spumapepsin		4BE0
AA	A09.001	spumapepsin		4BE1
AA	A09.001	spumapepsin		4BE2
AA	A09.001	spumapepsin		4E7H
AA	A09.001	spumapepsin		4E7I
AA	A09.001	spumapepsin		4E7J
AA	A09.001	spumapepsin		4E7K
AA	A09.001	spumapepsin		4E7L
AA	A09.001	spumapepsin		4IKF
AA	A09.001	spumapepsin		4ZTF
AA	A09.001	spumapepsin		4ZTJ
AA	A09.001	spumapepsin	NMR structure	2JYS
AD	A22.001	presenilin 1	NMR structure; CTF subunit	2KR6
AD	A22.001	presenilin 1		4UIS
AD	A22.001	presenilin 1		5A63
AD	A22.001	presenilin 1		5FN2
AD	A22.001	presenilin 1		5FN3
AD	A22.001	presenilin 1		5FN4
AD	A22.001	presenilin 1		5FN5
AD	A22.001	presenilin 1	complex with a notch fragment	6IDF_B
AD	A22.001	presenilin 1	recognition of the amyloid precursor protein by human gamma-secretase	6IYC_B
AD	A22.007	signal peptide peptidase-like protein 2A		2FC7
AD	A22.007	signal peptide peptidase-like protein 2A		2YUM
AD	A22.015	intramembrane aspartyl peptidase (Methanoculleus marisnigri JR1)		4HYC
AD	A22.015	intramembrane aspartyl peptidase (Methanoculleus marisnigri JR1)		4HYD
AD	A22.015	intramembrane aspartyl peptidase (Methanoculleus marisnigri JR1)		4HYG
AD	A22.015	intramembrane aspartyl peptidase (Methanoculleus marisnigri JR1)	complex with an inhibitor	4Y6K_A
AD	A24.016	FlaK peptidase		3S0X
AE	A25.001	gpr peptidase	precursor	1C8B_A
AF	A26.001	omptin		1I78_A
AF	A26.003	plasminogen activator Pla	Ala106Asp mutant	2X4M
AF	A26.003	plasminogen activator Pla		2X55
AF	A26.003	plasminogen activator Pla		2X56
AF	A26.003	plasminogen activator Pla		4DCB_A
AA	A28.001	DNA-damage inducible protein 1		2I1A
AA	A28.001	DNA-damage inducible protein 1		2MR9
AA	A28.001	DNA-damage inducible protein 1		2MRO
AA	A28.001	DNA-damage inducible protein 1		2MRP
AA	A28.001	DNA-damage inducible protein 1		2MWS
AA	A28.001	DNA-damage inducible protein 1		4Z2Z
AA	A28.001	DNA-damage inducible protein 1		3S8I_A
AA	A28.003	DNA-damage inducible protein 2	human dna damage-inducible protein: from protein chemistry and 3d structure to deciphering its cellular role	4RGH_A
AA	A28.A01	gene name 1700011N24Rik (Mus musculus)	NMR structure	1V5O
AA	A28.UPA	subfamily A28A unassigned peptidases	protease-like domain	5YQ8_A
AA	A28.UPA	subfamily A28A unassigned peptidases	protease-like domain	5YS4_A
AE	A31.001	HybD peptidase		1CFZ_A
AE	A31.001	HybD peptidase	NMR structure	2KML
AE	A31.003	HycI peptidase		3PU6_A
AE	A31.007	TK2004 peptidase		5ZBY
AE	A31.008	TK2066 peptidase		5IJA
AE	A31.UPW	family A31 unassigned peptidases		5TTX_A
AE	A31.UPW	family A31 unassigned peptidases		2E85_A
AA	A32.002	RC1339 g.p. (Rickettsia conorii)		5C9B
AA	A32.002	RC1339 g.p. (Rickettsia conorii)		5C9D
AA	A32.002	RC1339 g.p. (Rickettsia conorii)		5C9F
CA	C01.001	papain	complex with carbobenzyloxy-Leu-leucinal inhibitor	1BP4
CA	C01.001	papain	complex with carboxybenzyloxy-Leu-Leu-methoxymethylketone	1BQI
CA	C01.001	papain	complex with inhibitor CLIK148	1CVZ
CA	C01.001	papain	theoretical model; complex with N-acetyl-p-benzoquinone imine	1EFF
CA	C01.001	papain	complex with Z-Leu-Phe-Gly-diazomethylketone inhibitor	1KHP
CA	C01.001	papain	complex with Z-Leu-Phe-Gly-diazomethylketone inhibitor (orthorhombic form)	1KHQ
CA	C01.001	papain	Cys25Ac-Ala-Ala-Phe-methylenylAla derivative	1PAD
CA	C01.001	papain	complex with E64C	1PE6
CA	C01.001	papain	complex with Suc-Gln-Vla-Val-Ala-Ala-pNA	1PIP
CA	C01.001	papain	complex with leupeptin	1POP
CA	C01.001	papain	hydroxyethylthiopapain	1PPD
CA	C01.001	papain	Cys25 with bound atom	1PPN
CA	C01.001	papain	complex with E64C	1PPP
CA	C01.001	papain	complex with cystatin B Cys18Ser	1STF_E
CA	C01.001	papain	complex with ICP	2CIO_A
CA	C01.001	papain	cysteinyl derivative of Cys25	2PAD
CA	C01.001	papain	complex with chagasin	3E1Z_B
CA	C01.001	papain	complex with tarocystatin	3IMA_A
CA	C01.001	papain	complex with CTD of tarocystatin	3LFY_A
CA	C01.001	papain	precursor; thermostable variant	3TNX_A
CA	C01.001	papain	precursor; thermostable variant from a crystal soaked at ph 4	3USV_A
CA	C01.001	papain	TOS-methylenylLys derivative of Cys25	4PAD
CA	C01.001	papain	Ile86Leu mutant	4QRG_A
CA	C01.001	papain	Ile86Phe mutant	4QRV_A
CA	C01.001	papain	precursor mutant at ph 4.0	4QRX_A
CA	C01.001	papain	benzyloxycarbonyl-Gly-Phe-methylenylGly derivative	5PAD
CA	C01.001	papain	modified by achiral ru(ii)complex	6H8T_A
CA	C01.001	papain	benzyloxycarbonyl-Gly-Phe-methylenylGly derivative	6PAD
CA	C01.001	papain	Cys25 oxidized	9PAP
CA	C01.002	chymopapain		1YAL
CA	C01.003	caricain	theoretical model; Asp158Glu mutant; complex with carbobenzoxy-Phe-3-amino-butan-2-one	1C7X
CA	C01.003	caricain	theoretical model; Asp158Glu mutant in complex with E64c	1EUX
CA	C01.003	caricain	theoretical model; Asp158Glu mutant in complex with leupeptin	1F1I
CA	C01.003	caricain	Asp185Glu mutant; complex with E64	1MEG
CA	C01.003	caricain	precursor	1PCI
CA	C01.003	caricain	Cys25 with bound mercury	1PPO
CA	C01.004	glycyl endopeptidase	complex with benzyloxycarbonyl-Leu-Val-Gly-methylene bound to Cys25	1GEC
CA	C01.005	stem bromelain		1W0Q
CA	C01.007	actinidin	complex with E64	1AEC
CA	C01.007	actinidin	theoretical model; complex with ZPACK (Z-Phe-Ala-Ala-chloromethyl ketone)	1F3Q
CA	C01.007	actinidin	theoretical model; complex with leupeptin	1FOG
CA	C01.007	actinidin	theoretical model; complex with E64c	1FTV
CA	C01.007	actinidin		2ACT
CA	C01.009	cathepsin V	complex with 4-methylpiperazin-1-ylcarbonyl-Phe-3-amino-5-phenylpentane inhibitor	1FH0
CA	C01.009	cathepsin V	complex with clitocypin	3H6S_A
CA	C01.010	vignain	complex with D-Val-Leu-dexoxy-methyl-Lys.	1S4V_A
CA	C01.011	calotropain		0CDI
CA	C01.013	cathepsin X	precursor	1DEU
CA	C01.013	cathepsin X		1EF7
CA	C01.017	zingipain	tetramer	1CQD
CA	C01.018	cathepsin F	theoretical model	1D5U
CA	C01.018	cathepsin F		1M6D_A
CA	C01.024	endopeptidase-B (Hordeum-type)	isoform 2 (EP-B2); complex with leupeptin	2FO5_A
CA	C01.026	ananain	complex with E-64	6MIS_A
CA	C01.026	ananain	native ananain from ananas comosus	6OKJ_A
CA	C01.032	cathepsin L	precursor	1CJL
CA	C01.032	cathepsin L	procathepsin L	1CJL_P
CA	C01.032	cathepsin L	precursor	1CS8_A
CA	C01.032	cathepsin L	procathepsin L	1CS8_P
CA	C01.032	cathepsin L	complex with MHC class II associated P41 II fragment	1ICF_A
CA	C01.032	cathepsin L	complex with propeptide-based inhibitor biphenyl-4-yl-acetaldehyde-Cys-D-Arg-Tyr-2-phenylethylamine	1MHW
CA	C01.032	cathepsin L	complex with chagasin	2NQD_B
CA	C01.032	cathepsin L	cathsilicatein, a chimera	2VHS_A
CA	C01.032	cathepsin L	complex with a nitrile inhibitor	2XU1_A
CA	C01.032	cathepsin L	complex with a nitrile inhibitor	2XU3_A
CA	C01.032	cathepsin L	complex with a nitrile inhibitor	2XU4_A
CA	C01.032	cathepsin L	complex with a nitrile inhibitor	2XU5_A
CA	C01.032	cathepsin L	complex with a nitrile inhibitor	2YJ2_A
CA	C01.032	cathepsin L	complex with a nitrile inhibitor	2YJ8_A
CA	C01.032	cathepsin L	complex with a nitrile inhibitor	2YJ9_A
CA	C01.032	cathepsin L	complex with a nitrile inhibitor	2YJB_A
CA	C01.032	cathepsin L	complex with a nitrile inhibitor	2YJC_A
CA	C01.032	cathepsin L	exploring inhibitor binding at the s subsites of cathepsin l	3BC3_A
CA	C01.032	cathepsin L	complex with retro-binding inhibitor compound 4	3H89_A
CA	C01.032	cathepsin L	complex with retro-binding inhibitor compound 9	3H8B_A
CA	C01.032	cathepsin L	complex with retro-binding inhibitor compound 14	3H8C_A
CA	C01.032	cathepsin L	complex with az12878478	3HHA_A
CA	C01.032	cathepsin L	cathepsin l with az13010160	3HWN_A
CA	C01.032	cathepsin L	Cys25Ala mutant	3IV2_A
CA	C01.032	cathepsin L	Cys25Ala mutant; complex with Gln-Leu-Ala peptide	3K24_A
CA	C01.032	cathepsin L	complex with dipeptidyl glyoxal and diazomethylketone inhibitors	3OF8_A
CA	C01.032	cathepsin L	complex with adiazomethylketone inhibitor	3OF9_A
CA	C01.032	cathepsin L	human cathepsin l apo form with zn	4AXL_A
CA	C01.032	cathepsin L	triazine cathepsin inhibitor complex	4AXM_A
CA	C01.032	cathepsin L	complex with (2s,4r)-4-(2-chloro-4-methoxy- benzenesulfonyl)-1-[3-(5-chloro-pyridin-2-yl)-azetidine-3-carbonyl]- pyrrolidine-2-carboxylic acid (1-cyano-cyclopropyl)-amide	5F02_A
CA	C01.032	cathepsin L	cleaved cathepsin L bound to the active site of cathepsin L	5I4H_A
CA	C01.032	cathepsin L	complex with (2s,4r)-4-(2-chloro-4-methoxy- benzenesulfonyl)-1-[3-(5-chloro-pyridin-2-yl)-azetidine-3-carbonyl]- pyrrolidine-2-car boxylic acid (1-cyano-cyclopropyl)-amide	5MAE_A
CA	C01.032	cathepsin L	complex with 4-[cyclopentyl(imidazo[1,2-a]pyridin-2- ylmethyl)amino]-6-morpholino-1,3,5-triazine-2-carbonitrile	5MAJ_A
CA	C01.032	cathepsin L	complex with 4-[1,3-benzodioxol-5-ylmethyl(2- phenoxyethyl)amino]-5-fluoropyrimidine-2-carbonitrile	5MQY_A
CA	C01.032	cathepsin L	complex with (3s,14e)-19-chloro-n-(1-cyanocyclopropyl)-5-oxo-12,17-dioxa-4-azatricyclo[16.2.2.06,11]docosa-1(21),6(11),7,9, 14,18(22),19-heptaene-3-carboxamide	6EZP_A
CA	C01.032	cathepsin L	complex with (3s,14e)-19-chloro-n-(1-cyanocyclopropyl)-5-oxo-17-oxa-4-azatricyclo[16.2.2.06,11]docosa-1(21),6,8,10,14, 18(22),19-heptaene-3-carboxamide	6EZX_A
CA	C01.032	cathepsin L	complex with (3s,14e)-8-(azetidin-3-yl)-19-chloro-n-(1-cyanocyclopropyl)-5-oxo-12,17-dioxa-4-azatricyclo[16.2.2.06, 11]docosa-1(21),6,8,10,14,18(22),19-heptaene-3-carboxamide	6F06_A
CA	C01.032	cathepsin L	theoretical model	1MVV
CA	C01.033	cathepsin L1 (Fasciola sp.)	precursor	2O6X
CA	C01.034	cathepsin S	theoretical model	1BXF
CA	C01.034	cathepsin S	Cys25Ser mutant	1GLO
CA	C01.034	cathepsin S	complex with dipeptide nitrile inhibitor BLN	1MS6
CA	C01.034	cathepsin S	complex with inhibitor C1P	1NPZ
CA	C01.034	cathepsin S	complex with inhibitor C4P	1NQC
CA	C01.034	cathepsin S	precursor Cys25Ala mutant	2C0Y_A
CA	C01.034	cathepsin S	complex with non-covalent 2-(benzoxazol-2- ylamino)-acetamide	2F1G_A
CA	C01.034	cathepsin S	complex with CRA-27934, a nitrile inhibitor	2FRA_A
CA	C01.034	cathepsin S	complex with inhibitor CRA-26871	2FRQ_A
CA	C01.034	cathepsin S	complex with inhibitor CRA-29728	2FT2_A
CA	C01.034	cathepsin S	complex with inhibitor CRA-27566	2FUD_A
CA	C01.034	cathepsin S	complex with irreversible inhibitor CRA-14013	2FYE_A
CA	C01.034	cathepsin S	complex with vinyl sulfone inhibitor CRA-14009	2G6D_A
CA	C01.034	cathepsin S	complex with inhibitor CRA-16981	2G7Y_A
CA	C01.034	cathepsin S	complex with N-[(1S)-1-1-[(1R,3E)-1-acetylpent-3-en-1-yl]-1H-1,2,3-triazol-4-yl-1,2-dimethylpropyl]benzamide	2H7J_A
CA	C01.034	cathepsin S	complex with N-[(1R)-1-[(benzylsulfonyl)methyl]-2-[(1S)-1-methyl-2-[4-(trifluoromethoxy)phenyl]aminoethyl]amino-2-oxoethyl]morpholine-4-carboxamide	2HH5_A
CA	C01.034	cathepsin S	complex with non covalent arylaminoethyl amide.	2HHN_A
CA	C01.034	cathepsin S	complex with N-[(1S)-1-1-[(1R,3E)-1-acetylpent-3-en-1-yl]-1H-1,2,3-triazol-4-yl-1,2-dimethylpropyl]benzamide	2HXZ_A
CA	C01.034	cathepsin S	complex with a novel 2- arylphenoxyacetaldehyde inhibitor derived by the substrate activity screening (sas) method	2OP3_A
CA	C01.034	cathepsin S	complex with compound 15	2R9M_A
CA	C01.034	cathepsin S	complex with compound 26	2R9N_A
CA	C01.034	cathepsin S	complex with compound 8	2R9O_A
CA	C01.034	cathepsin S	complex with a pyrazole-based inhibitor with an arylalkynes as P1 binding element	3IEJ_A
CA	C01.034	cathepsin S	complex with 4-(3-trifluoromethylphenyl)-pyrimidine-2-carbonitrile	3N3G_A
CA	C01.034	cathepsin S	complex with 6-phenyl-1h-imidazo[4,5-c]pyridine-4-carbonitrile	3N4C_A
CA	C01.034	cathepsin S	complex with a covalent inhibitor with an aldehyde warhead	3OVX_A
CA	C01.034	cathepsin S	complex with a non-covalent inhibitor	4P6E_A
CA	C01.034	cathepsin S	complex with a non-covalent inhibitor.	4P6G_A
CA	C01.034	cathepsin S	complex with bound ligand	5QBU_A
CA	C01.034	cathepsin S	complex with bound ligand	5QBV_A
CA	C01.034	cathepsin S	complex with bound ligand	5QBW_A
CA	C01.034	cathepsin S	complex with bound ligand	5QBX_A
CA	C01.034	cathepsin S	complex with bound ligand	5QBY_A
CA	C01.034	cathepsin S	complex with bound ligand	5QBZ_A
CA	C01.034	cathepsin S	complex with bound ligand	5QC0_A
CA	C01.034	cathepsin S	complex with bound ligand	5QC1_A
CA	C01.034	cathepsin S	complex with bound ligand	5QC2_A
CA	C01.034	cathepsin S	complex with bound ligand	5QC3_A
CA	C01.034	cathepsin S	complex with bound ligand	5QC4_A
CA	C01.034	cathepsin S	complex with bound ligand	5QC5_A
CA	C01.034	cathepsin S	complex with bound ligand	5QC6_A
CA	C01.034	cathepsin S	complex with bound ligand	5QC7_A
CA	C01.034	cathepsin S	complex with bound ligand	5QC8_A
CA	C01.034	cathepsin S	complex with bound ligand	5QC9_A
CA	C01.034	cathepsin S	complex with bound ligand	5QCA_A
CA	C01.034	cathepsin S	complex with bound ligand	5QCB_A
CA	C01.034	cathepsin S	complex with bound ligand	5QCC_A
CA	C01.034	cathepsin S	complex with bound ligand	5QCE_A
CA	C01.034	cathepsin S	complex with bound ligand	5QCF_A
CA	C01.034	cathepsin S	complex with bound ligand	5QCG_A
CA	C01.034	cathepsin S	complex with bound ligand	5QCH_A
CA	C01.034	cathepsin S	complex with bound ligand	5QCI_A
CA	C01.034	cathepsin S	complex with bound ligand	5QCJ_A
CA	C01.034	cathepsin S	theoretical model; precursor	1M0H
CA	C01.034	cathepsin S		4BPV
CA	C01.034	cathepsin S		4BQV
CA	C01.034	cathepsin S		4BS5
CA	C01.034	cathepsin S		4BS6
CA	C01.034	cathepsin S		4BSQ
CA	C01.034	cathepsin S		4MZO
CA	C01.034	cathepsin S		4MZS
CA	C01.036	cathepsin K	complex with E64	1ATK
CA	C01.036	cathepsin K	complex with a covalent symmetric diacylaminomethyl ketone inhibitor	1AU0
CA	C01.036	cathepsin K	complex with a covant propanone inhibitor	1AU2
CA	C01.036	cathepsin K	complex with 1-[N[(phenylmethoxy)carbonyl]-l-leucyl-4-[[N/N-[(phenylmethoxy)carbonyl]-/NL-leucyl]amino]-3-pyrrolidinone	1AU3
CA	C01.036	cathepsin K	complex with 4-[[N-[(phenylmethoxy)carbonyl]-L-leucyl]amino]-1[(2S)-2-[[[4-(pyridinylmethoxy)carbonyl]amino]-4-methylpentyl]-3-pyrrolidinone	1AU4
CA	C01.036	cathepsin K	complex with 1,5-bis(N-benzyloxycarbonyl-L-leucinyl)carbohydrazide	1AYU
CA	C01.036	cathepsin K	complex with N-[2-[1-(N-benzyloxycarbonylamino)-3-methylbutyl]thiazol-4-ylcarbonyl]-N'-(benzyloxycarbonyl-L-leucinyl)hydrazide	1AYV
CA	C01.036	cathepsin K	complex with 1-(N-benzyloxycarbonyl-L-leucinyl)-5-(3-benzyloxy benzoyl)carbohydrazide	1AYW
CA	C01.036	cathepsin K	complex with covalent peptidomimetic inhibitor 1-[2-(3-bipheyl)-4-methylvaleryl)]-amino-3-(2-pyridylsulfonyl)amino-2-propanone	1BGO
CA	C01.036	cathepsin K	precursor	1BY8
CA	C01.036	cathepsin K	Ser149Ala mutant; complex with vinyl sulfone inhibitor	1MEM
CA	C01.036	cathepsin K	complex with covalent azepanone 5-(2-morpholin-4-ylethoxy)benzofuran-2-carboxylic acid ((S)-3-methyl-1-(S)-3-oxo-1-[2-(3-pyridin-2-ylphenyl)acetyl]azepan-4-ylcarbamoylbutyl)amide	1NL6
CA	C01.036	cathepsin K	complex with covalent azepanone benzofuran-2-carboxylic acid (S)-3-methyl-1-[3-oxo-1-(pyridin-2-ylsulfonyl)azepan-4-ylcarbamoyl]butylamide	1NLJ
CA	C01.036	cathepsin K	complex with T-butyl(1S)-1-cyclohexyl-2- oxoethylcarbamate	1Q6K_A
CA	C01.036	cathepsin K	complex with N2-([(4-bromophenyl)methyl]oxycarbonyl)-N1-[(1S)-1-formylpentyl]-L-leucinamide	1SNK
CA	C01.036	cathepsin K	complex with ketoamide inhibitor [1-(4-fluorobenzyl)cyclobutyl]methyl (1S)-1-[oxo(1h-pyrazol-5-ylamino)acetyl]pentylcarbamate	1TU6
CA	C01.036	cathepsin K	complex with the covalent inhibitor NVP-ABE854	1U9V_A
CA	C01.036	cathepsin K	complex with the covalent inhibitor NVP-ABI491	1U9W_A
CA	C01.036	cathepsin K	complex with the covalent inhibitor NVP-ABJ688	1U9X_A
CA	C01.036	cathepsin K	complex with N-(2-aminoethyl)-N~2~-(1S)-1-[4'-(aminosulfonyl)biphenyl-4-yl]-2,2,2-trifluoroethyl-L-leucinamide	1VSN_A
CA	C01.036	cathepsin K	complex with cyanopyrrolidine inhibitor N2-[(benzyloxy)carbonyl]-N1-[(3S)-1-cyanopyrrolidin-3-yl]-L-leucinamide	1YK7
CA	C01.036	cathepsin K	complex with cyanamide-based inhibitor tert-butyl 2-cyano-2-methylhydrazinecarboxylate	1YK8_A
CA	C01.036	cathepsin K	complex with (1R)-2,2-dimethyl-1-(5-[4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2-ylmethyl)propyl (1S)-1-oxo[(2-oxo-1,3-oxazolidin-3-yl)amino]acetylpentylcarbamate	1YT7
CA	C01.036	cathepsin K	complex with myocrisin	2ATO_A
CA	C01.036	cathepsin K	complex with semicarbazone inhibitor (1R)-2-methyl-1-(phenylmethyl)propyl[(1S)-1-formylpentyl]carbamate	2AUX
CA	C01.036	cathepsin K	complex with semicarbazone inhibitor 1-(phenylmethyl)cyclopentyl[(1S)-1-formylpentyl]carbamate	2AUZ_A
CA	C01.036	cathepsin K	complex with (3S)-1-[(3,5-dimethylisoxazol-4-yl)amino]carbonyl-4,4-dimethylpyrrolidin-3-yl(1s)-1-[1-hydroxy-2-oxo-2-[(1R)-1-phenylethyl]aminoethyl]pentylcarbamate	2BDL
CA	C01.036	cathepsin K	complex with a pyrrolopyrimidine inhibitor	2R6N_A
CA	C01.036	cathepsin K	complex with chondroitin sulfate	3C9E
CA	C01.036	cathepsin K	variant M5; complex with chondroitin-4-sulfate	3H7D_A
CA	C01.036	cathepsin K	complex with a triazine ligand	3KW9_A
CA	C01.036	cathepsin K	complex with a dioxo-triazine inhibitor	3KWB_X
CA	C01.036	cathepsin K	complex with a non-selective 2-cyano-pyrimidine inhibitor	3KWZ_A
CA	C01.036	cathepsin K	complex with a selective 2-cyano-pyrimidine inhibitor	3KX1_A
CA	C01.036	cathepsin K	complex with a cyano-pyrimidine inhibitor	3O0U_A
CA	C01.036	cathepsin K	complex with a 2-cyano pyrimidine inhibitor with a benzyl p3 group.	3O1G_A
CA	C01.036	cathepsin K	complex with a covalent inhibitor with a ketoamide warhead	3OVZ_A
CA	C01.036	cathepsin K	cathepsin k inhibitor	4DMX_A
CA	C01.036	cathepsin K	cathepsin k inhibitor	4DMY_A
CA	C01.036	cathepsin K	complex with dermatan sulfate	4N79_A
CA	C01.036	cathepsin K	complex with chondroitin sulfate	4N8W_A
CA	C01.036	cathepsin K	development of n-(functionalized benzoyl)-homocycloleucyl- glycinonitriles as potent cathepsin k inhibitors.	4X6H_A
CA	C01.036	cathepsin K	development of n-(functionalized benzoyl)-homocycloleucyl- glycinonitriles as potent cathepsin k inhibitors.	4X6I_A
CA	C01.036	cathepsin K	development of n-(functionalized benzoyl)-homocycloleucyl- glycinonitriles as potent cathepsin k inhibitors.	4X6J_A
CA	C01.036	cathepsin K	complex with lichostatinal	4YV8_A
CA	C01.036	cathepsin K	co-crystallized with actinomycetes extract	4YVA_A
CA	C01.036	cathepsin K	Cys25Ser mutant; complex with the allosteric effector nsc13345	5J94_A
CA	C01.036	cathepsin K	Cys25Ser mutant; complex with the allosteric effector nsc94914	5JA7_A
CA	C01.036	cathepsin K	Cys25Ser mutant	5JH3_A
CA	C01.036	cathepsin K	complex with a covalently-linked inhibitor	5TDI_A
CA	C01.036	cathepsin K		5TUN_A
CA	C01.036	cathepsin K	pycnonodysostosis disease related Ile249Thr mutant	5Z5O_A
CA	C01.036	cathepsin K	complex with a non-active site inhibitor	6ASH_A
CA	C01.036	cathepsin K	complex with n-desmethyl thalassospiramide c	6HGY_A
CA	C01.036	cathepsin K	complex with an alkyne moiety	6QBS_A
CA	C01.036	cathepsin K		7PCK
CA	C01.036	cathepsin K		5T6U_A
CA	C01.036	cathepsin K	Thr101Ala variant	6BKI_A
CA	C01.040	cathepsin H	theoretical model	1BZN
CA	C01.040	cathepsin H	precursor	6CZK_A
CA	C01.040	cathepsin H	Cys26Ser mutant	6CZS_A
CA	C01.040	cathepsin H	complex with cystatin A	1NB3_A
CA	C01.040	cathepsin H	complex with cystatin A	1NB5_A
CA	C01.040	cathepsin H		8PCH
CA	C01.046	falcipain-2	complex with egg-white cystatin	1YVB_A
CA	C01.046	falcipain-2	complex with E64	3BPF_A
CA	C01.046	falcipain-2	complex with PBICP-C	3PNR_A
CA	C01.060	cathepsin B		1CSB
CA	C01.060	cathepsin B		1CSB_A
CA	C01.060	cathepsin B	complex with a dipeptidyl nitrile inhibitor	1GMY
CA	C01.060	cathepsin B		1GMY_A
CA	C01.060	cathepsin B		1HUC
CA	C01.060	cathepsin B		1HUC_A
CA	C01.060	cathepsin B	recombinant precursor	1PBH
CA	C01.060	cathepsin B	recombinant precursor	1PBH_A
CA	C01.060	cathepsin B	tetragonal form	2IPP_A
CA	C01.060	cathepsin B	recombinant precursor	2PBH
CA	C01.060	cathepsin B	recombinant precursor	2PBH_A
CA	C01.060	cathepsin B		3AI8
CA	C01.060	cathepsin B	complex with chagasin	3CBJ_A
CA	C01.060	cathepsin B	complex with chagasin	3CBK_A
CA	C01.060	cathepsin B		3K9M_A
CA	C01.060	cathepsin B	recombinant precursor	3PBH
CA	C01.060	cathepsin B	recombinant precursor	3PBH_A
CA	C01.060	cathepsin B	complex with darpin 81	5MBL_A
CA	C01.060	cathepsin B	complex with covalently linked compound 28	6AY2_A
CA	C01.060	cathepsin B	complex with E64c	1ITO
CA	C01.060	cathepsin B	complex with CA074 inhibitor	1QDQ
CA	C01.060	cathepsin B	complex with NS-134, a two headed epoxysuccinyl inhibitor	1SP4_A
CA	C01.060	cathepsin B		2DC6
CA	C01.060	cathepsin B		2DC7
CA	C01.060	cathepsin B		2DC8
CA	C01.060	cathepsin B		2DC9
CA	C01.060	cathepsin B		2DCA
CA	C01.060	cathepsin B		2DCB
CA	C01.060	cathepsin B		2DCC
CA	C01.060	cathepsin B		2DCD
CA	C01.060	cathepsin B	Ser115Ala mutant	1CPJ
CA	C01.060	cathepsin B		1CTE
CA	C01.060	cathepsin B	precursor	1MIR
CA	C01.060	cathepsin B	Ser115Ala mutant; complex with Z-Arg-Ser(OBzl) chloromethylketone	1THE_B
CA	C01.062	cathepsin B-like peptidase (platyhelminth)	complex with ca074 inhibitor	3QSD_A
CA	C01.062	cathepsin B-like peptidase (platyhelminth)	complex with k11017 inhibitor	3S3Q_A
CA	C01.062	cathepsin B-like peptidase (platyhelminth)	complex with k11777 inhibitor	3S3R_A
CA	C01.062	cathepsin B-like peptidase (platyhelminth)	zymogen	4I04_A
CA	C01.062	cathepsin B-like peptidase (platyhelminth)	structure of intermediate processing form of cathepsin b1 from schistosoma mansoni	4I05_A
CA	C01.062	cathepsin B-like peptidase (platyhelminth)	mature form	4I07_A
CA	C01.062	cathepsin B-like peptidase (platyhelminth)	complex with wrr391 inhibitor	5OGQ_A
CA	C01.062	cathepsin B-like peptidase (platyhelminth)	complex with wrr286 inhibitor	5OGR_A
CA	C01.062	cathepsin B-like peptidase (platyhelminth)	theoretical model	1MF3
CA	C01.063	falcipain-3	complex with leupeptin	3BPM_A
CA	C01.063	falcipain-3	complex with the vinyl sulfone derived inhibitor K11017	3BWK_A
CA	C01.068	vitellogenic cathepsin B	theoretical model	1MHG
CA	C01.070	dipeptidyl-peptidase I		1JQP
CA	C01.070	dipeptidyl-peptidase I	exclusion domain	1K3B_A
CA	C01.070	dipeptidyl-peptidase I	complex with the inhibitor Gly-Phe-CHN2	2DJF_A
CA	C01.070	dipeptidyl-peptidase I	re-refinement of the native structure of human dipeptidyl peptidase i (cathepsin c)	2DJG_A
CA	C01.070	dipeptidyl-peptidase I	discovery of novel cyanamide-based inhibitors of cathepsin c	3PDF_A
CA	C01.070	dipeptidyl-peptidase I	human dpp1 in complex with (2s)-2-amino-n-((1s)-1-cyano-2-(4- phenylphenyl)ethyl)butanamide	4CDC_A
CA	C01.070	dipeptidyl-peptidase I	human dpp1 in complex with (2s)-n-((1s)-1-cyano-2-(4-(4-cyanophenyl) phenyl)ethyl)piperidine-2-carboxamide	4CDD_A
CA	C01.070	dipeptidyl-peptidase I	human dpp1 in complex with 4-amino-n-((1s)-1-cyano-2-(4-(4- cyanophenyl)phenyl)ethyl)tetrahydropyran-4-carboxamide	4CDE_A
CA	C01.070	dipeptidyl-peptidase I	human dpp1 in complex with (2s,4s)-n-((1s)-1-cyano-2-(4-(4- cyanophenyl)phenyl)ethyl)-4-hydroxy-piperidine-2-carboxamide	4CDF_A
CA	C01.070	dipeptidyl-peptidase I	complex with dipeptide substrates	4OEL_A
CA	C01.070	dipeptidyl-peptidase I	complex with dipeptide substrates	4OEM_A
CA	C01.070	dipeptidyl-peptidase I	complex with dipeptidyl cyclopropyl nitrile inhibitor 2	6IC5_A
CA	C01.070	dipeptidyl-peptidase I	complex with cyclopropyl peptidyl nitrile inhibitor 1	6IC6_A
CA	C01.070	dipeptidyl-peptidase I	complex with dipeptidyl cyclopropyl nitrile inhibitor 3	6IC7_A
CA	C01.070	dipeptidyl-peptidase I	theoretical model	1BMU
CA	C01.072	rhodesain	complex with the vinyl sulfone derived inhibitor K11777	2P7U_A
CA	C01.072	rhodesain	complex with the vinyl sulfone derived inhibitor K11002	2P86_A
CA	C01.072	rhodesain	complex with a macrolactam inhibitor	6EX8_A
CA	C01.072	rhodesain	complex with a macrolactam inhibitor	6EXO_A
CA	C01.072	rhodesain	complex with a macrolactam inhibitor	6EXQ_A
CA	C01.073	peptidase 1 (mite)	precursor; mutant form	1XKG
CA	C01.073	peptidase 1 (mite)		2AS8_A
CA	C01.073	peptidase 1 (mite)	c2 crystal form of mite allergen der p 1	3F5V_A
CA	C01.073	peptidase 1 (mite)		3RVW
CA	C01.073	peptidase 1 (mite)		3RVX
CA	C01.073	peptidase 1 (mite)		4PP1
CA	C01.073	peptidase 1 (mite)		4PP2
CA	C01.073	peptidase 1 (mite)	complex with fab fragment of mab 5h8	5VCN_A
CA	C01.073	peptidase 1 (mite)	complex with fab fragment of mab 10b9	5VCO_A
CA	C01.073	peptidase 1 (mite)	complex with fab 4c1	5VPG_A
CA	C01.073	peptidase 1 (mite)	complex with fab 4c1	5VPH_A
CA	C01.073	peptidase 1 (mite)		3D6S_A
CA	C01.073	peptidase 1 (mite)		3RVV
CA	C01.073	peptidase 1 (mite)		5VPK_A
CA	C01.073	peptidase 1 (mite)	complex with fab 4c1	5VPL_A
CA	C01.074	CPB peptidase	theoretical model	1BMJ
CA	C01.075	cruzipain	catalytic domain, Gly213 stop.	1AIM
CA	C01.075	cruzipain	complex with WRR-99	1EWL_A
CA	C01.075	cruzipain	complex with WRR-112	1EWM
CA	C01.075	cruzipain	complex with WRR-204	1EWO
CA	C01.075	cruzipain	complex with N-carbonylmorpholine-Leu-homophenylalanylmethane inhibitor	1EWP
CA	C01.075	cruzipain	complex with vinyl sulfone-derived inhibitor VS1	1F29
CA	C01.075	cruzipain	complex with vinyl sulfone-derived inhibitor VS2	1F2A
CA	C01.075	cruzipain	complex with vinyl sulfone-derived inhibitor VS3	1F2B
CA	C01.075	cruzipain	complex with vinyl sulfone-derived inhibitor VS4	1F2C
CA	C01.075	cruzipain	complex with [1-(3-hydroxy-2-oxo-1-phenethyl-propylcarbamoyl)2-phenyl-ethyl]-carbamic acid pyridin-4-ylmethyl ester	1ME3
CA	C01.075	cruzipain	complex with [1-(1-benzyl-3-hydroxy-2-oxo-propylcarbamoyl)-2-phenyl-ethyl]-carbamic acid benzyl ester	1ME4
CA	C01.075	cruzipain	complex with [1-(1-methyl-4,5-dioxo-pent-2-enylcarbamoyl)-2-phenyl-ethyl]-carbamic acid benzyl ester	1U9Q_X
CA	C01.075	cruzipain	catalytic domain; complex with Bz-Arg-Ala-fluoromethylketone	2AIM
CA	C01.075	cruzipain	complex with vinyl sulfone derived inhibitor WR483	2EFM_A
CA	C01.075	cruzipain	complex with the vinyl sulfone derived inhibitor K11777	2OZ2_A
CA	C01.075	cruzipain		3HD3
CA	C01.075	cruzipain		3I06
CA	C01.075	cruzipain		3IUT
CA	C01.075	cruzipain		3KKU
CA	C01.075	cruzipain		3LXS
CA	C01.075	cruzipain		4KLB
CA	C01.075	cruzipain		4PI3
CA	C01.075	cruzipain		4QH6
CA	C01.075	cruzipain		4W5B
CA	C01.075	cruzipain		4W5C
CA	C01.075	cruzipain		4XUI
CA	C01.075	cruzipain	apo-form	6N3S_A
CA	C01.075	cruzipain	complex with mmts inhibitor	6O2X_A
CA	C01.084	bleomycin hydrolase (animal)		1CB5
CA	C01.084	bleomycin hydrolase (animal)	Cys73Ser mutant	2CB5
CA	C01.085	bleomycin hydrolase (yeast)	Cys73Ala mutant	1A6R
CA	C01.085	bleomycin hydrolase (yeast)		1GCB
CA	C01.085	bleomycin hydrolase (yeast)	Asn392Ala mutant	2DZY_A
CA	C01.085	bleomycin hydrolase (yeast)	Asn392Val mutant	2DZZ_A
CA	C01.085	bleomycin hydrolase (yeast)	Asn392Leu mutant	2E00_A
CA	C01.085	bleomycin hydrolase (yeast)	His369la mutant	2E01_A
CA	C01.085	bleomycin hydrolase (yeast)	His369Leu mutant	2E02_A
CA	C01.085	bleomycin hydrolase (yeast)	Asnq67e mutant	2E03_A
CA	C01.085	bleomycin hydrolase (yeast)	Cys73Ala mutant	3GCB
CA	C01.098	CPC peptidase	theoretical model	1MJ6
CA	C01.098	CPC peptidase	theoretical model	1BF7
CA	C01.098	CPC peptidase	complex with ca074	3HHI_A
CA	C01.098	CPC peptidase		3MOR_A
CA	C01.098	CPC peptidase		4HWY_A
CA	C01.098	CPC peptidase	trypanosoma brucei procathepsin b structure solved by serial microcrystallography using synchrotron radiation	4N4Z_A
CA	C01.098	CPC peptidase	procathepsin b s9 from trypanosoma congolense	5FPW_A
CA	C01.099	ervatamin B		1IWD
CA	C01.101	cathepsin B-like peptidase, nematode	theoretical model	1MNW
CA	C01.116	ervatamin C		1O0E_A
CA	C01.116	ervatamin C		2PNS_A
CA	C01.125	Cwp84 peptidase		4CI7
CA	C01.125	Cwp84 peptidase	Cys116Ala mutant; mature protein	4D59
CA	C01.125	Cwp84 peptidase	Cys116Ala mutant; mature protein	4D5A
CA	C01.128	xylellain		3OIS
CA	C01.134	mexicain		2BDZ
CA	C01.137	ervatamin A	complex with E64	2PSC
CA	C01.137	ervatamin A	complex with E64	3BCN
CA	C01.137	ervatamin A		2PNS
CA	C01.137	ervatamin A	ervatamin-C; complex with E64	2PRE_A
CA	C01.149	TgCPL peptidase (Toxoplasma-type)	complex with propeptide	3F75_A
CA	C01.171	Pd_dinase (Parabacteroides distasonis)		3PW3
CA	C01.171	Pd_dinase (Parabacteroides distasonis)		5WDK_A
CA	C01.171	Pd_dinase (Parabacteroides distasonis)		5WDL_A
CA	C01.984	serine-repeat antigen (Plasmodium sp.)		2WBF
CA	C01.984	serine-repeat antigen (Plasmodium sp.)		3CH2
CA	C01.984	serine-repeat antigen (Plasmodium sp.)		3CH3
CA	C01.987	papain-like protein SPE31 (Pachyrhizus erosus)		2B1M
CA	C01.987	papain-like protein SPE31 (Pachyrhizus erosus)		2B1N
CA	C01.UPA	subfamily C1A unassigned peptidases	complex with N-[(1S)-1-([(3S,4S,7R)-3-hydroxy-7-methyl-1-(pyridin-2-ylsulfonyl)-2,3,4,7-tetrahydro-1H-azepin-4-yl]aminocarbonyl)-3-methylbutyl]-1-benzofuran-2-carboxamide	2FTD
CA	C01.UPA	subfamily C1A unassigned peptidases	structural basis for the limited antibody cross reactivity between themite allergens blo t 1 and der p 1	5JT8_A
CA	C01.UPA	subfamily C1A unassigned peptidases	structure of digestive procathepsin l2 proteinase from tenebrio molitor larval midgut	3QJ3_A
CA	C01.UPA	subfamily C1A unassigned peptidases	precursor	5EF4_A
CA	C01.UPA	subfamily C1A unassigned peptidases	precursor	5EGW_A
CA	C02.001	calpain-1	complex with inhibitor Z-Leu-Leu-Tyr-CH2F	1ZCM
CA	C02.001	calpain-1	catalytic domain only	2ARY
CA	C02.001	calpain-1	catalytic domain only	1KXR_A
CA	C02.001	calpain-1		1QXP_A
CA	C02.001	calpain-1	protease core; complex with leupeptin	1TL9_A
CA	C02.001	calpain-1	peptidase unit only; complex with E64	1TLO
CA	C02.001	calpain-1	calpain 1 proteolytic core;ncomplex with snj-1715, a cyclic hemiacetal-type inhibitor	2G8E_A
CA	C02.001	calpain-1	proteolytic core; complex with snj-1945, a alpha-ketoamide-type inhibitor.	2G8J_A
CA	C02.001	calpain-1	calpain 1 proteolytic core inactivated by wr18(s,s), an epoxysuccinyl-type inhibitor.	2NQG_A
CA	C02.001	calpain-1	calpain 1 proteolytic core inactivated by wr13(r,r), an epoxysuccinyl-type inhibitor.	2NQI_A
CA	C02.001	calpain-1	calpain 1 proteolytic core inactivated by zlak-3001, an alpha-ketoamide	2R9C_A
CA	C02.001	calpain-1	calpain 1 proteolytic core inactivated by zlak-3002, an alpha-ketoamide	2R9F_A
CA	C02.002	calpain-2		1KFU_L
CA	C02.002	calpain-2		1KFX_L
CA	C02.002	calpain-2		2NQA
CA	C02.002	calpain-2	Complex with light chain	1DF0_A
CA	C02.002	calpain-2	protease core	1MDW_A
CA	C02.002	calpain-2		1QXP_A
CA	C02.002	calpain-2	Lys10Thr mutant	1U5I_A
CA	C02.002	calpain-2	complex with light chain with calpastatin	3BOW_A
CA	C02.002	calpain-2	complex with light chain and calpastatin	3DF0_A
CA	C02.004	calpain-3		1Y9V
CA	C02.004	calpain-3		4OKH
CA	C02.004	calpain-3	crystal structure of human calpain-3 protease core mutant-Cys129Ser	6BDT_A
CA	C02.004	calpain-3	crystal structure of human calpain-3 protease core mutant-Cys129Ala	6BGP_A
CA	C02.004	calpain-3	protease core; complex with E-64	6BJD_A
CA	C02.004	calpain-3	protease core; complex with leupeptin	6BKJ_A
CA	C02.006	calpain-9	catalytic domain only	1ZIV
CA	C02.006	calpain-9	complex with leupeptin	2P0R_A
CA	C02.011	calpain-5	core peptidase domain	6P3Q
CA	C02.020	calpain-13		2I7A
CA	C02.029	calpain (Plasmodium-type)	C2 domain	2QFE
PA	C03.001	poliovirus-type picornain 3C		1L1N_A
PA	C03.001	poliovirus-type picornain 3C	coxsackievirus Ala24Val mutant; complex with the d1-d2 fragment of icam-1	6EIT_3
PA	C03.005	hepatitis A virus-type picornain 3C		1HAV_A
PA	C03.005	hepatitis A virus-type picornain 3C	complex with inhibitor iodoacetyl-Val-Phe-amide	1QA7
PA	C03.005	hepatitis A virus-type picornain 3C	complex with peptide-based ketone inhibitor N-acetyl-L-leucyl-L-alanyl-N-[(1S)-4-(dimethylamino)-1-(fluoroacetyl)-4-oxobutyl]-L-alaninamide	2H6M
PA	C03.005	hepatitis A virus-type picornain 3C	complex with peptide-based ketone inhibitor N-acetyl-L-Leu-L-Ala-N-[(1S)-4-(dimethylamino)-1-(fluoroacetyl)-4-oxobutyl]-L-alaninamide	2H9H
PA	C03.005	hepatitis A virus-type picornain 3C	complex with peptide-based ketone inhibitor N-acetyl-L-Leu-L-Phe-N-[(1S,2R)-1-(2-carboxyethyl)-3-fluoro-2-hydroxypropyl]-L-phenylalaninamide	2HAL
PA	C03.007	human rhinovirus 2-type picornain 3C	complex with AG7088 inhibitor	1CQQ_A
PA	C03.007	human rhinovirus 2-type picornain 3C		1AYM_4
PA	C03.007	human rhinovirus 2-type picornain 3C		1AYN_4
PA	C03.007	human rhinovirus 2-type picornain 3C		1R1A
PA	C03.007	human rhinovirus 2-type picornain 3C		2HWD
PA	C03.007	human rhinovirus 2-type picornain 3C		2HWE
PA	C03.007	human rhinovirus 2-type picornain 3C		2HWF
PA	C03.008	foot-and-mouth disease virus picornain 3C	type A10(61); crystal packing mutant (Lys51Gln)	2J92_A
PA	C03.008	foot-and-mouth disease virus picornain 3C	complex with a decameric peptide corresponding to the vp1-2a cleavage junction	2WV4_A
PA	C03.008	foot-and-mouth disease virus picornain 3C	complex with a decameric peptide corresponding to the vp1-2a cleavage junction with a gln to glu substitution at p1	2WV5_A
PA	C03.008	foot-and-mouth disease virus picornain 3C	crystal structure of the 3c protease from south african territories type 2 foot-and-mouth disease virus	5HM2_A
PA	C03.008	foot-and-mouth disease virus picornain 3C		1QMY
PA	C03.008	foot-and-mouth disease virus picornain 3C		1QOL_A
PA	C03.008	foot-and-mouth disease virus picornain 3C		1QQP
PA	C03.008	foot-and-mouth disease virus picornain 3C		2JQF_R
PA	C03.008	foot-and-mouth disease virus picornain 3C		2JQG
PA	C03.008	foot-and-mouth disease virus picornain 3C		4QBB
PA	C03.008	foot-and-mouth disease virus picornain 3C	fmdv leader protease bound to substrate isg15	6FFA_A
PA	C03.011	Coxsackievirus-type picornain 3C	coxsackievirus b3 coat protein	1COV_1
PA	C03.011	Coxsackievirus-type picornain 3C		2VB0_A
PA	C03.011	Coxsackievirus-type picornain 3C	complex with epdtc	2ZTX_A
PA	C03.011	Coxsackievirus-type picornain 3C	space group c2	2ZTY_A
PA	C03.011	Coxsackievirus-type picornain 3C	space group p21	2ZTZ_A
PA	C03.011	Coxsackievirus-type picornain 3C	Cys147Ala mutant	2ZU1_A
PA	C03.011	Coxsackievirus-type picornain 3C		2ZU3_A
PA	C03.011	Coxsackievirus-type picornain 3C	the novel asymmetric entry intermediate of a picornavirus captured with nanodiscs	3JD7_1
PA	C03.011	Coxsackievirus-type picornain 3C	crystal structure of 3c protease of coxsackievirus b3	3ZYD_A
PA	C03.011	Coxsackievirus-type picornain 3C	Thr68Ala mutant	3ZYE_A
PA	C03.011	Coxsackievirus-type picornain 3C	crystal structure of 3c protease mutant (Asn126Tyr) of coxsackievirus b3	3ZZ3_A
PA	C03.011	Coxsackievirus-type picornain 3C	Thr68Ala and Asn126Tyr mutant	3ZZ4_A
PA	C03.011	Coxsackievirus-type picornain 3C	complex with alpha, beta-unsaturated ethyl ester inhibitor 74	3ZZ5_A
PA	C03.011	Coxsackievirus-type picornain 3C	complex with michael receptor inhibitor 75	3ZZ6_A
PA	C03.011	Coxsackievirus-type picornain 3C	complex with alpha, beta-unsaturated ethyl ester inhibitor 81	3ZZ7_A
PA	C03.011	Coxsackievirus-type picornain 3C	complex with alpha, beta-unsaturated ethyl ester inhibitor 82	3ZZ8_A
PA	C03.011	Coxsackievirus-type picornain 3C	complex with alpha, beta-unsaturated ethyl ester inhibitor 83	3ZZ9_A
PA	C03.011	Coxsackievirus-type picornain 3C	complex with alpha, beta-unsaturated ethyl ester inhibitor 84	3ZZA_A
PA	C03.011	Coxsackievirus-type picornain 3C	complex with alpha, beta-unsaturated ethyl ester inhibitor 85	3ZZB_A
PA	C03.011	Coxsackievirus-type picornain 3C	Thr68Ala and Asn126Tyr mutant; complex with alpha, beta-unsaturated ethyl ester inhibitor 83	3ZZC_A
PA	C03.011	Coxsackievirus-type picornain 3C	Thr68Ala and Asn126Tyr mutant; complex with alpha, beta-unsaturated ethyl ester inhibitor 85	3ZZD_A
PA	C03.011	Coxsackievirus-type picornain 3C	echovirus 18 native particle	6HBG_A
PA	C03.011	Coxsackievirus-type picornain 3C	echovirus 18 a-particle	6HBH_A
PA	C03.011	Coxsackievirus-type picornain 3C	echovirus 18 empty particle	6HBJ_A
PA	C03.011	Coxsackievirus-type picornain 3C	echovirus 18 open particle without one pentamer	6HBK_A
PA	C03.011	Coxsackievirus-type picornain 3C	echovirus 18 open particle without three pentamers	6HBL_A
PA	C03.011	Coxsackievirus-type picornain 3C		3ZV8
PA	C03.011	Coxsackievirus-type picornain 3C	complex with Michael receptor inhibitor 74	3ZV9
PA	C03.011	Coxsackievirus-type picornain 3C	complex with Michael receptor inhibitor 75	3ZVA
PA	C03.011	Coxsackievirus-type picornain 3C	complex with Michael receptor inhibitor 81	3ZVB
PA	C03.011	Coxsackievirus-type picornain 3C	complex with Michael receptor inhibitor 82	3ZVC
PA	C03.011	Coxsackievirus-type picornain 3C	complex with Michael receptor inhibitor 83	3ZVD
PA	C03.011	Coxsackievirus-type picornain 3C	complex with Michael receptor inhibitor 84	3ZVE
PA	C03.011	Coxsackievirus-type picornain 3C	complex with Michael receptor inhibitor 85	3ZVF
PA	C03.011	Coxsackievirus-type picornain 3C	complex with Michael receptor inhibitor 98	3ZVG
PA	C03.011	Coxsackievirus-type picornain 3C	crystal structure of the main protease (3c) from human enterovirus b ev93	3Q3X_A
PA	C03.011	Coxsackievirus-type picornain 3C	complex with compound 1 (ag7404)	3Q3Y_A
PA	C03.011	Coxsackievirus-type picornain 3C	complex with rupintrivir (ag7088)	3RUO_A
PA	C03.014	human enterovirus 71 3C peptidase	human enterovirus 71 3c protease	3OSY_A
PA	C03.014	human enterovirus 71 3C peptidase	Glu71Asp mutant; complex with rupintrivir	3QZQ_A
PA	C03.014	human enterovirus 71 3C peptidase	Glu71Ala mutant; complex with rupintrivir	3QZR_A
PA	C03.014	human enterovirus 71 3C peptidase	His133Gly mutant; complex with rupintrivir	3R0F_A
PA	C03.014	human enterovirus 71 3C peptidase	human enterovirus 71 in complex with capsid binding inhibitor win51711	3ZFE_A
PA	C03.014	human enterovirus 71 3C peptidase	human enterovirus 71 in complex with capsid binding inhibitor win51711	3ZFF_A
PA	C03.014	human enterovirus 71 3C peptidase	human enterovirus 71 in complex with capsid binding inhibitor win51711	3ZFG_A
PA	C03.014	human enterovirus 71 3C peptidase	crystal structure of human enterovirus 71	4AED_A
PA	C03.014	human enterovirus 71 3C peptidase	cryo-em reconstruction of enterovirus 71 in complex with a neutralizing antibody e18	4C0U_A
PA	C03.014	human enterovirus 71 3C peptidase	cryo-em reconstruction of empty enterovirus 71 in complex with a neutralizing antibody e18	4C0Y_A
PA	C03.014	human enterovirus 71 3C peptidase	cryo-em reconstruction of empty enterovirus 71 in complex with a neutralizing antibody e19	4C10_4
PA	C03.014	human enterovirus 71 3C peptidase	crystal structure of human enterovirus 71 in complex with the uncoating inhibitor gpp2	4CDQ_A
PA	C03.014	human enterovirus 71 3C peptidase	crystal structure of human enterovirus 71 in complex with the uncoating inhibitor gpp3	4CDU_A
PA	C03.014	human enterovirus 71 3C peptidase	crystal structure of human enterovirus 71 in complex with the uncoating inhibitor gpp4	4CDW_A
PA	C03.014	human enterovirus 71 3C peptidase	crystal structure of human enterovirus 71 in complex with the uncoating inhibitor gpp12	4CDX_A
PA	C03.014	human enterovirus 71 3C peptidase	crystal structure of human enterovirus 71 in complex with the uncoating inhibitor ald	4CEW_A
PA	C03.014	human enterovirus 71 3C peptidase	crystal structure of human enterovirus 71 in complex with the uncoating inhibitor nld	4CEY_A
PA	C03.014	human enterovirus 71 3C peptidase	Cys110Ala mutant	4FVB_A
PA	C03.014	human enterovirus 71 3C peptidase	Cys110Ala mutant; complex with substrate	4FVD_A
PA	C03.014	human enterovirus 71 3C peptidase		4GHQ_A
PA	C03.014	human enterovirus 71 3C peptidase	complex with ag7088	4GHT_A
PA	C03.014	human enterovirus 71 3C peptidase	human enterovirus 71 uncoating intermediate captured at atomic resolution	4N43_C
PA	C03.014	human enterovirus 71 3C peptidase	complex with compound xb	5C1U_A
PA	C03.014	human enterovirus 71 3C peptidase	complex with compound viii	5C1X_A
PA	C03.014	human enterovirus 71 3C peptidase	complex with compound 1	5C1Y_A
PA	C03.014	human enterovirus 71 3C peptidase	complex with compound 2	5C20_A
PA	C03.014	human enterovirus 71 3C peptidase	complex with compound 2	5DP3_A
PA	C03.014	human enterovirus 71 3C peptidase	complex with compound 3	5DP4_A
PA	C03.014	human enterovirus 71 3C peptidase	complex with compound 4	5DP5_A
PA	C03.014	human enterovirus 71 3C peptidase	complex with compound 7	5DP6_A
PA	C03.014	human enterovirus 71 3C peptidase	complex with compound 5	5DP7_A
PA	C03.014	human enterovirus 71 3C peptidase	complex with compound 8	5DP8_A
PA	C03.014	human enterovirus 71 3C peptidase	complex with compound 9	5DP9_A
PA	C03.014	human enterovirus 71 3C peptidase	complex with compound 6	5DPA_A
PA	C03.014	human enterovirus 71 3C peptidase	complex with nk-1.8k	5GSO_A
PA	C03.014	human enterovirus 71 3C peptidase	complex with n69s 1.8k	5GSW_A
PA	C03.014	human enterovirus 71 3C peptidase	complex with rupintrivir	5WQ2_A
PA	C03.014	human enterovirus 71 3C peptidase	cryo-em structure of cva6 vlp	5YHQ_C
PA	C03.020	enterovirus picornain 2A		2IJD_1
PA	C03.020	enterovirus picornain 2A	poliovirus type 3 (strain saukett) stabilized virus-like particle	5O5B_4
PA	C03.020	enterovirus picornain 2A	poliovirus type 3 (strain saukett) stabilized virus-like particle in complex with the pocket factor compound gpp3	5O5P_4
PA	C03.020	enterovirus picornain 2A	complex with antiviral agent sch48973	1EAH_1
PA	C03.020	enterovirus picornain 2A	NMR structure	1Z8R
PA	C03.020	enterovirus picornain 2A	identification of a druggable vp1-vp3 interprotomer pocket in the capsid of enteroviruses	6GZV_A
PA	C03.020	enterovirus picornain 2A		4MG3
PA	C03.020	enterovirus picornain 2A		5C8C
PA	C03.020	enterovirus picornain 2A	human enterovirus 71 uncoating intermediate captured at atomic resolution	4N43_B
PA	C03.020	enterovirus picornain 2A	structural model of human decay-accelerating factor bound to echovirus7 from cryo-electron microscopy	1M11_1
PA	C03.020	enterovirus picornain 2A		5X45
PA	C03.021	rhinovirus picornain 2A		2HRV_A
PA	C03.023	parechovirus picornain 3C		4UDF
PA	C03.023	parechovirus picornain 3C		4Z92
PA	C03.UNA	subfamily C3A non-peptidase homologues		1QGC
PA	C03.UNA	subfamily C3A non-peptidase homologues		4WYL
PA	C03.UNA	subfamily C3A non-peptidase homologues		4WYW
PA	C03.UNA	subfamily C3A non-peptidase homologues		4WZM
PA	C03.UNA	subfamily C3A non-peptidase homologues		4WZQ
PA	C03.UNA	subfamily C3A non-peptidase homologues		4X2B
PA	C03.UPA	subfamily C3A unassigned peptidases		1MEC
PA	C03.UPA	subfamily C3A unassigned peptidases		2M7Y
PA	C03.UPA	subfamily C3A unassigned peptidases		2MEV
PA	C03.UPA	subfamily C3A unassigned peptidases		2MMH
PA	C03.UPA	subfamily C3A unassigned peptidases		2MMI
PA	C03.UPA	subfamily C3A unassigned peptidases		2MMK
PA	C03.UPA	subfamily C3A unassigned peptidases		2MML
PA	C03.UPA	subfamily C3A unassigned peptidases		4NYZ
PA	C03.UPA	subfamily C3A unassigned peptidases		4NZ0
PA	C03.UPA	subfamily C3A unassigned peptidases		4Y2C
PA	C03.UPA	subfamily C3A unassigned peptidases		4Y3C
PA	C03.UPA	subfamily C3A unassigned peptidases	crystal structure of the 3c protease from coxsackievirus a16	3SJ8_A
PA	C03.UPA	subfamily C3A unassigned peptidases	Cys147Ala mutant; complex with faglrqavtq peptide	3SJ9_A
PA	C03.UPA	subfamily C3A unassigned peptidases	complex with rupintrivir (ag7088)	3SJI_A
PA	C03.UPC	subfamily C3C unassigned peptidases		3CJI
PA	C04.004	tobacco etch virus NIa peptidase	inactive form; complex with substrate	1LVB_A
PA	C04.004	tobacco etch virus NIa peptidase	complex with product	1LVM
PA	C04.004	tobacco etch virus NIa peptidase	Cys151Ala mutant	1Q31
CE	C05.001	adenain	complex with peptide cofactor	1AVP_A
CE	C05.001	adenain	complex with 11 amino acid cofactor	1NLN_A
CE	C05.001	adenain		4EKF
CE	C05.001	adenain	complex with N-benzyl-2-[(Z)-iminomethyl]pyrimidine-5- carboxamide	4PID
CE	C05.001	adenain	complex with N-(2S)-2-(3-chlorophenyl)-2-[(methylsulfonyl)amino]acetyl- L-phenylalanyl-N-[(2Z)-2-iminoethyl]glycinamide	4PIE
CE	C05.001	adenain	structure of human adenovirus 2 protease with cofactor pvic	5FGY_A
CE	C05.001	adenain	complex with N-[(3,5-dichlorophenyl)acetyl]-L-threonyl- N-[(2Z)-2-iminoethyl]glycinamide	4PIQ
CE	C05.001	adenain	complex with N~2~-[(2R)-2-(3,5-dichlorophenyl)-2-(dimethylamino)acetyl]- N-(2-[(Z)-iminomethyl]pyrimidin-4-ylmethyl)- L-isoleucinamide	4PIS
CE	C05.001	adenain	complex with a nitrile inhibitor	4WX4_A
CE	C05.001	adenain	crystal structure of human adenovirus 8 protease with an irreversible vinyl sulfone inhibitor	4WX6_A
CE	C05.001	adenain	crystal structure of adenovirus 8 protease with a nitrile inhibitor	4WX7_A
CA	C06.001	potato virus Y-type helper component peptidase		1LVM_A
CA	C06.001	potato virus Y-type helper component peptidase		1Q31_A
CA	C06.001	potato virus Y-type helper component peptidase		3MMG
CA	C06.001	potato virus Y-type helper component peptidase		3RNV
CN	C09.001	sindbis virus-type nsP2 peptidase		4GUA
CN	C09.001	sindbis virus-type nsP2 peptidase		3GPG
CN	C09.001	sindbis virus-type nsP2 peptidase		3GPO
CN	C09.001	sindbis virus-type nsP2 peptidase		3GPQ
CN	C09.001	sindbis virus-type nsP2 peptidase		3TRK
CN	C09.001	sindbis virus-type nsP2 peptidase		4TU0
CN	C09.001	sindbis virus-type nsP2 peptidase		4ZTB
CN	C09.002	equine encephalitis alphavirus nsP2 peptidase		2HWK
CN	C09.002	equine encephalitis alphavirus nsP2 peptidase	venezuelan equine encephalitis virus (veev) nonstructural protein 2 (nsp2) cysteine protease	5EZQ_A
CN	C09.002	equine encephalitis alphavirus nsP2 peptidase	complex with E64d	5EZS_A
CA	C10.001	streptopain	precursor; Cys47Ser mutant	1DKI_A
CA	C10.001	streptopain	complex with inhibitor	1PVJ
CA	C10.001	streptopain	mature peptidase	2UZJ
CA	C10.004	interpain A	structure of prevotella intermedia prointerpain a fragment 39-359 (mutant c154a)	3BB7_A
CA	C10.004	interpain A	structure of active wild-type prevotella intermedia interpain a cysteine protease	3BBA_A
CA	C100.001	agglutinin peptidase (Marasmius oreades)	complex with trisaccharide Gal-Gla-GlcNAc	2IHO
CA	C100.001	agglutinin peptidase (Marasmius oreades)	complex with trisaccharide Galalpha(1,3)[Fucalpha(1,2)]Gal	3EF2
CA	C100.001	agglutinin peptidase (Marasmius oreades)	complex with Z-Val-Ala-Asp-CH(2)F, direct orientation	5D61
CA	C100.001	agglutinin peptidase (Marasmius oreades)	complex with Z-Val-Ala-Asp-CH(2)F, inverted orientation	5D62
CA	C100.001	agglutinin peptidase (Marasmius oreades)	complex with Z-Val-Ala-Asp-CH(2)F, dual orientation	5D63
CA	C100.UNW	family C100 non-peptidase homologues	complex with trisaccharide Neu5Aca2-6Galb1-4GlcNAc	3PHZ
CA	C100.UPW	family C100 unassigned peptidases	complex with E64	5MUA
CA	C101.001	OTULIN peptidase		3ZNV
CA	C101.001	OTULIN peptidase		3ZNX
CA	C101.001	OTULIN peptidase		3ZNZ
CA	C101.001	OTULIN peptidase	OTU domain	4KSJ
CA	C101.001	OTULIN peptidase	complex with ubiquitin	4KSK
CA	C101.001	OTULIN peptidase	complex with linear di-ubiquitin	4KSL
CA	C101.001	OTULIN peptidase		4OYK
CA	C101.001	OTULIN peptidase		4P0B
CA	C101.001	OTULIN peptidase	structure of otulin bound to the met1-linked diubiquitin activity probe	5OE7_A
CA	C101.001	OTULIN peptidase	structure of the otu domain of otulin g281r mutant	6I9C_A
CA	C101.950	protein FAM105A	otu domain of fam105a	6DRM_A
CA	C102.001	GtgE peptidase		4MI7
CA	C102.001	GtgE peptidase		5KDG
CA	C104.001	PlyC phage lysin	complex with PlyCB	4F88
PA	C107.UPW	family C107 unassigned peptidases	semet labeled derivative of cavally virus 3cl protease	5LAC_A
PA	C107.UPW	family C107 unassigned peptidases	ligand-bound structure of cavally virus 3cl protease *caveat 5lak tyr i 2 has wrong chirality at atom ca tyr k 2 has wrong *caveat 2 5lak chirality at atom ca	5LAK_A
CR	C108.001	Prp peptidase (Staphylococcus aureus)		2P92
CR	C108.001	Prp peptidase (Staphylococcus aureus)		2IDL
CR	C108.001	Prp peptidase (Staphylococcus aureus)		2G0I
CR	C108.UPW	family C108 unassigned peptidases		1S12
CD	C11.003	PmC11 peptidase (Parabacteroides merdae)		3UWS
CD	C11.003	PmC11 peptidase (Parabacteroides merdae)	complex with peptide inhibitor Ac-VLTK-AOMK	4YEC
CD	C11.004	fragipain (Bacteroides fragilis)		5DYN_A
CD	C11.005	thetapain
CD	C11.006	clostripain-related protein (Bacteroides thetaiotaomicron)	complex with biotin-Val-Leu-Thr-Lys-AOMK	5L20
CD	C11.006	clostripain-related protein (Bacteroides thetaiotaomicron)	Arg154Ala mutant	6NAG
CD	C11.007	distapain (Parabacteroides distasonis)	zymogen	6MZO
CA	C111.001	coagulation factor XIIIa	with bound calcium	1EVU
CA	C111.001	coagulation factor XIIIa	zymogen; Trp279Phe mutant	1EX0
CA	C111.001	coagulation factor XIIIa	recombinant form	1F13
CA	C111.001	coagulation factor XIIIa	recombinant form	1FIE
CA	C111.001	coagulation factor XIIIa		1GGT
CA	C111.001	coagulation factor XIIIa	with bound calcium	1GGU
CA	C111.001	coagulation factor XIIIa	with bound ytterbium	1GGY
CA	C111.001	coagulation factor XIIIa	with bound strontium	1QRK
CA	C111.001	coagulation factor XIIIa	complex with peptide-like ligand	4KTY
C-	C116.001	dermonecrotic toxin (Pasteurella multocida)		2EBF
C-	C116.001	dermonecrotic toxin (Pasteurella multocida)		2EBH
C-	C116.001	dermonecrotic toxin (Pasteurella multocida)		2EC5
CA	C117.001	SpvD g.p. (Salmonella enterica)	Arg161 variant	5LQ6
CA	C117.001	SpvD g.p. (Salmonella enterica)	Gly161 variant	5LQ7
CA	C12.001	ubiquitinyl hydrolase-L1		2ETL
CA	C12.001	ubiquitinyl hydrolase-L1		2LEN
CA	C12.001	ubiquitinyl hydrolase-L1		3IFW
CA	C12.001	ubiquitinyl hydrolase-L1		3IRT
CA	C12.001	ubiquitinyl hydrolase-L1		3KVF
CA	C12.001	ubiquitinyl hydrolase-L1		3KW5
CA	C12.001	ubiquitinyl hydrolase-L1		4DM9
CA	C12.001	ubiquitinyl hydrolase-L1		4JKJ
CA	C12.002	ubiquitinyl hydrolase-YUH1	complex with human ubiquitin	1CMX
CA	C12.003	ubiquitinyl hydrolase-L3		1UCH
CA	C12.003	ubiquitinyl hydrolase-L3	complex with ubiquitin	1XD3
CA	C12.003	ubiquitinyl hydrolase-L3	complex with Lys27-linked di-ubiquitin	6ISU_A
CA	C12.005	ubiquitinyl hydrolase-L5		3A7S
CA	C12.005	ubiquitinyl hydrolase-L5		3IHR
CA	C12.005	ubiquitinyl hydrolase-L5	catalytic domain only	3RII
CA	C12.005	ubiquitinyl hydrolase-L5	catalytic domain only	3RIS
CA	C12.005	ubiquitinyl hydrolase-L5		3TB3
CA	C12.005	ubiquitinyl hydrolase-L5		4UEL
CA	C12.005	ubiquitinyl hydrolase-L5		4UEM
CA	C12.005	ubiquitinyl hydrolase-L5		4UF5
CA	C12.005	ubiquitinyl hydrolase-L5		4UF6
CA	C12.005	ubiquitinyl hydrolase-L5		4WLP
CA	C12.005	ubiquitinyl hydrolase-L5		4WLQ
CA	C12.005	ubiquitinyl hydrolase-L5		4WLR
CA	C12.A09	CG8445 g.p. (Drosophila melanogaster)	complex with pr	6CGA_A
CA	C12.A09	CG8445 g.p. (Drosophila melanogaster)	complex with DEUBAD of ASX	6HGC
CE	C122.001	SdeA (Legionella pneumophila)		5CRA
CE	C122.001	SdeA (Legionella pneumophila)		5CRB
CE	C122.001	SdeA (Legionella pneumophila)		5CRC
CE	C122.001	SdeA (Legionella pneumophila)		5YSI
CE	C122.001	SdeA (Legionella pneumophila)		5YSJ
CE	C122.001	SdeA (Legionella pneumophila)		5YSK
CE	C122.001	SdeA (Legionella pneumophila)		6B7Q
CE	C122.001	SdeA (Legionella pneumophila)		6G0C
CD	C13.001	legumain (plant beta form)	complex with AAN peptide	6AZT
CD	C13.004	legumain, animal-type	complex with Ac-Tyr-Val-Ala-Asp-chloromethylketone	4AW9
CD	C13.004	legumain, animal-type	complex with Ac-Tyr-Val-Ala-Asp-chloromethylketone at pH 5.0	4AWA
CD	C13.004	legumain, animal-type	complex with Z-Ala-Ala-AzaAsn-chloromethylketone	4AWB
CD	C13.004	legumain, animal-type	precursor	4FGU
CD	C13.004	legumain, animal-type	oxidised form in complex with cystatin E/M	4N6N_A
CD	C13.004	legumain, animal-type	complex with cystatin E/M	4N6O_A
CD	C13.004	legumain, animal-type	YVAD-CMK bound form; complex with compound 11b	5LU8_C
CD	C13.004	legumain, animal-type	YVAD-CMK bound form; complex with compound 11	5LU9_C
CD	C13.004	legumain, animal-type	complex with compound 11b	5LUA_A
CD	C13.004	legumain, animal-type	complex with compound 11	5LUB_B
CD	C13.004	legumain, animal-type	activated at pH 3.5	4NOJ
CD	C13.004	legumain, animal-type	precxursor at pH 7.5	4NOK
CD	C13.004	legumain, animal-type	Asp223Ala mutant; precursor at pH 7.5	4NOL
CD	C13.004	legumain, animal-type	activated at pH 4.5	4NOM
CD	C13.004	legumain, animal-type		4D3X
CD	C13.004	legumain, animal-type	precursor	4D3Y
CD	C13.004	legumain, animal-type	precursor; trigonal space group	4D3Z
CD	C13.006	legumain (plant gamma form)	two-chain activation state	5NIJ
CD	C13.006	legumain (plant gamma form)	isoform gamma in complex with Ac-YVAD-CMK	5OBT
CD	C13.010	OaAEP1 (Oldenlandia affinis)		5H0I
CD	C14.001	caspase-1	complex with (3S)-N-methanesulfonyl-3-(1-[N-(2-naphtoyl)-Val]-Proamino)-4-oxobutanamide inhibitor	1BMQ
CD	C14.001	caspase-1	complex with inhibitor ac-Trp-Glu-His-Asp	1IBC
CD	C14.001	caspase-1	complex with inhibitor Ac-Tyr-Val-Ala-Asp-H	1ICE
CD	C14.001	caspase-1	complex with 3-(2- mercapto-acetylamino)-4-oxo-pentanoic acid	1RWK_A
CD	C14.001	caspase-1	complex with 4-oxo- 3-[2-(5-[4-(quinoxalin-2-ylamino)-benzoylamino]-methyl- thiophen-2-yl)-acetylamino]-pentanoic acid	1RWM_A
CD	C14.001	caspase-1	complex with 3-2- ethyl-6-[4-(quinoxalin-2-ylamino)-benzoylamino]- hexanoylamino-4-oxo-butyric acid	1RWN_A
CD	C14.001	caspase-1	complex with 4-oxo- 3-6-[4-(quinoxalin-2-ylamino)-benzoylamino]-2-thiophen-2- yl-hexanoylamino-pentanoic acid	1RWO_A
CD	C14.001	caspase-1	complex with 3-6- [(8-hydroxy-quinoline-2-carbonyl)-amino]-2-thiophen-2-yl- hexanoylamino-4-oxo-butyric acid	1RWP_A
CD	C14.001	caspase-1	complex with 5-[5- (1-carboxymethyl-2-oxo-propylcarbamoyl)-5-phenyl- pentylsulfamoyl]-2-hydroxy-benzoic acid	1RWV_A
CD	C14.001	caspase-1	complex with 4-oxo- 3-[(6-[4-(quinoxalin-2-ylamino)-benzoylamino]-methyl- pyridine-3-carbonyl)-amino]-butyric acid	1RWW_A
CD	C14.001	caspase-1	complex with 4-oxo- 3-6-[4-(quinoxalin-2-yloxy)-benzoylamino]-2-thiophen-2-yl- hexanoylamino-butyric acid	1RWX_A
CD	C14.001	caspase-1	Cys285Ala mutant	1SC1
CD	C14.001	caspase-1	Cys285Ala mutant; complex with malonate	1SC3
CD	C14.001	caspase-1	Cys285Ala mutant; after malonate complex dissociation	1SC4
CD	C14.001	caspase-1	Cys285Ala, Cys362Ala, Cys364Ala, Cys397Ala mutant; complex with 1-methyl-3- trifluoromethyl-1H-thieno[2,3-C]pyrazole-5-carboxylic acid (2-mercapto-ethyl)-amide	2FQQ_A
CD	C14.001	caspase-1	Cys362Ala, Cys364Ala, Cys397Ala mutant; complex with 3-[2-(2- benzyloxycarbonylamino-3-methyl-butyrylamino)- propionylamino]-4-oxo-pentanoic acid (z-VAD-FMK)	2H48_A
CD	C14.001	caspase-1	Glu390Asp mutant; complex with 3-[2-(2-benzyloxycarbonylamino-3-methyl- butyrylamino)-propionylamino]-4-oxo-pentanoic acid (z-vad- fmk)	2H4W_A
CD	C14.001	caspase-1	Arg286Lys mutant; complex with 3-[2-(2-benzyloxycarbonylamino-3-methyl- butyrylamino)-propionylamino]-4-oxo-pentanoic acid (z-vad- fmk)	2H4Y_A
CD	C14.001	caspase-1	Glu390Asp, Arg286Lys mutant; complex with 3-[2-(2- benzyloxycarbonylamino-3-methyl-butyrylamino)- propionylamino]-4-oxo-pentanoic acid	2H51_A
CD	C14.001	caspase-1	Thr388Ala mutant; complex with 3-[2-(2-benzyloxycarbonylamino-3-methyl- butyrylamino)-propionylamino]-4-oxo-pentanoic acid (z-vad- fmk)	2H54_A
CD	C14.001	caspase-1	complex with 3-[2-(2-benzyloxycarbonylamino-3-methyl-butyrylamino)- propionylamino]-4-oxo-pentanoic acid (z-VAD-FMK)	2HBQ_A
CD	C14.001	caspase-1	Arg286Ala mutant; complex with 3-[2-(2-benzyloxycarbonylamino-3-methyl- butyrylamino)-propionylamino]-4-oxo-pentanoic acid (z-VAD- FMK)	2HBR_A
CD	C14.001	caspase-1	Glu390Ala mutant; complex with 3-[2-(2-benzyloxycarbonylamino-3-methyl- butyrylamino)-propionylamino]-4-oxo-pentanoic acid (z-VAD- FMK)	2HBY_A
CD	C14.001	caspase-1	Arg286Ala, Glu390Ala mutant; complex with 3-[2-(2-benzyloxycarbonylamino-3- methyl-butyrylamino)-propionylamino]-4-oxo-pentanoic acid (Z-VAD-FMK)	2HBZ_A
CD	C14.001	caspase-1		3D6F
CD	C14.001	caspase-1		3D6H
CD	C14.001	caspase-1		3D6M
CD	C14.001	caspase-1	procaspase-1 zymogen domain crystal strucutre	3E4C_A
CD	C14.001	caspase-1		3NS7
CD	C14.001	caspase-1	crystal structure of human caspase-1 with 2-((2-naphthoyl)-l-valyl)-4-hydroxy-n-((3s)-2-hydroxy-5-oxotetrahydrofuran-3-yl)-2- azabicyclo[2.2.2]octane-3-carboxamide (compound 1)	5MMV_A
CD	C14.001	caspase-1	crystal structure of human caspase-1 with (3s,6s,10as)-n-((2s,3s)-2- hydroxy-5-oxotetrahydrofuran-3-yl)-6-(isoquinoline-1-carboxamido)-5- oxodecahydropyrrolo[1,2-a]azocine-3-carboxamide (pge-3935199)	5MTK_A
CD	C14.001	caspase-1	complex with ac-fltd-cmk	6BZ9_A
CD	C14.001	caspase-1	crystal structure of human caspase-1 with n-3-[1-((s)-2-hydroxy-5- oxo-tetrahydro-furan-3-ylcarbamoyl)-ethyl]-1-methyl-2,4-dioxo-1,2,3, 4-tetrahydro-pyrimidin-5-yl-4-(quinoxalin-2-ylamino)-benzamide	6F6R_A
CD	C14.002	CED-3 peptidase		4M9R
CD	C14.003	caspase-3	complex with tetrapeptide inhibitor acetyl-Asp-Val-Ala-Asp-fluoromethylketone	1CP3
CD	C14.003	caspase-3	complex with isatin sulfonamide inhibitor 1-methyl-5-(2-phenoxymethyl-pyrrolidine-1-sulfonyl)-1H-indole-2,3-dione	1GFW
CD	C14.003	caspase-3	complex with BIRC-4 protein	1I3O_A
CD	C14.003	caspase-3		1NME
CD	C14.003	caspase-3		1NMQ
CD	C14.003	caspase-3		1NMS
CD	C14.003	caspase-3	complex with acetyl-Asp-Glu-Val-Asp-CHO	1PAU_A
CD	C14.003	caspase-3		1QX3
CD	C14.003	caspase-3	complex with nicotinic acid aldehyde (3S)-3-[(5-bromopyridin-3-yl)carbonyl]amino-4-oxobutanoic acid	1RE1_A
CD	C14.003	caspase-3	complex with pryazinone inhibitor 3-(2-5-tert-butyl-3-[(4-methyl-furazan-3-ylmethyl)-amino]-2-oxo-2H-pyrazin-1-yl-butyrylamino)-5-(hexyl-methyl-amino)-4-oxo-pentanoic acid anion	1RHJ_A
CD	C14.003	caspase-3	complex with phenyl- propyl-ketone N-acetyl-L-alpha-aspartyl-L-alpha-glutamyl-N-[(1S)-1-(carboxymethyl)-2-oxo-5-phenylpentyl]-L-valinamide	1RHK_A
CD	C14.003	caspase-3	complex with nicotinic acid aldehyde 4-[5-(2-carboxy-1-formyl-ethylcarbamoyl)-pyridin-3-yl]-benzoic acid	1RHM_A
CD	C14.003	caspase-3	complex with bromomethoxyphenyl inhibitor 5-S-benzyl-3-(N-[(5-bromo-2-methoxyphenyl)acetyl]- L-valylamino)-2,3-dideoxy-5-thio-D-erythro- pentonic acid	1RHQ_A
CD	C14.003	caspase-3	complex with cinnamic acid methyl ester (3S)-5-[(2-chloro-6-fluorobenzyl)sulfanyl]-3-[N-(2-ethoxy-5-[(1E)-3-methoxy-3-oxoprop-1-enyl]phenylacetyl)-D-valyl]amino-4-oxopentanoic acid	1RHR_A
CD	C14.003	caspase-3	complex with 5,6,7 tricyclic peptidomimetic inhibitor (3S)-3-[((2S)-5-[(N-acetyl-L-alpha-aspartyl)amino]-4-oxo-1,2,4,5,6,7-hexahydroazepino[3,2,1-hi]indol-2-ylcarbonyl)amino]-5-(benzylsulfanyl)-4-oxopentanoic acid	1RHU_A
CD	C14.003	caspase-3	complex with (5S,8R,11S)-8-(2-carboxyethyl)-5-(carboxymethyl)-14-(4-ethoxy-4-oxobutanoyl)-11-(1-methylethyl)-3,6,9,12-tetraoxo-1-phenyl-2-oxa-4,7,10,13,14-pentaazahexadecan-16-oic acid	2C1E_A
CD	C14.003	caspase-3	complex with (5S,8R,11S)-8-(2-carboxyethyl)-5-(carboxymethyl)-14-(4-ethoxy-4-oxobutanoyl)-11-(1-methylethyl)-3,6,9,12-tetraoxo-1-phenyl-2-oxa-4,7,10,13,14-pentaazahexadecan-16-oic acid	2C2K_A
CD	C14.003	caspase-3	complex with (5S,8R,11S)-14-[4-(benzyloxy)-4-oxobutanoyl]-8-(2-carboxyethyl)-5-(carboxymethyl)-11-(1-methylethyl)-3,6,9,12-tetraoxo-1-phenyl-2-oxa-4,7,10,13,14-pentaazahexadecan-16-oic acid	2C2M_A
CD	C14.003	caspase-3	complex with Cbz-Asp-Glu-Val-AAsp-CHCH-CON(CH3)CH2Ph	2C2O_A
CD	C14.003	caspase-3	complex with CBZ-Asp-Glu-Val-azaAsp-EP-CO-N(CH2PH)2	2CDR_A
CD	C14.003	caspase-3	extended substrate recognition in caspase-3 revealed by high resolution x-ray structure analysis	2CJX_A
CD	C14.003	caspase-3	extended substrate recognition in caspase-3 revealed by high resolution x-ray structure analysis	2CJY_A
CD	C14.003	caspase-3	complex with CBZ-Asp-Glu-Val-azaAsp-EP-COO-CH2Ph	2CNK_A
CD	C14.003	caspase-3	complex with CBZ-Asp-Glu-Val-azaAsp-EP-CO-NH-CH2Ph	2CNL_A
CD	C14.003	caspase-3	complex with CBZ-Ile-Glu-Thr-azaAsp-EP-CO-Ala-NH-CH2-Ph	2CNN_A
CD	C14.003	caspase-3	complex with CBZ-Glu-Val-azaAsp-(S,S)EP-CO-NHCH2CH2Ph	2CNO_A
CD	C14.003	caspase-3	extended substrate recognition in caspase-3 revealed by high resolution x-ray structure analysis	2DKO_A
CD	C14.003	caspase-3	complex with inhibitor Ac-DEVD-CHO	2H5I_A
CD	C14.003	caspase-3	complex with inhibitor Ac-DMQD-CHO	2H5J_A
CD	C14.003	caspase-3	complex with inhibitor Ac-VDVAD-CHO	2H65_A
CD	C14.003	caspase-3		2J30
CD	C14.003	caspase-3		2J31
CD	C14.003	caspase-3		2J32
CD	C14.003	caspase-3		2J33
CD	C14.003	caspase-3		2XYG
CD	C14.003	caspase-3		2XYH
CD	C14.003	caspase-3		2XYP
CD	C14.003	caspase-3		2XZD
CD	C14.003	caspase-3		2XZT
CD	C14.003	caspase-3		2Y0B
CD	C14.003	caspase-3		3DEH
CD	C14.003	caspase-3		3DEI
CD	C14.003	caspase-3		3DEJ
CD	C14.003	caspase-3		3DEK
CD	C14.003	caspase-3	complex with inhibitor Ac-LDESD-CHO	3EDQ_A
CD	C14.003	caspase-3	caspase-3 binds diverse p4 residues in peptides	3GJQ_A
CD	C14.003	caspase-3	caspase-3 binds diverse p4 residues in peptides	3GJR_A
CD	C14.003	caspase-3	caspase-3 binds diverse p4 residues in peptides	3GJS_A
CD	C14.003	caspase-3	caspase-3 binds diverse p4 residues in peptides	3GJT_A
CD	C14.003	caspase-3		3H0E
CD	C14.003	caspase-3		3ITN
CD	C14.003	caspase-3		3KJF
CD	C14.003	caspase-3		3PCX
CD	C14.003	caspase-3		3PD0
CD	C14.003	caspase-3		3PD1
CD	C14.003	caspase-3		4DCJ
CD	C14.003	caspase-3		4DCO
CD	C14.003	caspase-3		4DCP
CD	C14.003	caspase-3		4EHA
CD	C14.003	caspase-3		4EHD
CD	C14.003	caspase-3		4EHF
CD	C14.003	caspase-3		4EHH
CD	C14.003	caspase-3		4EHK
CD	C14.003	caspase-3		4EHL
CD	C14.003	caspase-3		4EHN
CD	C14.003	caspase-3		4JJE
CD	C14.003	caspase-3		4JQY
CD	C14.003	caspase-3		4JQZ
CD	C14.003	caspase-3		4JR0
CD	C14.003	caspase-3		4PRY
CD	C14.003	caspase-3		4PS0
CD	C14.003	caspase-3		4QTX
CD	C14.003	caspase-3		4QTY
CD	C14.003	caspase-3		4QU0
CD	C14.003	caspase-3		4QU5
CD	C14.003	caspase-3		4QU8
CD	C14.003	caspase-3		4QU9
CD	C14.003	caspase-3		4QUA
CD	C14.003	caspase-3		4QUB
CD	C14.003	caspase-3		4QUD
CD	C14.003	caspase-3		4QUE
CD	C14.003	caspase-3		4QUG
CD	C14.003	caspase-3		4QUH
CD	C14.003	caspase-3		4QUI
CD	C14.003	caspase-3		4QUJ
CD	C14.003	caspase-3		4QUL
CD	C14.003	caspase-3	Val266Ala mutant	5I9B_A
CD	C14.003	caspase-3	Val266Cys mutant	5I9T_A
CD	C14.003	caspase-3	Val266Asp mutant	5IAB_A
CD	C14.003	caspase-3	Val266Phe mutant	5IAE_A
CD	C14.003	caspase-3	Val266Gln mutant	5IAG_A
CD	C14.003	caspase-3	Val266Leu mutant	5IAJ_A
CD	C14.003	caspase-3	Val266Ser mutant	5IAK_A
CD	C14.003	caspase-3	Val266Asn mutant	5IAN_A
CD	C14.003	caspase-3	Val266Trp mutant	5IAR_A
CD	C14.003	caspase-3	Val266Tyr mutant	5IAS_A
CD	C14.003	caspase-3	Val266Ile mutant	5IBC_A
CD	C14.003	caspase-3	Val266Met mutant	5IBP_A
CD	C14.003	caspase-3	Val266Lys mutant	5IBR_A
CD	C14.003	caspase-3	complex with DEVE peptide	5IC4_A
CD	C14.003	caspase-3	caspase-3 mutant - t245d,s249d	6BFJ_A
CD	C14.003	caspase-3	caspase-3 mutant- t245a	6BFK_A
CD	C14.003	caspase-3	caspase-3 mutant- d9a,d28a,t245d	6BFL_A
CD	C14.003	caspase-3	caspase-3 mutant- t245d	6BFO_A
CD	C14.003	caspase-3	Asp9Ala/Asp28Ala/Ser150Asp mutant	6BG0_A
CD	C14.003	caspase-3	Asp9Ala/Asp28Ala/Ser150Glu mutant	6BG1_A
CD	C14.003	caspase-3	caspase-3 mutant- t152d	6BG4_A
CD	C14.003	caspase-3	caspase-3 mutant- d9a,d28a,t152d	6BGK_A
CD	C14.003	caspase-3	Ser150Asp mutant	6BGQ_A
CD	C14.003	caspase-3	caspase-3 mutant - s150e	6BGR_A
CD	C14.003	caspase-3	caspase-3 mutant - s150y	6BGS_A
CD	C14.003	caspase-3	caspase-3 mutant - t152a	6BH9_A
CD	C14.003	caspase-3	caspase-3 mutant - t152v	6BHA_A
CD	C14.003	caspase-3	complex with ac-dw3-ke	6CKZ_A
CD	C14.003	caspase-3	complex with ac-ats009-ke	6CL0_A
CD	C14.003	caspase-3	zebra fish caspase-3 *caveat 5jft caspase should be connected to the chloromethyl ketone caveat 2 5jft residual terminus of the inhibitor through hemithioacetal caveat 3 5jft bond, but the model does not reflect the ideal *caveat 4 5jft hemithio	5JFT_A
CD	C14.004	caspase-7	complex with acetyl-Asp-Glu-Val-Asp-CHO	1F1J
CD	C14.004	caspase-7	precursor	1GQF
CD	C14.004	caspase-7	complex with XIAP	1I4O_A
CD	C14.004	caspase-7	complex with XIAP inhibitor	1I51_A
CD	C14.004	caspase-7		1K86
CD	C14.004	caspase-7	precursor	1K88
CD	C14.004	caspase-7	complex with XIAP-BIR2	1KMC_A
CD	C14.004	caspase-7	theoretical model; complex with AC-DEVD inhibitor	1MIA
CD	C14.004	caspase-7	complex with dica allosteric inhibitor	1SHJ_A
CD	C14.004	caspase-7	complex with FICA allosteric inhibitor	1SHL
CD	C14.004	caspase-7	complex with inhibitor Ac-DMQD-CHO	2QL5_A
CD	C14.004	caspase-7	complex with inhibitor Ac-IEPD-CHO	2QL7_A
CD	C14.004	caspase-7	complex with inhibitor Ac-DQMD-CHO	2QL9_A
CD	C14.004	caspase-7	complex with inhibitor Ac-ESMD-CHO	2QLB_A
CD	C14.004	caspase-7	complex with inhibitor Ac-DNLD-CHO	2QLF_A
CD	C14.004	caspase-7	complex with inhibitor Ac-WEHD-CHO	2QLJ_A
CD	C14.004	caspase-7	complex with acetyl- LDESD-CHO	3EDR_A
CD	C14.004	caspase-7	mature caspase-7 i213a with devd-cho inhibitor bound to active site	3H1P_A
CD	C14.004	caspase-7	complex with acetyl-yvad- cho	3IBC_A
CD	C14.004	caspase-7	crystal structure of unliganded caspase-7	3IBF_A
CD	C14.004	caspase-7	redox-controlled	3R5K_A
CD	C14.004	caspase-7	crystal structure of caspase-7	4FDL_A
CD	C14.004	caspase-7	complex with allosteric inhibitor	4FEA_A
CD	C14.004	caspase-7	crystal structure of mutant form of caspase-7	4HQ0_A
CD	C14.004	caspase-7	crystal structure of mutant form of caspase-7	4HQR_A
CD	C14.004	caspase-7	complex with darpin c7_16	4JB8_A
CD	C14.004	caspase-7	caspase-3 specific unnatural amino acid peptides	4JJ8_A
CD	C14.004	caspase-7	precursor in complex with Ac-DEVD-CMK	4JR1
CD	C14.004	caspase-7	human procaspase-7/caspase-7 heterodimer bound to ac-devd-cmk	4JR2_A
CD	C14.004	caspase-7	complex with darpin d7.18	4LSZ_A
CD	C14.004	caspase-7	caspase-7 variant 4 (v4) with reprogrammed substrate specificity due to y230v/w232y/s234v/q276d substitutions bound to veid inhibitor.	4ZVO_A
CD	C14.004	caspase-7	caspase-7 variant 2 (v2) with reprogrammed substrate specificity due to y230v/w232m/q276c substitutions bound to devd inhibitor.	4ZVP_A
CD	C14.004	caspase-7	caspase-7 variant 2 (v2) with reprogrammed substrate specificity due to y230v/w232m/q276c substitutions bound to veid inhibitor.	4ZVQ_A
CD	C14.004	caspase-7	caspase-7 variant 4 (v4) with reprogrammed substrate specificity due to y230v/w232y/s234v/q276d substitutions bound to devd inhibitor.	4ZVR_A
CD	C14.004	caspase-7	caspase-7 variant 1 (v1) with reprogrammed substrate specificity due to y230a/w232m/s234n substitutions, bound to devd inhibitor.	4ZVS_A
CD	C14.004	caspase-7	caspase-7 variant 1 (v1) with reprogrammed substrate specificity due to y230a/w232m/s234n substitutions, bound to veid inhibitor.	4ZVT_A
CD	C14.004	caspase-7	caspase-7 wild-type bound to the caspase-6 cognate tetrapeptide inhibitor ac-veid-cho	4ZVU_A
CD	C14.004	caspase-7	complex with DEVE peptide	5IC6_A
CD	C14.004	caspase-7	caspase-7 s239e phosphomimetic	5K20_A
CD	C14.004	caspase-7	crystal structure of human caspase-7 soaked with allosteric inhibitor 2-[(2-acetylphenyl)sulfanyl]benzoic acid	5V6U_A
CD	C14.004	caspase-7	crystal structure of human caspase-7 soaked with allosteric inhibitor 2-[2-(4-chlorophenyl)-2-oxoethyl]sulfanylbenzoic acid	5V6Z_A
CD	C14.004	caspase-7	complex with ac-dw3-ke	6CL1_A
CD	C14.004	caspase-7	complex with ac-ats009-ke	6CL2_A
CD	C14.005	caspase-6	theoretical model; complex with AC-IETD inhibitor	1MI9
CD	C14.005	caspase-6		2WDP
CD	C14.005	caspase-6		3K7E
CD	C14.005	caspase-6		3NKF
CD	C14.005	caspase-6		3NR2
CD	C14.005	caspase-6		3OD5
CD	C14.005	caspase-6		3P45
CD	C14.005	caspase-6		3P4U
CD	C14.005	caspase-6		3QNW
CD	C14.005	caspase-6		3S70
CD	C14.005	caspase-6		3S8E
CD	C14.005	caspase-6		3V6L
CD	C14.005	caspase-6		3V6M
CD	C14.005	caspase-6		4EJF
CD	C14.005	caspase-6		4FXO
CD	C14.005	caspase-6		4HVA
CD	C14.005	caspase-6		4IYR
CD	C14.005	caspase-6		4N5D
CD	C14.005	caspase-6		4N6G
CD	C14.005	caspase-6		4N7J
CD	C14.005	caspase-6		4N7M
CD	C14.005	caspase-6		4NBK
CD	C14.005	caspase-6		4NBL
CD	C14.005	caspase-6		4NBN
CD	C14.005	caspase-6	Ala109Thr mutant	6DEU_A
CD	C14.005	caspase-6	Glu35Lys mutant	6DEV_A
CD	C14.006	caspase-2	complex with acetyl-Leu-Asp-Glu-Ser-Asp-CHO	1PYO_A
CD	C14.006	caspase-2	inhibition of caspase-2 by a designed ankyrin repeat protein (darpin)	2P2C_A
CD	C14.006	caspase-2	crystal structure of active caspase-2 bound with ac-advad-cho	3R5J_A
CD	C14.006	caspase-2	crystal structure of active caspase-2 bound with ac-vdvad-cho	3R6G_A
CD	C14.006	caspase-2	caspase-2 t380a bound with ac-vdvad-cho	3R6L_A
CD	C14.006	caspase-2	complex with one molecule of Ac-DVAD-CHO	3R7B_A
CD	C14.006	caspase-2	complex with two molecules of Ac-DVAD-CHO	3R7N_A
CD	C14.006	caspase-2	crystal structure of apo caspase2	3R7S_A
CD	C14.006	caspase-2	complex with chdi ligand 33c	3RJM_A
CD	C14.009	caspase-8	complex with Z-Asp-Glu-Val-Asp-CHO inhibitor	1F9E
CD	C14.009	caspase-8	complex with baculovirus P35 inhibitor	1I4E_B
CD	C14.009	caspase-8	complex with tripeptide ketone inhibitor Z-Glu-Val-Asp-dichloromethylketone	1QDU
CD	C14.009	caspase-8	complex with acetyl-Ile-Glu-Thr-aspartic aldehyde	1QTN
CD	C14.009	caspase-8	complex with	2C2Z_A
CD	C14.009	caspase-8	alternative p35-caspase-8 complex	2FUN_B
CD	C14.009	caspase-8	complex with darpin-8.4	2Y1L_A
CD	C14.009	caspase-8	zymogen; complex with c-flipl	3H11_B
CD	C14.009	caspase-8	complex with a covalent inhibitor	3KJN_A
CD	C14.009	caspase-8	complex with a covalent inhibitor	3KJQ_A
CD	C14.009	caspase-8	caspase-3 specific unnatural amino acid-based peptides	4JJ7_A
CD	C14.009	caspase-8	caspase-8 specific unnatural amino acid peptides	4PRZ_A
CD	C14.009	caspase-8	caspase-8 specific unnatural amino acid peptides	4PS1_A
CD	C14.010	caspase-9	cleaved form lacking caspase recruitment domain	1JXQ
CD	C14.010	caspase-9	complex with BIR-4 protein	1NW9_B
CD	C14.010	caspase-9	dimeric form	2AR9_A
CD	C14.010	caspase-9	ciap1-bir3 in complex with n-terminal peptide from caspase- 9 (atpfqe)	3D9T_C
CD	C14.010	caspase-9	complex with NleF	3V3K_A
CD	C14.010	caspase-9	propeptide only; complex with apoptotic protease activating factor 1	3YGS
CD	C14.015	caspase (insect 1)		1M72
CD	C14.015	caspase (insect 1)	structure of pro-sf-caspase-1	2NN3_C
CD	C14.015	caspase (insect 1)		3SIP_A
CD	C14.015	caspase (insect 1)		3SIR
CD	C14.019	caspase DRONC (Drosophila melanogaster)	complex with DIAP1	1Q4Q_K
CD	C14.019	caspase DRONC (Drosophila melanogaster)	Cys284Arg, Cys318Ala double mutant	2FP3
CD	C14.019	caspase DRONC (Drosophila melanogaster)		3J9K
CD	C14.026	paracaspase		2G7R
CD	C14.026	paracaspase		3BFO
CD	C14.026	paracaspase		3K0W
CD	C14.026	paracaspase	complex with Val-Arg-Pro-Arg inhibitor	3UO8
CD	C14.026	paracaspase	complex with Val-Arg-Pro-Arg inhibitor	3UOA
CD	C14.026	paracaspase		3V4O
CD	C14.026	paracaspase		3V55
CD	C14.026	paracaspase		4I1P
CD	C14.026	paracaspase		4I1R
CD	C14.026	paracaspase	human malt1(329-728) in complex with mlt-747	6F7I_A
CD	C14.026	paracaspase	human malt1(329-728) in complex with mlt-748	6H4A_A
CD	C14.026	paracaspase		3V4L
CD	C14.033	metacaspase-4 (Arabidopsis-type)		6W8R
CD	C14.035	metacaspase Yca1 (Saccharomyces cerevisiae-type)		4F6O
CD	C14.035	metacaspase Yca1 (Saccharomyces cerevisiae-type)		4F6P
CD	C14.044	metacaspase TbMCA2		4AF8
CD	C14.044	metacaspase TbMCA2	in presence of Samarium	4AFP
CD	C14.044	metacaspase TbMCA2	Cys213Ala mutant	4AFR
CD	C14.044	metacaspase TbMCA2	in presence of calcium chloride	4AFV
CD	C14.048	bacterial metacaspase		3BIJ_A
CD	C14.971	FLIP protein	zymogen; complex with caspase-8	3H11_A
CD	C14.971	FLIP protein	c-flipl protease-like domain	3H13_A
CD	C14.UPA	subfamily C14A unassigned peptidases	complex with ACE-DEVD inhibitor	6WI4
CF	C15.001	pyroglutamyl-peptidase I (prokaryote)		1AUG
CF	C15.001	pyroglutamyl-peptidase I (prokaryote)		3RNZ
CF	C15.001	pyroglutamyl-peptidase I (prokaryote)		3RO0
CF	C15.001	pyroglutamyl-peptidase I (prokaryote)		3GIU_A
CF	C15.001	pyroglutamyl-peptidase I (prokaryote)		1A2Z_A
CF	C15.001	pyroglutamyl-peptidase I (prokaryote)		1IOF
CF	C15.001	pyroglutamyl-peptidase I (prokaryote)	Cys142, C188 deletion mutant	1IOI
CF	C15.001	pyroglutamyl-peptidase I (prokaryote)	structure of mutant pyrrolidone carboxyl peptidase (e192a) from a hyperthermophile, pyrococcus furiosus	1X10_A
CF	C15.001	pyroglutamyl-peptidase I (prokaryote)	structure of mutant pyrrolidone carboxyl peptidase (e192d) from a hyperthermophile, pyrococcus furiosus	1X12_A
CF	C15.001	pyroglutamyl-peptidase I (prokaryote)	structure of mutant pyrrolidone carboxyl peptidase (e192q) from a hyperthermophile, pyrococcus furiosus	1Z8T_A
CF	C15.001	pyroglutamyl-peptidase I (prokaryote)	structure of mutant pyrrolidone carboxyl peptidase (e192i) from a hyperthermophile, pyrococcus furiosus	1Z8W_A
CF	C15.001	pyroglutamyl-peptidase I (prokaryote)	structure of mutant pyrrolidone carboxyl peptidase (e192v) from a hyperthermophile, pyrococcus furiosus	1Z8X_A
CF	C15.001	pyroglutamyl-peptidase I (prokaryote)	fragment 1-204	2DF5_A
CF	C15.001	pyroglutamyl-peptidase I (prokaryote)	Ala199Pro mutant	2EO8
CF	C15.001	pyroglutamyl-peptidase I (prokaryote)		1IU8
CF	C15.001	pyroglutamyl-peptidase I (prokaryote)	crystal structure of pyrrolidone carboxylate peptidase i from deionococcus radiodurans r1	5Z40_A
CF	C15.001	pyroglutamyl-peptidase I (prokaryote)	crystal structure of pyrrolidone carboxylate peptidase i with disordered loop a from deinococcus radiodurans r1	5Z47_A
CF	C15.001	pyroglutamyl-peptidase I (prokaryote)	crystal structure of pyrrolidone carboxylate peptidase i from deinococcus radiodurans r1 bound to pyroglutamate	5Z48_A
CF	C15.001	pyroglutamyl-peptidase I (prokaryote)		3LAC
CF	C15.001	pyroglutamyl-peptidase I (prokaryote)		2EBJ
CF	C15.001	pyroglutamyl-peptidase I (prokaryote)	crystal structure of a pyrrolidone-carboxylate peptidase 1 (target id nysgrc-012831) from xenorhabdus bovienii ss-2004	4GXH_A
CF	C15.001	pyroglutamyl-peptidase I (prokaryote)	crystal structure of a pyrrolidone-carboxylate peptidase 1 (target id nysgrc-012831) from xenorhabdus bovienii ss-2004 in space group p21	4HPS_A
CA	C16.005	avian infectious bronchitis coronavirus papain-like peptidase		3EJF
CA	C16.005	avian infectious bronchitis coronavirus papain-like peptidase		3EKE
CA	C16.005	avian infectious bronchitis coronavirus papain-like peptidase		4X2Z
CA	C16.005	avian infectious bronchitis coronavirus papain-like peptidase	Cys101Ser mutant; complex with ubiquitin	5BZ0_A
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		1P76
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		1P9T
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		1PA5
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		1PUK
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		1Q1X
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		1Q2W
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		1QZ8
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		1UJ1
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		1UK2
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		1UK3
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		1UW7
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		1WOF
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		1YSY
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		1Z1I
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		1Z1J
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		2A5A
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		2A5I
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		2A5K
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		2ACF
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		2AHM
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		2AJ5
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		2ALV
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		2AMD
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		2AMQ
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		2BX3
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		2BX4
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		2C3S
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		2D2D
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		2DUC
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		2FAV
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		2FE8
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		2FYG
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		2G9T
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		2GA6
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		2GDT
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		2GRI
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		2GX4
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		2GZ7
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		2GZ8
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		2GZ9
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		2H2Z
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		2HOB
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		2HSX
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		2IDY
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		2KAF
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		2KQV
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		2KQW
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		2KYS
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		2LIZ
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		2OP9
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase	Gly11Ala mutant	2PWX_A
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase	Asn214Ala mutant	2QC2_A
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase	monomeric form of mutant	2QCY_A
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase	structure-based design and synthesis and biological evaluation of peptidomimetic sars-3clpro inhibitors	2QIQ_A
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		2W2G
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		2WCT
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		2YY4_A
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		2Z3C
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		2Z3D
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		2Z3E
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase	complex with tdt	2Z94_A
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase	complex with pma	2Z9G_A
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase	complex with epdtc	2Z9J_A
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase	complex with jmf1600	2Z9K_A
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase	complex with jmf1586	2Z9L_A
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		2ZU4
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		2ZU5
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		3ATW
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		3AVZ
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		3AW0
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		3AW1
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase	development of broad-spectrum halomethyl ketone inhibitors against coronavirus main protease 3clpro	3D62_A
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		3E91
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase	a new class of papain-like protease/deubiquitinase inhibitors blocks sars virus replication	3E9S_A
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		3EA7
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		3EA8
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		3EA9
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		3EAJ
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		3EE7
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		3F9E
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		3F9F
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		3F9G
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		3F9H
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		3FZD
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		3IWM
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		3M3S
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		3M3T
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		3M3V
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		3MJ5
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		3R24
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		3SN8
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		3SNA
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		3SNB
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		3SNC
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		3SND
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		3SNE
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		3SZN
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		3TIT
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		3TIU
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		3TNS
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		3TNT
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		3V3M
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		3VB3
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		3VB4
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		3VB5
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		3VB6
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		3VB7
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		4HI3
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		4M0W
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		4MDS
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		4MM3
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		4OVZ
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase		4OW0
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase	complex with glycerol	5Y3E_A
CA	C16.009	severe acute respiratory syndrome coronavirus papain-like peptidase	crystal structure of sars coronavirus papain-like protease conjugated with beta-mercaptoethanol	5Y3Q_A
CA	C16.011	Middle East respiratory syndrome coronavirus papain-like peptidase		5KO3
CA	C16.011	Middle East respiratory syndrome coronavirus papain-like peptidase		4P16
CM	C18.001	hepatitis C virus peptidase 2		2A4G
CM	C18.001	hepatitis C virus peptidase 2		2GVF
CM	C18.001	hepatitis C virus peptidase 2	catalytic domain of the NS2 protein only	2HD0
CM	C18.001	hepatitis C virus peptidase 2		3HKW
CM	C18.001	hepatitis C virus peptidase 2		3KN2
CM	C18.001	hepatitis C virus peptidase 2	avoiding drug resistance against hcv ns3/4a protease inhibitors	3M5M_C
CM	C18.001	hepatitis C virus peptidase 2	visualizing atp-dependent rna translocation by the ns3 helicase from hcv	3O8B_A
CM	C18.001	hepatitis C virus peptidase 2	visualizing atp-dependent rna translocation by the ns3 helicase from hcv	3O8C_A
CM	C18.001	hepatitis C virus peptidase 2	visualizing atp-dependent rna translocation by the ns3 helicase from hcv	3O8D_A
CM	C18.001	hepatitis C virus peptidase 2	visualizing atp-dependent rna translocation by the ns3 helicase from hcv	3O8R_A
CM	C18.001	hepatitis C virus peptidase 2		3QGH
CM	C18.001	hepatitis C virus peptidase 2		3QGI
CM	C18.001	hepatitis C virus peptidase 2		3RC4
CM	C18.001	hepatitis C virus peptidase 2		3RC5
CM	C18.001	hepatitis C virus peptidase 2	crystal structure of hepatitis c virus ns3 helicase inhibitor co- complex with fragment 1 [(5-bromo-1h-indol-3-yl)acetic acid]	4OJQ_A
CM	C18.001	hepatitis C virus peptidase 2	crystal structure of hepatitis c virus ns3 helicase inhibitor co- complex with compound 7 [[1-(3-chlorobenzyl)-1h-indol-3-yl]acetic acid]	4OK3_A
CM	C18.001	hepatitis C virus peptidase 2	crystal structure of hepatitis c virus ns3 helicase inhibitor co- complex with compound 9 [1-(3-ethynylbenzyl)-1h-indol-3-yl]acetic acid]	4OK5_A
CM	C18.001	hepatitis C virus peptidase 2	crystal structure of hepatitis c virus ns3 helicase inhibitor co- complex with compound 13 [[1-(2-methoxy-5-nitrobenzyl)-1h-indol-3- yl]acetic acid]	4OK6_A
CM	C18.001	hepatitis C virus peptidase 2	crystal structure of hepatitis c virus ns3 helicase inhibitor co- complex with compound 19 [[6-(3,5-diaminophenyl)-1-(2-methoxy-5- nitrobenzyl)-1h-indol-3-yl]acetic acid]	4OKS_A
CA	C19.001	ubiquitin-specific peptidase 5		2DAG
CA	C19.001	ubiquitin-specific peptidase 5		2DAK
CA	C19.001	ubiquitin-specific peptidase 5		2G43
CA	C19.001	ubiquitin-specific peptidase 5		2G45
CA	C19.001	ubiquitin-specific peptidase 5		3IHP
CA	C19.004	Ubp3 ubiquitin peptidase		2QIY
CA	C19.010	ubiquitin-specific peptidase 4		2Y6E
CA	C19.010	ubiquitin-specific peptidase 4		3JYU
CA	C19.011	ubiquitin-specific peptidase 8		1WHB
CA	C19.011	ubiquitin-specific peptidase 8	N-terminal domain	2A9U
CA	C19.011	ubiquitin-specific peptidase 8	catalytic domain only	2GFO
CA	C19.011	ubiquitin-specific peptidase 8	complex with RING finger protein 41	2GWF
CA	C19.011	ubiquitin-specific peptidase 8		3N3K
CA	C19.011	ubiquitin-specific peptidase 8		1UJ0
CA	C19.012	ubiquitin-specific peptidase 13		2L80
CA	C19.012	ubiquitin-specific peptidase 13		2LBC
CA	C19.013	ubiquitin-specific peptidase 2	complex with ubiquitin	2HD5
CA	C19.013	ubiquitin-specific peptidase 2	complex with ubiquitin	2IBI
CA	C19.013	ubiquitin-specific peptidase 2		3NHE
CA	C19.013	ubiquitin-specific peptidase 2		3V6C
CA	C19.013	ubiquitin-specific peptidase 2		3V6E
CA	C19.013	ubiquitin-specific peptidase 2	complex with ubiquitin and 6- thioguanine	5XU8_A
CA	C19.013	ubiquitin-specific peptidase 2	Cys276Ser mutant; complex with ubiquitin	5XVE_A
CA	C19.013	ubiquitin-specific peptidase 2	ubiquitin variant bound to usp2	6DGF_A
CA	C19.014	ubiquitin-specific peptidase 11		4MEL
CA	C19.015	ubiquitin-specific peptidase 14		2AYN
CA	C19.015	ubiquitin-specific peptidase 14	complex with ubiquitin aldehyde	2AYO
CA	C19.015	ubiquitin-specific peptidase 14	26S proteasome; complex with USP14-UbAl	5GJQ_x
CA	C19.015	ubiquitin-specific peptidase 14	usp14 catalytic domain with iu1	6IIK_A
CA	C19.015	ubiquitin-specific peptidase 14	catalytic domain; complex with iu1-47	6IIL_A
CA	C19.015	ubiquitin-specific peptidase 14	usp14 catalytic domain with iu1-206	6IIM_A
CA	C19.015	ubiquitin-specific peptidase 14	usp14 catalytic domain with iu1-248	6IIN_A
CA	C19.015	ubiquitin-specific peptidase 14		1WGG
CA	C19.016	ubiquitin-specific peptidase 7	catalytic domain only	1NB8_A
CA	C19.016	ubiquitin-specific peptidase 7	complex with ubiquitin aldehyde	1NBF
CA	C19.016	ubiquitin-specific peptidase 7		1YY6
CA	C19.016	ubiquitin-specific peptidase 7		1YZE
CA	C19.016	ubiquitin-specific peptidase 7		2F1W
CA	C19.016	ubiquitin-specific peptidase 7		2F1X
CA	C19.016	ubiquitin-specific peptidase 7		2F1Y
CA	C19.016	ubiquitin-specific peptidase 7		2F1Z
CA	C19.016	ubiquitin-specific peptidase 7		2FOJ
CA	C19.016	ubiquitin-specific peptidase 7		2FOO
CA	C19.016	ubiquitin-specific peptidase 7		2FOP
CA	C19.016	ubiquitin-specific peptidase 7		2KVR
CA	C19.016	ubiquitin-specific peptidase 7		2XXN
CA	C19.016	ubiquitin-specific peptidase 7		2YLM
CA	C19.016	ubiquitin-specific peptidase 7		3MQR
CA	C19.016	ubiquitin-specific peptidase 7		3MQS
CA